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Chapter 1 
General introduction 
1. NORMAL PUBERTY 
1.1 The hypothaiamo'pituitary-gonadai (HPG) axis 
Normal puberty is the result of the maturation of the hypothalamo-pituitary-gonadal (HPG) 
axis. Primary and secondary sexual characteristics develop by the increase in the serum 
levels of gonadal steroids: oestradiol in girls and testosterone in boys. 
The main players in the process of normal puberty are the hypothalamus, by 
producing pulsatile Gonadotrophin Releasing Hormone (GnRH), and the pituitary. GnRH 
influences the pituitary via the portal vein system and the pituitary secretes the 
gonadotrophins Luteinizing Hormone and Follicle Stimulating Hormone (LH and FSH). LH 
and FSH in turn stimulate the gonads to develop the cells essential for reproduction and to 
secrete the gonadal steroids. (Figure 1) 
hypolhalamus ~ 
~PilUilary 
/ \ 
pulsatile 
GnRH 
Figure 1: 
Reproductive system. 
E2= oestradiol; 
T = testosterone 
LH FSH 
LH action: 
~: role in E2 production 
d': Leydig cells: T production 
FSH action: 
: ~: maturation of follicles (3': SertoH cells ~ spermatogenesis 
In girls this maturational process primarily leads to the development of the breasts and 
internal genitalia. Menarche follows as a result of ongoing maturation. In boys it results in 
growth of the testes, pubic and axillary hair, lowering of the voice and spermarche. In both 
sexes, a pubertal growth spurt occurs as well as further psychosocial and psychosexual 
development. 
1.2 Onset of puberty 
The onset of puberty is one of the intriguing yet unresolved issues in paediatric 
endocrinology. In recent years progress in basic science has led to further insight in the 
control of the onset of puberty (1). There is a central role for the GnRH cells, unusual cells 
that originate from outside the brain and migrate in early development from the olfactory 
placode to the hypothalamic region. Later in fetal development the GnRH cells stimulate fetal 
gonadotrophic activity. In late fetal life this GnRH activity is suppressed by fetoplacental 
steroids. From birth up to puberty, except for the early neonatal period, the GnRH activity 
appears to be suppressed or compromised (2, 3). However, when using ultrasensitive LH 
assays some activity is measurable in prepubertal children (4~7). 
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The general view on the onset of puberty has been that increased maturation of GnRH 
neurons leads to pulsatile GnRH release. This view has been debated in the last few years 
(8). 
The issue of the pubertal 're-awakening , of the GnRH pulse generator is complex 
and many mediators have been described to have a particular role: 
I. Glutamate 
Studies in explanted hypothalamic tissue of rats have shown the involvement of glutamate 
receptors of the N-methyl-D-aspartate (NMDA) subtype in the increase in GnRH pulse 
frequency at the onset of puberty (9, 10). NMDA administration was shown to have a 
stimulatory effect with regard to the onset of puberty (11,12). However, both an inhibitory 
and a facilitatory role of NMDA receptors have been described (10). A possible mechanism is 
that glutamate reduces the inhibitory effect of NMDA receptors on GnRH secretion. 
II. Gamma aminobutyric acid (GABA) 
Gamma aminobutyric acid (GABA) is an inhibitory neurotransmitter to GnRH release in vivo. 
It has extensively been studied in primates. A reduction in endogenous GABA release is 
suggested to lead to the pubertal increase in GnRH release (8, 13). The mechanisms for this 
reduction may be a decrease in the number of GABA-ergic neurons, a reduced GABA 
synthesis or enhanced degradation, or a reduction in the neural activity of GABA-ergic 
neurons during hypothalamic development. Recent research connects the findings on 
glutamate and GABA by showing that release of glutamate follows the disinhibition of the 
GnRH neuronal system to further increase GnRH release at the onset of puberty (13). 
Glutamic-acid-decarboxylase 67 (GAD67) is a catalytic enzyme that synthesises GABA from 
glutamate, thus probably an important player in the mechanism of the onset of puberty (13). 
III. Transforming growth factor-alpha (TGF-a) and other glial-derived substances 
The concept that GnRH neuronal function is not only influenced by neurotransmitters, but 
also by molecules of astrocytic origin has created a lot of research and the support for this 
hypothesis is emerging. 
Clinically, the occurrence of precocious puberty in children with hypothalamic 
hamartomas (14-16) has led to the hypothesis that hamartomas contain an ectopic GnRH 
pulse generator. However, histologic examination of tumour tissue showed no GnRH 
neurons present. Astroglial cells producing TGF-a were demonstrated in the tumour, thus 
suggesting that lesion-induced precocity is mediated by increased expression of TGF-a in 
glial cells causing activation of GnRH neuronal network in the hypothalamus (17-19). TGF-a 
affects the GnRH neuronal network inducing glia to produce bio-active substances, such as 
prostaglandin-E2, that stimulates the release of GnRH (20, 21). TGF-a production is 
stimulated by glutamate (22). Oestradiol seems to enhance TGF-a gene expression in 
hypothalamic astrocytes (22). TGF-a is probably not involved in the inhibitory effect of 
oestradiol on GnRH neurons (23). 
IV. Leptin and neuropeptide Y (NPY) 
An overwhelming amount of literature on leplin has been published in the last few years, 
focussing on its relation to obesity. Indeed, the original ob/ob mice in whom the leptin gene 
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was cloned were obese (24). On the other hand the relationship of lepUn with the onset of 
puberty has extensively been studied since clinical data suggest a link between peripheral 
energy stores and central regulation of reproductive capacity (25-28). The potential role of 
leptin is demonstrated by the fact that lepUn deficient mice fail to undergo pubertal 
development, while administration of lepUn restores this process (29). 
The general view by now about the role of leptin in pubertal development is that leptin 
acts as a permissive signal for the onset of puberty (25, 30-33). 
" Many investigators have now reported that lepUn increases gradually in both sexes over the 
prepubertal years. At each age, girls tend to have higher levels than boys. The leplin peak is 
reached at Tanner genital stage (G) 2-3 in boys, but in girls lepUn continues to rise through 
puberty with a particular increase after menarche" (25). 
Leptin is regulated by several hormones (e.g, sex steroids, growth hormone and melatonin) 
and proinflammatory cytokines (31). Several hypothalamic neuropeptides are involved in 
leptin action: orexigenic neuropeptides, including for example neuropeptide Y (NPY) and 
alpha-melanocyte stimulating hormone (a-MSH) and anorexigenic neuropeptides including 
corticotropin releasing hormone (CRH) and cocaine- and amphetamine regulated transcript 
(CART). 
Leptin activates pro-opiomelanocortin (POMC) and CART neurons that project to the 
lateral hypothalamic area (J. Elmquist, Proceedings 5th international conference on the control of 
the onset of puberty, Luik 1999), thus linking leptin with neurons that regulate feeding 
behaviour, energy expenditure and body weight homeostasis. CART seems to be involved in 
the leptin effects on GnRH putsatility in rat hypothalamic explants (34). -
NPY has importance in dictating the ontogeny of the GnRH release. Removal of the 
inhibitory NPY input to the hypothalamic GnRH neurons may lead to the onset of puberty 
(35) 
v. Insulin-like Growth Factor (IGF) system 
In the hypothalamus and pituitary IGF receptors have been localised and in vitro studies 
showed possible effects on GnRH expression. Probable mechanisms involve interactions 
with sex steroids and other hormones, extensively reviewed in (36). From a clinical point of 
view the elevated lGF-llevels during puberty and precocious puberty suggest a role of IGF-I 
(37-40). Since IGF~I is nutrition-dependent refeeding after malnutrition may cause a rise in 
IGF-I acting as a stimulating signal for the timing of sexual maturation, which is probably age 
dependent (41). 
VI. Other mediators 
Nitric oxide is reported to be a mediator in the induction of GnRH release; norepinephrine, 
glutamic acid and oxytocin may stimulate the release of GnRH by activation of nitric oxide 
synthase (42). Recently, local regulatory effects of GnRH on the hypothalamus were 
described suggesting that local regulatory effects of the neuropeptide could supplement the 
primary hypothalamic mechanism for the control of episodic gonadotrophin secretion. 
Changes in melatonin secretion were suggested to have influence on the timing of puberty 
as well (43, 44). 
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Based on recent literature reviewed above, the following tentative scheme is suggested (22, 
25) (see Fig. 2) 
Neurons 
Neurotransmitters 
GABA (-) 
Glutamate (+) 
NPY (+/-) 
Leplin (+) 
CART(+) 
Nitric Oxide (+) 
I 
Astrocytes 
t TGF-a 1 
Neuro·active 
substances 
L 
GnRH neurons 
Pulsatile GnRH 
Puberty 
Peripheral signals 
IGF system (+) 
Leplin (+) 
Figure 2: Mediators with a role in the onset of puberty; summary from animal and human 
data. In brackets: proposed direction of action, see text for details. 
1.3 Timing of puberly 
In The Netherlands four consecutive growth studies have been performed showing a 
continuing secular change towards tall stature. Fredriks et af. reported another increase of 
final height in the most recent survey of 1997 (45). From 1955 to 1980 this increase in adult 
height was accompanied by a decrease in the age of onset of puberty and of menarche (46· 
48). In 1997 the age of onset of puberty in girls has been reported to be 10.7 years, in boys 
11.5 years, suggesting a stabilisation in the age of onset (45). Menarcheal age in this study 
was 13.14 years, slightly lower than in 1980. 
The timing of puberty in South America, Asia or Africa differs from the timing in 
Western Europe or the United States. In Asian and African countries menarche is often later 
than in the western world. This is understandable from a biological point of view, since fertility 
demands a healthy biologic status and acceptable body composition. In table 1 the age of 
menarche is shown for a variety of countries outside Europe. 
In The Netherlands each year many children have been adopted from developing 
countries. The Dutch government reports that in 1999 most adopted children originate from 
China (n=271), Colombia (n=196), South Korea (n=77) and Haiti (n=61). Between 1980 and 
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1995 many children were adopted from India, Sri Lanka and Indonesia. The earlier onset of 
puberty of children adopted from Asia or Africa to Europe is described more extensively in 
section 2.2.3. 
Table 1: Age of menarche (mean or PSO) from different countries 
reported in the literature 
country Age menarche (yr) Reference 
India (urban) 13.4 (49) 
India (rural) 14.0 
India (highest SES) 13.2 
India (lowest SES) 14.6 
SriLanka (Tamil girls) 13.8 (50) 
Thailand (urban) 12.4 (51) 
Bangladesh 13.0 (52) 
Nepal (high altitude) 16.2 (53) 
Senegal 16.1 (54) 
China 13.7 (55) 
Hong Kong 12.4 (56) 
Argentina (urban) 12.5 (57) 
Bolivia (all SES) 12.7 (58) 
Nigeria (urban) 13.5 (59) 
The Netherlands 
1980 13.3 (48) 
1997 13.1 (45) 
2. CENTRAL PRECOCIOUS PUBERTY (CPP) 
2.1 Definition 
In central precocious puberty, the age at onset of puberty is below the mean of normal onset 
minus 2 or 2.5 SD. In practice the cut-off limit of 8 years for girls and 9 years for boys is 
used. Because of the mat~ematjcal relation of the cut-off age with the mean age at onset of 
puberty of the normal population, one might argue that the secular trend of earlier onset of 
puberty in many countries should lead to adaptation of the age limits. The Lawson Wilkins 
Pediatric Endocrine Society advised to take a cut-off value of 7 years for white girls and 6 
years for African-American girls to look for a pathologic aetiology of precocious puberty (60). 
This was based on a cross-sectional population study that showed earlier onset of signs of 
puberty than in the data used for the common definition of precocious puberty (61). In The 
Netherlands the 1997 growth study did not show a further significant change towards earlier 
occurrence of puberty (45) (see chapter 2.2). Therefore, in this thesis the former definition of 
precocious puberty is used. Early puberty is defined as the onset of puberty in girls between 
8 and 10 years of age and in boys between 9 and 11 years of age. 
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2.2 Aetiology 
This thesis deals with CPP, or gonadotrophin dependent precocious puberty, which means 
that there is a normal mechanism of activation of the pituitary and subsequent gonadotrophin 
production. In girls the incidence of CPP is higher than in boys. 
2.1.1 Idiopathic CPP 
In idiopathic CPP no organic or external factor can be demonstrated that causes the GnRH 
pulse generator to be re~activated. In boys the percentage of idiopathic precocious puberty is 
lower than in girls (62). Recently it was reported that in 45 boys with CPP the aetiology was 
idiopathic in 60% and in 40% neurogenic (e.g. hamartoma or neurofibromatosis I) (63). An 
earlier report from the NIH described idiopathic precocious puberty to be present in 6% of the 
boys and 63% of girls (62). In girls the overall incidence of neurogenic abnormalities varied 
from 18 to 37% (62, 64). 
2.1.2 Organic CPP 
Organic causes of CPP are given in table 2. The mechanisms underlying the onset of 
puberty in these conditions are not known in detail. It can be assumed that local pressure or 
increased intracranial pressure stimUlates the GnRH neurons in the case of hydrocephalus 
and meningo~myelocele (MMC), as well as in brain tumours. Another hypothesis is that the 
compression and stretch may cause disruption of the inhibitory fibers, thus removing their 
inhibitory actions (65). Decompression of arachnoid cysts was described to reverse the 
precocious pubertal development (66). 
Table 2: Organic causes of CPP 
Causes of organic CPP 
Hamartoma 
Neurofibromatosis I 
Braintumors: craniopharyngeoma, astrocytoma 
Hydrocephalus and meningo-myelocele 
Cerebral infections 
Cerebral trauma 
Arachnoid cyst 
In hamartomas recent findings suggest local production of TGF-a stimulating the 
GnRH neuronal network (17). The diagnosis of hamartoma is established neuroradiologically 
(67). In general a hamartoma needs no neurosurgical intervention. 
Exposure to oestrogen containing substances may mimic precocious puberty with 
accelerated growth and advanced bone age (68, 69). 
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MRI evaluation of the hypothalamo-pituitary region showed that in cases, clinically regarded 
as idiopathic, an intracerebral process may be present, in most cases a hamartoma (15, 63, 
70). In 304 girls evaluated by CT or MRI a neurogenic abnormality was demonstrated in 
18.4% of cases, of which 26/56 were just diagnosed at presentation of CPP (64). 
2.2.3 Early puberty and CPP in adopted children 
In several countries in Europe it was described that adopted children from developing 
countries are overrepresented among children suffering from CPP or early puberty (71-77). 
Compared to an incidence of about 1/10.000 for idiopathic CPP, in Belgium 20-25% of 
children with CPP were adopted from developing countries (41, 78), estimating the incidence 
of CPP in adopted children 1 per 54 adoptions (J-P Bourguignon, communication Copenhagen 
Workshop on Endocrine Disrupters 2000). 
In auxological studies in adopted chHdren catch-Up growth was demonstrated (72, 79-
81). Theoretlcally, this should result in a higher mean final height than in the country of origin. 
However, due to the early occurrence of menarche mean final height did not substantially 
exceed the final height in the country of origin (82, 83). 
The high prevalence of early onset of puberty in adopted children may serve as an 
experiment of nature. However, the factors involved remain unclear as long as we do not 
know the perinatal medical history of the child, nor the health status of the mother. 
In comparison to the normal age of menarche in the countries of origin, an early 
menarche is observed when the girls migrate to the western world. Proos et al. showed that 
menarcheal age was 11.6 years (median) in a sample of 107 girls from India, whereas the 
normal age of menarche in India varies from 12.8 years in privileged girls to 14.4 yrs in girls 
in rural areas (71). 
The same pattern of early menarche was observed by Oostdijk in the Netherlands. In 
446 girls adopted from four different countries, mean age at menarche was 12.0 (SD 1.5) 
years, varying from 11.2 years in Indian girls to 12.4 years in girls from South Korea (82). 
The mean age of menarche was significantly lower than the mean for Dutch girls. In the 
studies of Oostdijk and Proos a positive correlation was found between menarcheal age and 
final height. Although in bivariate correlations later arrival was associated with earlier 
menarche, in multiple regression analysis the menarcheal age was associated with height at 
arrival, but not with age at arrival (83, 84). Height at arrival, the velocity of height catch-Up 
growth and menarcheal age appeared to be significantly correlated with FH (83). 
Proos studied the natural growth of 66 adopted children in Sweden. Their height at 
arrival was -2.8 SOS, increasing to -0.8 SOS 2 years before the peak height velocity. At FH, 
however, H-SOS was -1.8 SO. These data suggest that despite the promising magnitude of 
catCh-Up growth FH-SOS is substantially lower. Pubertal height gain was reported to be 
equivalent to that of Swedish girls (85), suggesting a negative effect of shortening of the 
prepubertal growth phase. The study of Oostdijk showed that in 34 adopted children H-SDS 
at arrival was -1.8 and increased to a mean H-SDS of -0.5 between 6 and 8 years of age, 
where FH-SDS was around -1 SD (76). 
Some authors speculate on genetic reasons for the fall in H-SDS, for example that a 
certain height potential is already fulfilled at an earlier age than in the country of origin, as a 
result of genomic imprinting of a growth pattern appropriate for that country (81). 
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The differences in expression of genes derived from the fhther and the mother are already marked in 
early developmcnt (86). The mechanism of this imprinting might be differential methylation of 
specific gene sites. Imprinted genes are involved in many aspects of development including fetal and 
placental growth (87). Genomic imprinting of regions of ehromosomc 14, especially of a gene 
involved in the onset of puberty, was related to llniparental disomy in a boy with preeociolls puberty, 
low birth weight and growth abnOnllalities and some dysmorphic features and developmental delay 
(88). In a latcr report intrauterine growth retardation was linked to a compamblc uniparental disomy of 
chromosome 14 (89). The combination of phenotypes with intrauterine gro\\1h retardation and early 
onset ofpuberly in chromosome 14 abnonnalities may stimulate further rcsearch on the genetic basis 
of early puberty. 
However, several studies show that environmental factors can increase final height in a 
population, as was shown in the consecutive Dutch growth studies. 
One might speculate early puberty to occur as a result of transition from a situation 
with low socia-economic conditions to the highly affluent western world during a specifiC, 
maybe even critical period after birth. Specifically, Virdis suggests a role of the dietary 
change in adopted children from low protein and low energy vegetarian diet to a balanced 
enriched diet after adoption (73). The presence of oestrogen- like substances in food 
(phytoestrogens) (90) and other endocrine disrupters in their new environment influencing 
the pubertal development of adopted children remains to be studied (91). The influence of 
environmental factors on the timing of puberty in healthy Dutch children seems minimal, as 
no further decrease in the age at onset of puberty was shown (chapter 2.1). 
The occurence of early puberty in adopted children might be related to the 
improvement of nutritional status in early life, possibly facilitated by an increase in leptin 
levels acting as permissive factor for the onset of puberty by interacting with several 
neuropeptides (see section 1 of this introduction). In male rats it was demonstrated that 
unrestricted feeding after nutritional deprivation in a specific period after birth resulted in 
accelerated hypothalamic and testicular maturation (41). In that study the role of increased 
IGF~I is suggested as an important mediator. 
On the other hand, Engelbregt et at. studied the role of early undernutrition pre- or 
postnatally on pubertal development in rats (92). Food restriction in each of these periods 
resulted in a change of programming of pubertal development: early malnutrition resulted in 
delayed onset of puberty in intra-uterine growth retarded (IUGR) male and female rats, as 
well as in male food-restricted rats. In female food restricted rats the onset of puberty was 
normal. This study and other data suggest that there may be environmental factors in the 
pre- or postnatal period having long term effects on the hypothalamo-pituitary action (93). 
As it can be assumed that many adopted children are born from mothers from the 
lower social classes and thus at risk for unfavourable circumstances in utero. The 
comparison of these adopted children with children born small for gestational age (SGA) is 
challenging. The long-term influence of intra-uterine growth retardation on several endocrine 
axes has been described, especially by Barker and co-workers (94-99). With regard to the 
HPG axis an earlier menopause and altered hypothalamic control of LH release were 
described to have an association with IUGR (94, 95). It can therefore be assumed that 
programming of the setting of the GnRH pulse generator is influenced by prenatal factors. 
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2.2 Effects of CPP 
2.2.1 Height 
The oldest reports of the deteriorating effects of CPP on final height (FH) date back from the 
nineteen sixties, when Thamdrup reported a series of 56 untreated patients with a mean final 
height of 151.3 (SO: 8.8) em in 26 girls and of 155.4 (8.3) em in 8 boys. Mean parental height 
was 166.6 (4.6) em and 166.8 (5.1) em respectively (100). Summarising the available data in 
girls, FH in untreated CPP without slow progressive forms, range from 149.6 to 161.7 cm 
(101). The decrease in final height is due to acceleration of the fusion of the epiphyseal 
plates as a result of the sex steroid exposure, combined with the early interruption of the 
prepubertal growth period. 
Factors negatively influencing FH in girls were reported to be an early age at start of 
puberty and menarche, short parental height and a large difference between bone age and 
height age (100). 
2.2.2 Reproduction 
The reports of the effects of precocious sexual maturation on reproductive capacity are 
scarce. A relation with early polycystic-ovary-like symptoms was suggested since an 
abnormal adrenal response after adrenocorticotropic hormone (ACTH) stimulation was 
observed in 55.4% of girls in early stages of CPP. However, it did not result in clinical signs 
of a hyperandrogenic state, nor in abnormal elevation of baseline androgen levels (102,103). 
Thamdrup described the occurrence of pregnancies in girls with CPP from literature dating 
back from the 18th to 20th century (100). 
Ovarian ultrasound in children with CPP revealed an increased prevalence of 
polycyslic ovarian appearance, related to either precocious puberty itself or its treatment 
(104). However, other reports did not confirm the presence of PCO (105, 106) after GnRHa 
treatment. 
2.2.3 Body proportions 
The studies of Thamdrup also address body proportions in untreated precocious puberty. In 
most cases the ratio of upper to lower segment is above normal for age during the course of 
puberty and also after completion of growth. It is concluded that in most cases the patients 
preserve the childlike body proportions with relatively short limbs and a large head in 
proportion to the trunk; the later onset of puberty, the more chance of attaining normal 
proportions (100). The observation of the relative large trunk compared to the limbs was 
confirmed in a later study, although in that study several children received treatment (107). 
2.2.4 Malignancy 
The precocious exposition to natural oestrogens in girls with CPP might theoretically lead to 
oestrogen induced tumors in later life. However, no prospective study was performed to 
evaluate this relationship. There are epidemiologic studies that suggest a relationship of 
breast cancer with an earlier menarche (108). The mutagenic or carcinogenic properties of 
oestradiol are weak, but induction of genetic lesions might occur with low frequency (109). 
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3. DIAGNOSIS OF CPP 
3.1 Physical examination 
Physical examination is the basis for the clinical diagnosis of GPP. The child is carefully 
examined for the presence of secondary sexual characteristics and these are scored 
according to the Tanner criteria (110). In boys testicular volume is assessed using an 
orchidometer. In girls palpation and measurement of the diameter of the mammary gland is 
a valuab[e option. To define the onset of puberty B2 stage in girls should be present, and in 
boys the testicular volume should be 4 ml or more. A 3 ml cut-off is suggested by some 
authors (111,112). 
The general physical examination further includes careful inspection of the skin for 
signs of any dysplasia, cate au [a it spots or signs of neurofibromatosis. Neuro[ogical 
examination should be periormed as well. The visual fields need attention in case of possible 
brain tumours. Other signs include the presence of acne, oily hair and transpiration odour. 
Furthermore, height, weight and sitting height should be recorded in order to evaluate the 
effect of possible interventions and the progression of pubertal development. Increase in 
height velocity is an important means to demonstrate that there is progression of pubertal 
development over time. 
3.2 Radiological evaluation 
3.2.1 Bone age (BA) 
Bone maturation is used as a marker for the biological maturation of a child. An X-ray of the 
left hand is made for BA assessment. In GPP bone age assessment is usually performed by 
the Greulich and Pyle method (113,114) and the difference between chronological age (CA) 
and BA is assessed. The more BA is advanced over GA, the more height will be lost in case 
of no treatment (100). 
To predict adult height the tables of Bay[ey and Pinneau (BP) are used for height 
prediction (115). Most children with CPP have a SA advance of 1 year or more. In this 
condition, the traditional method of height prediction used the accelerated BP tables. For a 
long time, it was questioned to what extent the abnormal growth process in GPP was to be 
analysed by tables for the normal population. Kauli showed that using the accelerated tables 
the predicted adult height (PAH) was overestimated. She suggested that it would be better to 
use the average tables in children with CPP (116). 
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~--------- Intermezzo: Bonc age and finlll hcight predictions ~~~-------
The assessment of bone age (SA) is used as a marker of biological maturation of a child 
(113, 117). In all techniques an X-ray of the left hand is used and maturily indicalors are 
scored (118). 
• The Greulich and Pyle (GP) method assumes Ihat all bones have idenlical skeletal age 
so that a skeletal age can be assigned to an X-ray as a whole. 
• The Tanner & Whitehouse 2 (TW2) method uses a bone-specific approach, assessing 
the maturity of 20 bones that are matched to a series of written criteria. The RUS (radius, 
ulna, short bones) score is a shortened form of TW2 without scoring of the carpal bones. 
• The FELS method introduced by Roche, is based on 98 maturity indicators. In only few 
studies this method was used. 
In the evaluation of children with precocious puberty the GP method is most common and it 
is linked wilh the Bayley and Pinneau lables for prediclion of adull height (115). 
For several reasons there is a need for new standards: the standards of GP and 
TW2 SA assessment date back from nineteen thirties and fifties, and the samples consisted 
of relatively lower class children in the TW2 sample and upper-middle class children in the 
GP sample. Now. after several decades with a secular trend towards earlier maturation and 
taller stature the reliability of the old standards might be waning. Furthermore, SA 
assessments are largely dependent on the observator's experience and inter-individual 
differences in SA assessment are inevitable. 
For research purposes all SA assessments over a long period of time should be 
performed by the same observer. An improvement of the generalising GP method would be a 
bone age based upon assessing the maturity of each of the 20 bones. The average of these 
ages Ihen should be calculated 10 eslablish bone age (S.1. Pyle referenced in (118)). This 
time-consuming approach has been reported to have an inter-observer-difference between 
0.1 and 0.34 'years\ and mean intra-observer difference ranging from 0.15 to 0.63 years. 
King reported a mean difference between 3 observers of 0.74 years for the TW2 method and 
of 0.96 years for the GP method, whereas the intra-observer variation in TW2 method was 
0.33 years (95% CI: -0.87 - 1.53) (119). Comparing TW2 and GP Ihe 95% confidence 
interval of intra-observer variation amounts to 2.28 to -1.52 years (120). 
New methods in SA determination using computer imaging have been developed, but 
still positioning and exposure of the image cannot fully be automated (121-127). 
Several studies showed that GP method was preferable in clinical conditions, such as 
precocious puberty (118. 128). Height predictions in untreated CPP patients were performed 
wilh BP prediclions, showing a correlation of 0.85 wilh the atlained final height (114). In 
precocious puberty in girls it was shown by Kauli that the use of the accelerated tables of 
Bayley and Pinneau resulted in overestimation of final height. Therefore, it would be more 
appropriale to use Ihe average lables (116). 
The problem in children with early or precocious puberty is that SA maturation is 
beyond the physiologic range, thus reducing the expected final height In contrast, early 
maturing girls -still in the normal range - show a more intensive growth reaching their FH 
earlier, but also with a greater gain in height per bone age advance (116). 
In general, predicting final height suffers from a limited accuracy, with a mean 
prediction error of 7 - 9 cm depending on the bone age (129). An additional error could be 
introduced by using western world standards to children from Africa, Asia or South-America, 
as in adopted children, refugees or immigrants. No data is available on the bone age 
progression during catch-Up growth in adopted children or during recovery of undernutrition. 
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In our clinical practice in adopted children we frequently observed dissociated maturation 
between carpal and phalangeal bones, as was also observed in children with precocious 
puberty and congenital adrenal hyperplasia (130). Possibly. the early exposure to androgens 
and! or estrogens has different effects on the ossification of carpal bones than on phalangeal 
bones. Thus, in children from other ethnicity who have increased risk of the development of 
early puberty, one should be aware that height prediction is very complicated and should be 
performed with caution. In the group of adopted children studied in chapter 6 we observed a 
mean difference between carpal and phalangeal bones of 0.5 'years' (range 0.1- 1.1). 
The literature on the relationship between skeletal maturation in non-European 
countries and western world standards for bone age assessment shows variable results 
(131-133), suggesting that children of the higher socia-economic classes can beUer be 
compared with the European standards than can children in situations of lower socio-
economic circumstances, malnutrition and poor health. 
To assess the chronological age in cases where the birth date is uncertain one should 
always be careful to focus on bone age only. Other methods include for example 
determination of dental age, which was described to be reliable regardless of sex and race 
but still difficult in cases with uncertain birth date (134). Another marker for biological 
maturation is the closure of the epiphyseal plates of the clavicle, which is highly independent 
of external factors (135). Its use however is limited to forensic age determination, for 
example in young adolescent refugees. 
3.2.2 Magnetic Resonance Imaging (MRI) 
The use of MRI in the diagnosis of CPP is mainly of interest in those cases in which no 
known underlying disorder is present. In those patients labelled as having idiopathic CPP 
intracranial pathology can be excluded by MRI (15, 64, 70).The relevance of these findings 
for follow-up of these patients can be disputed, as most of the hamartomas do not increase 
in size. 
The indication for MRI is especially important in young girls and in boys with 
precocious puberty. However, Cisternino reported that neurogenic abnormalities not 
previously known were also detected by MRI in 7.4 % of girls between 7 and 7.9 years of age 
(64). 
3.2.3 Ullrasound 
Ultrasound is used in the evaluation of CPP for assessing the size and aspects of uterus and 
ovaries. Several studies in normal children provided reference values for the ovarian 
volumes or uterine size (136-139). In CPP the sizes of ovaries and uterus increase in a 
comparable sequence as in normal puberty, follicles become visible in the ovaries and the 
delineation between endometrial and myometrial tissue will be present in later stages. 
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A considerable overlap between ovarian size of normal girls and girls with precocious 
puberty has been observed (106, 140) 
Another application of ultrasound is the assessment of glandular tissue in the breast in 
case of doubt whether the breast volume is increased by adipose tissue or by the mammary 
gland (141, 142). 
3.3 Biochemical evaluation 
3.3.1 Basal values of gonadotrophins 
The assessment of basal values of gonadotrophins with the conventional assays does not 
contribute to the diagnosis of CPP. More sensitive assays could be used to demonstrate 
early activation of the hypothalamo-pituitary axis (143-145). 
3.3.2 Stimulated values of gonadotrophins in the GnRH stimulation test 
Classically, the GnRH stimulation test has been used to demonstrate the central origin of 
precocious puberty by stimulating the pituitary to produce LH and FSH. LH serum levels 
above a certain cut off (dependent on the assay) or a ratio of LH/FSH > 1 have been 
considered criteria for central activation (146). However, the use of this test especially in 
children with recent onset of puberty has been challenged (see chapter 3). 
3.3.3 Stimulated values of gonadotrophins in the GnRH agonist stimulation test 
To improve the diagnostic process in early pubertal children agonists of GnRH with higher 
potency were used. As in clinical practice a considerable number of children with Tanner 
stage 2 showed no pubertal response in the GnRH stimulation test, the more potent GnRH 
agonist was used for diagnostic use. Ibanez et al. demonstrated that a pubertal response of 
> 8 lUlL for LH had a good correlation with clinical progression of puberty (147). 
3.3.4 Basal and stimulated sex steroid levels in serum 
Thusfar, the levels of oestradiol and testosterone in the diagnosis of precocious puberty can 
not be regarded as essential, although they can be indicative in the diagnosis of pseudo-
precocious puberty. The levels can be used for the follow-up of treatment of precocious 
puberty. In stimulation tests no reference values for the sex steroids are available. In a GnRH 
agonist stimulation test clinically relevant oestradiol levels were found in absence of 
'pubertal' LH responses (148). The time interval between the stimulUS and production of 
ovarian oestradiol is probably between 6 and 9 hours, due to the time required for 
aromatization (149). 
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4. TREATMENT 
4.1 Treatment options 
4.1.1 Agonists of GnRH 
Currently, potent agonists of GnRH are the treatment of choice in central precocious puberty. 
The publication of Belchetz et al. in 1978 showed that intermittent administration of potent 
GnRH agonists initially stimulated but subsequently inhibited LH and FSH release (150). 
This led to the development of several GnRH agonists with addition of an aminoacid at 
position 6 or replacement of the Gly-NH, terminal group by N-EtNH, (151). GnRH agonists 
are widely used in reproductive medicine to achieve ovarian suppression before stimulation 
with exogenous gonadotrophins (152, 153). In 1981 the use of a daily administered GnRH 
analogue was reported in children with precocious puberty (154). 
To improve Ihe suppressing capacity of GnRH agonists slow-release depot 
preparations were developed (155-159). These preparations were shown to suppress 
pubertal activity better then short-acting preparations (160). An extensive review on GnRH 
agonists in paediatrics is given by Lahlou et al. (161). 
In the Netherlands triptorelin and leuprolide-acetate depot preparations are available 
as monthly injections with 3.75 mg to be given each 28 days. A depot with leuprolide-acetate 
11.25 mg for injections once in 3 months has been introduced in patients with prostate 
carcinoma (162, 163). The use of this preparation in children with CPP is still under 
investigation. In the United States a 7.5 mg preparation is commonly used as 1M injection 
every 28 days. 
Recently, the use of GnRHa for delay of pubertal development in a transsexual 
adolescent has been reported (164). 
4.1.2 Acute and long-term side effects of GnRHa 
During treatment with depot GnRHa several minor side effects were reported. Most common 
is the occurence of local reactions during leuprolide acetate treatment (165-167). Other 
reports with only very small numbers of patients included hair loss (168), prolonged vaginal 
bleeding (169) and hyperprolactinaemia (170). 
After long-term use of GnRH agonist resumption of the activity of the reproductive 
axis was reported (171-173) with normal pregnancies (171, 174). The mean period beween 
discontinuation of treatment and menarche is about 12 months (174-176). No changes in 
pituitary size or shape during GnRHa treatment in girls with precocious puberty were 
observed (177). 
4.1.3 Antagonist of GnRH 
Antagonists of GnRH competitively bind to the pituitary GnRH receptors and block the 
receptors immediately. They do not induce gonadotropin release (178). These antagonists 
are currently used in reproductive medicine, as they prevent the occurence of an premature 
LH surge (179). Theoretlcally, they could be used for pubertal suppression in precocious 
puberty, but thusfar no publications have been describing this application. Further they can 
be used for androgen blockade in prostate cancer (180). 
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4.1.4 Aromatase inhibitors 
Recently, aromatase inhibitors were introduced in the hormonal therapy of breast cancer as 
treatment of advanced breast cancer after tamoxifen treatment or after failure of other 
hormonal therapies in postmenopausal women (181, 182). These drugs inhibit the 
conversion of androstenedione into oestrone and of testosterone into oestradiol. So, 
theoretically, they could be used in precocious puberty in order to inhibit the oestrogen driven 
effects of early puberty on skeletal maturation. The manufacturer reports that exemestane 
did not affect cortisol or aldosterone secretion at baseline or after ACTH stimulation (183). An 
advantage of this method of hormonal therapy is the oral route of administration. No data on 
the use in paediatric patients is available. 
4.2 Evaluation of the effect of treatment 
4.2.1 Physical examination and BA assessment 
During treatment with GnRHa the physical signs of puberty will be arrested or even regress. 
No increase in Tanner breast stage stage should be observed, and testicular volume should 
halt or regress during treatment. During treatment height velocity (HV) should not exceed 
prepubertal limits. 
In precocious puberty the ratio f1BAff1CA is > 1. During treatment a decrease to 
values < 1 should be obtained. In practice, the ratio 8BAf8CA in the first 6 months of 
treatment is often> 1 even in case of effective suppression (see chapter 4). Probably, the 
actual BA is the calcified representation of growth plate physiology of approximately 6 
months before. 
4.2.2 Biochemical methods 
During treatment, the levels of gonadotrophins and sex steroids are regularly measured at 
the end of the injection intervaL Most often a GnRH stimulation test is used in which a 
prepubertal response is expected after the stimulus. Values of sex steroids have to be at 
castration levels. The use of GnRHa testing during treatment might be useful (184). 
4.2.3 Adaptation of treatment 
In case of evidence of ineffective suppression the injection method and frequency should be 
checked. When these show no problems, the interval between 2 injections could be 
shortened to 3 weeks or the dose might be doubled to 7.5 mg each month. This is the 
commonly applied dose in the United States. 
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4.2.4 Rationale for addition of GH during GnRHa treatment. 
During treatment with GnRH agonists it is frequently observed that height velocity decreases, 
even below normal prepubertal levels (185,186). The effects of GnRHa treatment on the GH 
axis, both on GH secretion and IGF-1 levels remain controversial as reviewed by Walvoord 
(187). However, the reports on alterations in the GH axis in children with low growth 
velocities during GnRHa treatment have led to the hypothesis of a functional GH deficiency. 
4.3 Results of treatment 
4.3.1 Parameters of effect 
In the evaluation of the effect of treatment for precocious puberty several methodological 
issues arise. First, the issue of bone age assessment and the method of prediction; can they 
be applied as in healthy children in which the standards were developed? Second, what is 
the best marker for effect: is it the difference between initial height prediction and attained 
final height, the difference between FH and TH, or FH itself? Third, how can predictive 
factors for effect of treatment be assessed in view of the obvious interdependence between 
BA and height prediction? 
As a rule of thumb: in randomised studies with FH data both the difference between 
FH and initial prediction and the difference between FH and TH should be presented. When 
FH is not yet reached, the best option is to compare initial prediction with height prediction 
after discontinuation of treatment. In the latter situation one should take into account that FH 
will be lower than PAH at discontinuation of treatment ((105, 18B). Table 3 summarises 
possible effect parameters in the evaluation of GnRHa treatment. 
Table 3: Parameters of effect in the evaluation of GnRHa treatment 
Parameter of effect Comment 
FH To be used in comparative studies with untreated controls or 
differently treated patients; provided comparable baseline parameters 
FH-TH For comparison with parental growth potential; provided healthy 
parents without growth disorder 
FH-PAH start For comparison within the patients; provided the best prediction 
method is used and BA assessments performed by 1 observer 
PAHstop - PAH start For estimation of effect in case no FH is attained and no untreated 
control group is available 
4.3.2 Results of GnRHa treatment 
In the last few years several reports on the effects of GnRHa treatment have been published, 
Only the reports on FH in girls with CPP will be summarised in table 4. 
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Table 4: Results of GnRHa treatment in girls with CPP at final height 
1st author Number of Treatment duration FH - PAHstart (em) Ref 
girls Iyr) 
Arrigo 71 4.0 2.9 1(189) 
Carel 58 3.7 4.8 (176) 
Heger 50 4.4 5.9 ' (174) 
Oostdijk 31 3.4 3.4 (105) 
Galluzzi 22 4.0 3.2 (190) 
Bertelloni 14 3.9 4.6 (191 ) 
Kauli 8 2.4 5.8 116) 
4.3.3 Results of GnRHa treatment in combination with growth hormone (GH) 
The combination of GnRHa and GH was studied in several patient groups. Thus far, only a 
few studies have reported FH results (219). 
In adopted children, Tuvemo et al. showed that the combination of GnRHa and GH 
results in an increase in height velocity. After 2 years of treatment the increase in prediction 
of adult height is + 1.8 cm in the combination group and - 0.9 cm in the group with GnRHa 
alone (192). We report the results of a study in adopted children in chapter 6. 
In children with precocious puberty and low HV short term results show that HV 
increases and that PAH increases (185, 193). 
The application of GnRHa and GH in short girls or girls with idiopathic short stature 
with normally timed or early puberty was reported to result in a final height not different from 
controls (194) or from initial prediction (195). In contrast, Pasquino et al. reported a mean 
height gain at FH of 10 em (SD: 2.9), compared to 6.1 (4.4) em in a control group with GH 
alone (196). Short-term studies (treatment period 1 to 2 years) report that the PAH increases 
during combined treatment (197, 198). In chapter 7 a Dutch study with untreated controls is 
described. 
4.3.4 Effects on body composiUon, body proportions and reproductive function 
Many clinicians report their clinical impression that children become fat during GnRHa 
treatment. Measured by Dual Energy X-ray Absorptiometry (DEXA) fat mass-SDS and 
percentage fat 8DS increased during GnRHa treatment (199). Heger et al. found that obesity 
is a common problem in children with CPP already at start of treatment, but that GnRHa 
treatment does not aggravate this (174). The assessment of a pre-treatment Body Mass 
Index (BMI) can predict the development of obesity during GnRHa treatment, but the 
development of obesity appears to be unrelated to GnRHa treatment (200). 
27 
General introduction 
The treatment with GnRHa theoretically results in a decrease in bone mineral density (BMD) 
as a result of sex steroid depletion. The studies addressing this issue report either a 
decrease in BMD (201, 202) or, when expressed in comparison to healthy controls, normal 
BMD for chronological age, but [ow BMD for bone age after 2 years of treatment (199). At 
final height Heger et al. found a normal BMD for age in women after GnRHa treatment (174). 
In male patients at FH bone mineral density was normal too (203). 
CPP may lead to relatively short limbs compared to trunk length. After GnRHa 
treatment an improvement of body proportions was described at FH (174). 
Only few data is available on reproductive function or fecundity in women who had 
received GnRHa treatment for precocious puberty. After treatment the reversibility of gonadal 
suppression is demonstrated by spontaneous menses after about one year after 
discontinuation of treatment (105, 171, 173, 176, 204). Normal pregnancies have been 
described (171, 174). 
The PCO-syndrome is one of the forms of ovarian hyperandrogenism. In premature 
adrenarche the development of functional ovarian hyperandrogenism (clinical signs of 
androgen excess, and elevated ovarian 17 - hydroxy-progesterone (17-0HP) response after 
GnRHa stimulation) is frequently seen (205). The combination of hyperandrogenism and 
insulin resistance in this condition might be caused by a gain-of-function mutation of a single 
kinase causing hyperphosphorylation of the insulin receptor and of P450c17 causing 
hyperinsulinism and hyperandrogenism, respectively (206), In precocious puberty with 
GnRHa treatment ovarian ultrasound data demonstrated polycystic ovaries (PCO) in varying 
percentages (summarised in reference (174». In summary, PCO may occur in increased 
percentage after GnRHa treatment, but a clinical development of PCO-syndrome has not 
been demonstrated thus far. In this context, it has to be considered whether the right 
diagnosis of CPP was made at start of GnRHa treatment or that a premature adrenarche 
should have been diagnosed. Premature adrenarche is associated with PCO (207). 
5. PSYCHOLOGICAL ASPECTS OF CPP AND ITS TREATMENT 
It is known from an earlier report that, using the Child Behaviour Checklist (CBCl), early or 
precocious puberty leads to elevated scores on the internalising syndrome (withdrawal and 
anxious Idepressed) up to 2 years after start of treatment (208). Furthermore, it was reported 
that precocious puberty in girls is associated with a long-term risk of minor psychopathology 
(209-211). With respect to psychosexual development, early pubertal development was 
associated with earlier, but not extremely advanced psychosexual development (209, 210) 
During treatment with GnRH agonist problematic behaviour and functioning decreased slightly, 
particularly in the girls showing regression of breast development. In another study, perceived 
self-esteem was within the normal limits, but anxiety levels were increased (212). 
The delay between start of pubertal development and start of treatment may be 
lengthened as a result of a cultural taboo on sexuality and pubertal development (208). The 
initial totallQ score in CPP patients is not different from normal (208), although an effect of sex 
steroids on brain development, especially the [eft hemisphere is suggested, resulting in a 
higher verbal [Q score (213). 
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In a recent publication a relation between earlier menarche and later onset of schizofrenia -
only in girls~ was described. The authors speculate on oestrogen's protection against nerve cell 
loss and the preservation of neuronal connectivity (214). A glutamate dysfunction in 
schizophrenia is suggested with a rote of the NMDA glutamate receptor (215, 216). Whether 
this implies a dual involvement of NMDA receptor or an association of the onset of puberty 
with schizophrenia remains to be elucidated. 
6. ETHICAL ASPECTS 
The treatment of short children with growth hormone has long been restricted to clearly 
defined groups, for example those with GH deficiency. However, the wide availability of 
recombinant GH has widened the administration to many groups of children with any growth 
disorder without GH deficiency. As long~term results of GH treatment become available, 
questions arise whether we should treat "all" short children (217). There is no clear picture on 
the psycho~social effects of GH treatment in short children, and the lack of validated 
instruments to estimate the burden of short stature or the improvement of a variety of 
psycho~social indicators inhibits proper research in this field. 
[n adopted children growth promoting treatment either by GH or GnRHa was disputed 
specifically, as it was felt that early puberty was 'normal' for adopted children and that it was 
unethical to try to make adopted children as tall as their non-adopted peers (218). 
7. STRUCTURE AND SCOPE OF THE THESIS 
The thesis is divided into 5 parts, addressing a wide spectrum of questions with regard to the 
treatment of adopted and non*adopted children with early or precocious puberty. 
The auxology is presented in chapters 1 to 8 and contains effects of treatments with 
GnRHa with or without GH, short*term results and evaluation of GnRHa treatment, diagnostic 
aspects and final height data after GnRHa treatment. 
Psychological aspects and motivation for treatment were studied in adopted chidren 
treated with GnRHa alone or in combination with GH. The results of these studies are 
reported in chapters 6.2. and 6.3. 
Ethical aspects of growth promoting and puberty delaying treatment come up for 
disussion in chapter 9. 
In the final part of the thesis (chapter 10)' the results will be summarised and 
discussed, and recommendations for future research and clinical work will be provided. 
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ABSTRACT 
We investigated pubertal development of 3909 boys and 3454 girls :>. 9 years of age 
participating in a cross-sectional nation-wide survey in the Netherlands and compared the 
results to those of two previous surveys using similar methodology. 
Reference curves for all pubertal stages were constructed. The 50th percentile of Tanner 
breast stage 2 was 10.7 years, and 50% of the boys had reached a testicular volume of 4 ml 
at 11.5 years of age. Median age at menarche was 13.15 years. 
The median age at which the various stages of pubertal development were observed has 
stabilised since 1980. The increase of the age at stage G2 between 1965 and 1997 is 
probably due to different interpretations of its definition. The age limits for the definition of 
precocious puberty that are currently in use (8 years for girls and 9 years for boys), are close 
to the 3rd percentile of these references. 
A high agreement was found between the pubic hair stages and stages of pubertal (genital 
and breast) development, but slightly more in boys than in girls. In 11.3% of the girls in stage 
81 pubic hair was present. In 10.2% of the boys in stage G1 pubic hair was observed. 
Menarcheal age was dependent on height, weight and 8MI. At a given age tall or heavy girls 
have a higher probability to have menarche compared to short or thin girls. A body weight 
exceeding 60 kg (+1 SDS), or a 8MI of> 20 (+1 SDS) does not further increase the chance 
to have menarche, while for height such ceiling effect was not observed. 
In conclusion, in The Netherlands the age at onset of puberty or menarche has stabilised 
since 1980. Height, weight and 8M! have a strong influence on the chance of menarche. 
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INTRODUCTION 
The development and first appearance of secondary sexual characteristics can be regarded 
as reflection of the overall physiological development in adolescence (1). The subdivision of 
the continuous process of pubertal development into discrete numerical stages, as proposed 
by Marshall and Tanner (2, 3), has been widely used and serves to label the phases of 
various elements of pubertal development more or less objectively. 
However, the assessment of pubertal stages in the individual child or adolescent in 
the clinic is only useful if reliable reference data from the same population is available for 
comparison. In many European countries a positive secular trend with regard to height has 
been accompanied by a decrease of the age at onset of puberty (1, 4, 5). This would imply 
that the definition of precocious and delayed puberty should change over time. In fact, in the 
United States it was recently proposed to revise the guidelines for the evaluation of girls with 
precocious puberty (6, 7). 
8esides clinical reasons, there are also scientific reasons to study pubertal 
development in a large population-based sample of healthy children and adolescents. First, it 
is unclear if the secular trend with regard to body stature is invariably associated with a trend 
towards earlier pubertal development. Second, there is little data on the association between 
the markers of the maturation process of the hypothalamo-pituitary-gonadal axis (breast 
development in girls and genital stage in boys) and pubic hair as a marker of adrenarche in 
the female (pubic hair) and of the combination of adrenarche and genital development in the 
male. While gonadal development and adrenarche usually occur in the same age period, the 
endocrine regulation of these processes is different (2, 8). 8ased on this background, one 
would hypothesise that the agreement between gonadal (G- or 8-stage) and pubic hair 
development (P-stage) should be higher in boys than in girls. Third, there are observations 
suggesting that pubertal development is influenced by anthropometric variables, particularly 
body weight (9, 10), but the exact nature of the correlation is unknown. 
In the Netherlands four consecutive growth studies have been performed since 1955 
(1,11-13). These studies provide the opportunity to thoroughly study the secular changes in 
height, weight and pubertal development. In two earlier papers on the study performed in 
1997 we concentrated on the secular trend of body stature, weight and body mass index 
(8MI) and only shortly discussed pubertal development (13,14). 
In this paper we present the reference data in more detail, as well as a comparison 
with the previous growth studies. Furthermore, we investigated the degree of concurrence of 
breast or genital stages with pubic hair stages and the relationship between the age at 
menarche and height, weight and 8Mf. 
PATIENTS AND METHODS 
In a cross-sectional design the presence of secondary sexual characteristics was studied. All 
participants of the 1997 nation-wide growth study aged.::: 9 years completed a questionnaire 
on demographic variables (3909 boys and 3454 girls). This sample can be regarded as 
representative for the general population. In a subgroup ('puberty sample') we determined 
the stage of sexual maturation and age at menarche. The age distribution in the puberty 
sample showed an overrepresentation of children < 15 years of age (around 250 in each age 
group) compared to children> 15 years (100 -150 per each group) (see Table 1). 
In the analyses in this article age was used as covariate, so this skewed age 
distribution will not affect the results. The composition of the puberty sample was comparable 
with the sample of a national survey with regard to region and level of education. 
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Table 1: Puberty sample characteristics, 3909 boys and 3454 girls 
Age (yrs) PH boys G boys TV boys PH girls B girls Men 
9·12 73.2% 72.9% 66.5% 78.1% 80.5% 85.6% 
12·15 54.4% 54.3% 51.3% 57.4% 58.5% 76.9% 
15·18 49.9% 49.9% 47.6% 51.1% 52.1% 74.8% 
18·21 42.5% 42.4% 40.4% 33.6% 33.9% 83.8% 
.. Partlclpatmg boys or gIrls per age group as percentage of age group m the national survey. PH: pubIC 
hair; G: genital stage; TV: testicular volume; B: breast slage; Men: menarche 
The measurements of height and weight were performed by trained staff. The pubertal 
stages were determined by visual inspection, using Tanner's criteria (15). In boys testicular 
volume was assessed using an orchidometer. To validate the accuracy of the measurement 
of testicular volume, the testicular volumes in 79 boys were measured by 2 observers. The 
Spearman correlation coefficient between the measurements of 2 observers was 0.82; the 95 
% confidence interval for the difference between observers appeared to be 0.4 - 2.0 ml (1.2 
± 0.8). In midpuberty the interobserver differences were highest. Zachman and Prader 
reported a correlation coefficient of 0.83 and a mean difference in testicular volume between 
2 observers of 2.9 ml (16). The age at menarche was determined by the status quo method, 
asking a girl whether she had had her first period at the moment of the survey. 
Demographic variables were assessed by a questionnaire. The highest level of 
completed education of the parents was used as a measure for socia-economic status. The 
country was divided in 5 geographical regions, one of them containing the 4 largest cities 
(13). 
STATISTICAL METHODS 
For menarche and stages of secondary sexual characteristics the reference curves were 
estimated by a generalised additive logistic model for each stage transition separately (17). 
This model describes the probability of each stage as a smooth function of age. The amount 
of smoothing was determined by cross-validation. LMS reference curves were derived for 
testicular volumes, where the measured volumes were considered as a continuous measure 
(18). To compare B or G stages and pubic hair stages in girls and boys we calculated kappa 
(K) as measure of agreement (19). 
RESULTS 
1. Reference curves for pubertal stages and testicular volume 
In figures 1 a-f we present the reference curves for sexual development. The dotted lines 
represent the crude data. The 50th percentile ages can be read from the figures. The 10th 
and 90th percentile ages, that were published earlier as numerical data (13), can also be 
read from these graphics being the ages at which the curves cross the 10th and 90th 
percentile respectively. 
Figure 1 also shows the intervals between the consecutive pubertal stages, with a 
general pattern of a shorter interval between the third and fourth stage compared to the 
interval between stage 2 and 3. In figure 1-g reference curves are presented for various 
testicular volumes. 
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The P3 for B2 and G2 were 8,2 and 9,8 years respectively, the PS7 values were 12.7 and 13.4 
years respectively 
2. Comparison with the 1965 and 1980 growth studies 
In figure 2 a-d we show comparisons between the timing of pubertal stages in this and the 
previous growth studies from 1965 and 1980. The Pso values are shown for both boys and 
girls. For all stages a decreasing trend is seen between 1965 and 1980 with a stablilsation 
afterwards, In contrast, G2 in boys increased from 11 years in 1965 to 11.5 years in 1997, 
whereas the P50 01 a testicular volume 01 4 ml decreased from 12.0 years in 1965 to 11.5 
years in 1997. In all studies the SO of the Poo ages is approximately 1. 
3. Relationship between pubertal stages 
In tables 2a and 2b the relationships between the P stage on the one hand and 8 or G 
stages on the other hand are shown in absolute numbers. In girls in 81 60/531 (11.3%) 
showed pubic hair development, while from the girls in P1 23.3% showed breast 
development. In boys, G1 was accompanied by the presence of pubic hair in 10,2%; boys in 
P1 had genital development in 24.9%. 
Table 2a: Distribution of Band P stages in girls 
N=2213 81 82 83 84 85 Total 
P1 471 124 19 -- -- 614 
P2 55 138 50 3 1 247 
P3 5 50 118 36 6 215 
P4 -- 4 58 186 71 319 
P5 -- -- 17 156 495 668 
P6 -- -- 5 23 122 150 
Total 531 316 267 404 695 2213 
kappa = 0.59 (p<0.001) 
Table 2b: Distribution of G and P stages in boys 
N-2360 G1 G2 G3 G4 G5 Total 
P1 529 151 21 2 l' 704 
P2 59 222 53 4 -- 338 
P3 1 47 124 20 1 193 
P4 -- 2 56 178 32 268 
P5 -- 1 10 130 387 528 
P6 -- -- 1 15 313 329 
Total 589 423 265 349 734 2360 
kappa= 0.63 (p<O.001); • thiS boy was 17,1 years old, testicular volume 20 ml 
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The agreement betvveen P and 8 or G stage was expressed as kappa (K) and Spearman 
correlation. The K'S were 0.59 and 0.63 for girls and boys respectively indicating moderate to 
substantial agreement. The difference between the 2 K'S was significant (p<0.05). Spearman 
rank-order correlation was 0.91 both in boys and girls (p < 0.001). 
Thus, in line with our hypothesis, in boys the gonadal and pubic hair development 
show a closer mutual agreement than in girls, although the difference in kappa is only small. 
4. Menarcheal age in relation to auxological variables 
In figure 3 a-f the probability to have menarche is depicted as function of age (X-axis) and 
weight, weight SOS, height, height SOS, BMI and BMI-SOS respectively (plotted on the y-
axis). 
All figures show the expected increase in probability of menarche with increasing age 
and the additional effect of weight, height and SOS (expressed as nominal values or as 
SOS). They demonstrate that at a given age the heavier and taller girls have a higher 
probability to have menarche. However, the shape of the probability curves is different for the 
indices of weight (Le. weight and BMI) and height. When weight or BMI exceeds a certain 
point, no or just a slight further increase in probability is observed anymore, as the curves 
have an almost vertical course from there. For weight this point is close to 62 kg (1 SOS), 
and for BMI it is approximately 20 kglm' or 1 SOS. 
In contrast, the figures on height show a continuing effect of height at a certain age. 
Some examples of the different ages at which there is 50 % probability to have menarche 
with various SO scores for weight, height or 8MI are shown in table 3. 
Table 3: Influence of different SO scores on the P50 age of chance of menarche 
SO score Age P" (vr)' 
Weight +2 12,1 
+1 12.7 
0 13.2 
-1 13.8 
-2 14.5 
Height +2 12.2 
+1 12.8 
0 13.3 
-1 13.7 
-2 14.0 
BMI +2 12.7 
+1 12.7 
0 13.1 
-1 13.8 
-2 14.7 
* estimated form the curves In fig 3b, d and f 
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DISCUSSION 
This study provides up-to-date references for pubertal stages in the Dutch population, which 
can be used for clinical purposes. [n the interpretation of the reference curves for the 
consecutive pubertal stages, one should be aware, however, that our data is derived from a 
cross-sectional study. The reliability of the data is high, due to the relatively large numbers of 
subjects. On the other hand no information is available about the tempo at which a child 
passes through the consecutive stages. Such information can only be obtained by a 
longitudinal study, like the longitudinal assessment of puberty in boys and girls performed by 
Marshall and Tanner (2, 3). [n general, reference centiles based on cross-sectional data 
have a larger variance than those based on longitudinal data, For pubertal development 
curves, this implies that the progression of stages for individuals is generally faster than the 
intervals between P50-stages obtained from cross-sectional references. 
The second finding is that the positive secular change towards an earlier 
development of puberty between 1965 and 1980 has almost stabilised thereafter. Over the 
whole period between 1965 and 1997 the P50 age of onset of puberty (stage 82) in girls 
decreased from 11.0 years in 1965 to 10,7 years in this study. The median age at menarche 
decreased by 0.25 yrs in the same period, and by 0,5 years from 1955. In the last 17 years 
only a small decrease of about 1.5 months from 13.28 to 13.15 years was observed. A 
similar pattern of an apparent stabilisation of a previously decreasing trend was observed in 
Oslo schoolgirls, where menarcheal age has reached a stable level for several decades (20). 
However, in Norway the secular trend in body stature appears to have stopped as well (20), 
Maybe the stabilisation reflects a situation in which the environmental conditions have 
allowed the child to reach the optimal genetiC potential given the actual environmental 
conditions (4). 
The only exception to this trend of a slow positive secular trend between 1965 and 
1980 followed by near stabilisation is the apparent increase of the median age at which boys 
reach G2 from 11.0 years in 1965 to around 11.5 years in 1997. This finding contrasts with a 
decrease of the median age at attaining a testicular volume of 4 m[ from 12.0 years in 1965 
to 11,5 years in 1997.The best way to control for the reliability of the observation of the 
increase in age at G2 would be to compare it with testicular development in the consecutive 
growth studies, However, testicular volume was not assessed in 1980. 
The most likely explanation of this discrepancy is that the interpretation of the 
definition of stage G2 must have been different in 1965 in comparison to 1980 (1, 21) and 
1997. In fact, the original definition of G2 as proposed by Marshall and Tanner (3) [eaves 
much room for confusion, as it states that "The scrotum and testes have enlarged and there 
is a change in the texture of the scrotal skin. There is also some reddening of the scrotal skin 
.... " This description is not pertinent about the question which of the three criteria mentioned 
is most relevant, and about whether all criteria have to be met or at least one or two of them, 
In addition, it does not strictly describe the minimum volume that the testis should have 
before the genital stage may be labelled as G2. For example, there are good arguments that 
a testicular volume of 3 ml can already be considered as a sign of puberty (16, 22). In the 
present study the observers were taught to describe the genital stage as G2 if both 
enlargement of testicular volume and scrotum was observed and reddening of the scrotal 
skin was present. It appears likely that in 1965 the observers might have labelled the genital 
stage as G2 if at least one of the three criteria was present. 
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Based on these findings, but also on our experience in clinical trials (23), we believe that it is 
opportune to come to a redefinition of stage G2, to prevent more confusion in the future. We 
would prefer that the testicular volume, the criterion that is most easily measured, should be 
used as the only criterion. Furthermore, a volume of 3 ml appears a better indication of the 
onset of puberty than 4 ml (22, 24). 
Uttle data is available on the accordance between P and G or M stages during 
puberty. Based on the theoretical view that for girls breast development is the initial event in 
pubertal development and testicular development for boys , these parameters should be 
used as markers in clinical practice. In girls P stage is a reflection of adrenal maturation and 
in boys of a combined adrenal and testicular maturation, so that a higher agreement would 
be expected in boys than in girls. In fact, we found a higher agreement between P and G or 
B stage (expressed as kappa) in boys than in girls, but both were significant. This suggests 
that pubertal development and pubic hair development frequently synchronise. With regard 
to the timing of both phenomena, we found that in general breast development starts 
somewhat earlier than pubic hair, in line with the findings of Marshall. However, pubic hair 
was seen before breast development in about a third of all girls in the English study (2), and 
in about 10 % in our study. In stages B3 and G3 the distribution of P stages is equally divided 
and in the higher B or G stages the P scores tend to shift to the right, especially in boys, with 
higher P than G or M stage. 
The definition of precocious puberty and delayed puberty should be based on the 
normal occurrence of secondary sexual characteristics in the population, but there is no 
consensus whether -2 SOS or -2.5 SOS should be used as a cut-off. We chose to use the 
usual cut-off measure of -2 SO, which is dose to the 3rd percentile, which can be read from 
the reference curves in figure 1. 
The third percentile age for 82 (8.2 years) is close to the age of 8.0 years which is 
generally and internationally used as age limit for the definition of precocious puberty, and 
we would therefore propose to continue using this figure. For boys the P3 of G2 stage is 9.8 
years, whereas no reliable P3 data for testicular volume of 4 ml can be presented. Thus, the 
current cut-off ages for precocious puberty, i.e. 8 years for girls and 9 years for boys, can be 
maintained in our country. 
For delayed puberty, the P97 for 82 and G2 presented in the results section, as well 
as the P97 age for testicular volume of 4 ml (13.8 years), point to a cut-off age for delayed 
puberty of 13 years in girls and 14 years in boys. 
As mentioned before, in the United States a decrease in the age at onset of puberty 
in girls was observed (6). However, in that study the sample was not representative for the 
general population, as the girls were examined when they visited a general practitioner. The 
girls were heavier and taller than in the national American growth survey, and in 15% of the 
girls rated B2 by visual inspection no breast tissue was found at palpation (7). 
We have shown that, besides age, weight, height and BMI influence the chance of 
having menarche in the age range 11-15 years as weI!. Interestingly, the probability lines for 
weight and BMI show a vertical pattern in the range where the SOS exceeds approximately 
1. Beyond such degree of (over)weight, weight or BMI does not affect the probability of 
having menarche anymore. The cut-off [evel for 8MI data is consistent with the results 
published in our earlier report, showing that premenarcheal girls in all age ranges had mean 
BMI < 20 kglm' (14). Our data are in contrast to those of Marshall, who stated that the 
occurrence of menarche was not related to the attainment of a particular height, weight or 
body composition, but mostly occurred after the peak of the adolescent growth spurt (8). 
However, the limited number of subjects in that study may have precluded the appearance of 
statistical significance in this respect. An interesting phenomenon is that height in contrast to 
weight and BMI, exerts its influence on the probability of menarche over the full range. 
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It is generally assumed that the increase in socio~economic conditions and general health is 
the main contributing factor for the trend towards earlier maturation (4, 25, 26). In most 
industrialised countries the increase in public health and socia-economic conditions was 
accompanied by an increase in adult height and a decreasing age at attainment of pubertal 
events (27). The mechanisms through which these changes occur are unknown. On the 
physiological substrate for earlier pubertal development several hypotheses were discussed, 
for example the so-called critical weight hypothesis (9, 28). Recent studies on leptin have 
suggested that this protein could act as a link between fat tissue and the central activation of 
the hypothalamus (29~31). Another line of research concerns the possible influences of 
estrogen-like substances in the environment on the timing of puberty, for example phyto~ 
estrogens present in soy-based feeding (32). However, no human data is available that show 
an influence of infant feeding, containing phytoestrogens, on sexual maturation (33). The 
stabilisation of the age at onset of puberty in a period where an increasing exposure to 
estrogen~like substances can be assumed, argues against a causal link. 
We conclude that the secular change towards earlier puberty has been stabilised in 
the last 2 decades in The Netherlands. No change in the definition of precocious puberty is 
warranted. The occurrence of menarche is not only dependent on age, but also on height, 
weight and 8M!. 8eyond a weight or 8MI of +1.0 SOS this dependency disappears. The 
agreement between the expression of gonadal maturation and pubic hair is slightly higher in 
boys than in girls. 
Acknowledgement: The contribution of Inge Everhardus, studying the observer 
characteristics for testicular volumes, is greatly acknowledged. 
Figure 1 :(pages 50 - 56): Reference curves for secondary sexual characteristics in The 
Netherlands 1997. a: breast stage in girls; b: pubic hair stage in girls; c: menarche; d: 
genital stage in boys; e: pubic hair stage in boys; f: mean testicular volume; g: specific 
testicular volumes in early and mid puberty. 
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Figure 2: (nextlwo pages): Sexual maturation in The Netherlands 1965 - 1997"; the P50 
values of the different pubertal stages are given. 
A: breast stage and menarche; b: pubic hair stage in girls; c: genital stage in boys and 
testicular volume 4 mf; d: pubic hair stage in boys. ('" refer 1 and 12 and data from this study) 
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(Previous page): Figure 3: Probability on having menarche as a function of age and weight 
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ABSTRACT 
The secular changes in growth and maturation can be seen as indicators of socia economic 
and health status. In most European countries the age at onset of puberty and menarcheal 
age is still decreasing in the last decades. The duration of puberty seems to decrease as well 
although only few studies have sufficient data. The four Dutch nation-wide growth surveys 
are useful examples assessing the secular trend in pubertal development over the last 45 
years. Genetic and environmental factors contribute to the secular changes. Environmental 
factors seem to be the most important ones. Recently, attention has been given to 
substances with oestrogen-like actions, present in nutrients. The possible role of these 
substances is discussed in this review. 
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INTRODUCTION 
Secular changes in growth and development should be regarded as indicators of socio· 
economic and socio-hygienic condition and of the state of health of a population. The term 
"secular trend "is often used to describe a slowly continuing change in growth and 
development over successive generations living in the same territories. Since these changes 
can be positive, nil, or negative, the term' secular changes" is preferred (i), but both terms 
will be used interchangeable in this text. 
During the course of the past two centuries a striking increase of mean stature and an 
earlier sexual maturation has been observed in all countries in Europe (2). However, this did 
not occur in the same period in every European country. 80th genetic and environmental 
factors result in population differences. The same environmental factors will not affect all 
children in the same manner, as their genetic sensitivities will be different (3). These secular 
changes towards a taller stature, heavier weight, and earlier maturation are predominantly 
linked to improvements in nutrition and health (3). Therefore, growth of a population can be 
phrased as" a mirror of conditions in society" (4). However, secular changes may slow-down 
and may become reversed as well. Negative trends have been observed in periods of socio· 
economic problems, e.g. during World War II. Observations of no change in tempo of growth 
might be explained by cessation of improvement of environmental conditions or that these 
already allowed the genetic potential for growing to be fully expressed. 
In The Netherlands, in 1955, 1965, 1980, and recently in 1997, large cross·sectional 
nation·wide growth studies were performed (5·8). In these studies, next to growth data, 
reference curves for menarcheal age and the stages of secondary sex characteristics were 
estimated. In the next paragraphs we will compare these data with the secular changes in 
several European countries. Further, we will highlight potential mediators of the process of 
the secular trend. 
SECULAR TREND IN THE ONSET OF PUBERTY 
The onset of puberty is mediated by the increase in pulsatile LH release by the pituitary, 
resulting in the production of male or female sex steroids that initiate the secondary sexual 
characteristics. There are many hypotheses regarding the primary event that causes 
activation of the hypothalamic GnRH pulse generator. An interesting hypothesis is that leptin, 
produced by human adipocytes interacts via several neuropeptides as a permissive factor for 
the onset of puberty (9), thus connecting an aspect of body composition with the onset of 
puberty. 
During the middle ages in Europe pubertal onset occurred around the age of 14 and 
became delayed until a markedly older age (1710 18 years) jusl around Ihe lurn of Ihe 191h 
cenlury (10). In Ihe lasl cenlury Ihe onsel of puberty progressively shifted back lowards 
younger ages in several countries of Europe, with a levelling off in the last decades. Table 1 
shows a comparison of average ages at onset of puberty (breast stage 2 (82) in girls and 
genital stage 2 (G2) in boys according to Tanner(11)} in various European studies. 
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Table 1: pubertal maturation in various European countries 
Country Girls Boys Reference 
. (Yr of study) 
B2 (yr) B5 (yr) B2-B5 (yr) G2 (yr) G5 (yr) G2-G5 (yr) 
Netherlands 
- 1965 11.0 15.2 4.2 11.0 15.85 4.9 6 
- 1980 10.54 14.21 3.7 11.33 15.33 4.0 7 
- 1997 10.72 14.34 3.6 11.45 15.30 3.8 8 
Sweden 
- 1970 11.0 15.6 4.6 12.2 15.1 2.9 derived from:12 
-
1980 10.8 14.8 4.0 11.6 15.1 3.5 12 
England 
- 1960 11.2 15.3 4.1 11.6 14.9 3.3 derived from: 12 
- 1975 10.8 14.0 3.2 - - - derived from: 12 
Switserland 
- 1970 10.9 14.0 3.1 11.2 14.7 3.5 derived from: 12 
In The Netherlands, comparison of the results of the fourth nation wide growth study with 
those of the three previous studies shows that the mean height of Dutch children, 
adolescents, and adults, in 1980 already among the world's tallest, has further increased 
during the past 17 years (8) (Table 2). 
Table 2 Final height, menarcheal age and change in menarcheal age per decade in Dutch 
girls 
.. . ... ...... . .......... 1955 .. 1965 1980 1997 ... ... 
Mean FH girls 163.0 166.3 168.3 170.6 
Menarche (yr) 13.75 13.40 13.28 13.15 
Observed shift per decade (yr) - - 0.35 -0.08 -0.08 
Usually, a positive secular growth change is accompanied by an advance of sexual 
maturation. However, in the Dutch boys the median age at G2 tended to increase during the 
past 30 years. In girls, the age of onset of puberty (age at B2) declined from 1955 to 1980, 
but tended to occur slightly later in the most recenl study (Table 1). Lindgren reported 
pubertal stages of Stockholm schoolchildren in 1980 and compared those with two earlier 
studies in the same area (table 1) (12). 
The girls of the 1980 study were somewhat earlier in breast and pubic hair 
development than the girls investigated in 1970 and 1975. The boys studied in 1980 entered 
G2 earlier than boys studied in 1970. Thus, in the last decades the tendency of an earlier 
start of puberty levelled off or came to a halt in some European countries. 
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SECULAR TREND IN TEMPO OF PUBERTY AND AGE OF MENARCHE 
Tempo of puberty 
The duration of puberty can be defined in several ways, for example as the interval between 
82 and menarche or 85 stage in girls and in boys between G2 and G5 stage. In this article 
we use the period between 82 and 85 for girls and for boys between G2 and G5. It should be 
noted that data from cross-sectional studies result in longer intervals than compared to data 
from longitudinal studies. From the different surveys it becomes clear that the secular trend 
towards earlier onset of puberty is accompanied by a decrease in duration of puberty. Not 
many studies do show all stages of sexual maturation from the onset of puberty to the last 
stage, thus we limited ourselves to studies providing complete data. In table 1 a summary of 
maturation data from 4 countries in the northern part of Europe is shown. 
From table 1 it can be concluded that there is a secular trend towards a higher tempo 
of sexual maturation in girls. In boys a similar trend can be assumed but only the Dutch data 
support the assumption. There is scarce data on pubertal development in boys due to lack of 
a marked indicator such as menarche is in girls. Only a few studies used spermarche as 
indicator for mate puberty (3). Some reports on peak height velocity (PHV) in boys are 
available but it is difficult to estimate these data from cross-sectional studies and a 
comparison to estimate a secular change can be assumed to be inaccurate (13). Factors that 
determine the tempo of puberty are not known. Clinical observations in children on growth 
hormone treatment and in several form of early pubertal development suggest a role of the 
GH-IGFaxis (14,15). 
A shorter dUration of puberty can, theoretically, cause less pubertal height gain, 
unless growth velocity is higher during that shorter period (16). The data on the secular 
increase in final height in the same periods as in which duration of puberty decreases, 
however, does show that either a higher stature at start of puberty or sufficient pubertal 
growth in a shorter period is obtained. It was reported that the largest part of the secular 
increase in adult height was established in childhood and due to increase in leg length (17) 
Methodological aspects of the assessment of age at menarche 
To compare the different studies on final height and age of menarche some methodological 
issues should be addressed. First the quality of the survey in terms of the composition of the 
study population, its representativeness for the whole population and a balanced distribution 
of all age groups (8). Then the assessment of the age of menarche. Several methods Can be 
used: one is the status quo method where it is asked whether or not the girl had had her first 
period. Another method is to ask at what age menarche occurred. The latter recall method 
was compared with the status quo method and resulted in comparable age at menarche (18). 
However, in most studies the status quo method is preferred as it was shown that the longer 
the recall period the more inaccurate the estimation of menarcheal age was (19). 
Changes in age of menarche 
Many studies address the age of menarche as a marker for the timing of puberty. It is well 
known and a world-wide phenomenon that there is a difference between urban and rural 
regions in menarcheal age, with the urban girls having their menarche earlier than rural girls 
(20, 21). In fig 1 a summary is shown of results from several growth studies providing data on 
menarcheal age over time. The largest decrease in the age of menarche was observed until 
the end of the seventies and early eighties. Thereafter, in some countries there is a 
continuous small decrease in the age at menarche (The Netherlands, Germany, Bulgary), 
while an increase in the age at menarche has been observed in Italy and Croatia. Age at 
menarche has not changed recently in Belgium and Norway (13). 
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The observation of a decreasing age of menarche should carefully be interpreted. It was 
shown that the decrease in number of late maturers was the most marked change observed 
(8, 13, 22). This phenomenon can contribute to a decrease in mean age and in the variability 
around the mean. One might speculate that the number of late maturers is a sensitive 
indicator of the effect of final changes in socia economic and health status. The cause of the 
reduction in number of late maturers can be the increasing awareness of delayed puberty 
and better treatment options available. 
Although the age at menarche is going down it seems that the size at menarche, 
based on body weight underwent only minor changes (23), This may lead to the hypothesis 
that the earlier occurrence of menarche is the result of the optimalisation of growth so that 
the minimal body size (needed for menarche) is achieved at an earlier age. This can explain 
why the decreasing age of menarche is not accompanied by a decrease in final height such 
as happens in case of precocious puberty (24) 
MEDIATORS IN SECULAR CHANGE IN TIMING AND PROGRESSION OF PUBERTY 
The age at onset of puberty and menarche is determined by genetic and environmental 
factors (25). The relative contribution of each of these is difficult to assess. Probably the 
secular trend towards earlier occurrence of pubertal onset and menarche is mainly due to 
environmental factors (26) such as increasing socia economic conditions, better health care 
and prevention (13), Because of improvement in general living conditions, favouring the 
lower social groups in particular, growth and maturation differences diminish between social 
groups (26), The effect of racial mixing might contribute to the secular changes as well (27), 
However, the phenotypic effect of heterosis (the increase in size, strenght, etc.often found in 
a hybrid as compared with inbred plants or animals) remains a controversial issue (3). 
Thereby, gene-environment interactions do occur. Modifications under the effect of external 
agents will especially become visible during periods of more intense change. In table 3 some 
factors that may contribute to secular change are summarised. 
Table 3 : Possible mediators explaining secular trend in timing and progression of puberty 
Genetic 
Migration 
Environmental 
Improvement of 
Growing urbanisation 
Reduction of family size 
Changes in nutrition 
Environmental pollutants (?) 
gene flows 
phenotypic effect of heterosis# 
socia-economic conditions 
hygienic conditions 
health service 
increased intake of animal proteins 
phyto- or xeno estrogen intake (?) 
# Heterosis: the increase in size, strenght, etc.often found in a hybrid as compared with inbred plants 
or animals (Webster's Dictionary) 
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The levelling off of the menarcheal age in some countries is either the effect of a ceasing 
improvement of environmental factors or of reaching the genetically determined limits of 
normality in menarcheal age (13). 
Nutritional differences between rural and urban populations still exist in some 
European countries with more vegetables and fruit, meat and milk-based products consumed 
in the urban areas (3). In The Netherlands, the general wealth of the population over the past 
42 years has increased considerably and at present virtually all children have easy access to 
food. With regard to the quality of food, a clear rise of consumption of animal protein and 
saturated fat was observed between 1936 and 1975 in The Netherlands and the present 
consumption of dairy products is one of the highest in the world (8). Recently, emphasis is 
placed on food-substances that have oestrogen related physiological effects such as phyto-
oestrogens and Hgnans. These substances act as either agonists or antagonists of 
oestrogens. They are found in vegetables, fruits, seeds, and grains and are substantial 
constituents of our daily food (28). Rat studies have shown that feeding lignan-rich food like 
flaxseed during pregnancy had dose dependent hormonal effects in the offspring such as an 
earlier age and lighter weight at puberty (29). Although it is often stated that soy-based 
formulae (containing relatively high isoflavonoid levels) do not alter the timing of puberty, 
there are in fact no studies of sexual maturation in relation to the type of infant feeding (30). 
In women intake of some phyto-estrogens was shown to be related to a reduction in breast 
cancer risk (31). 
Figure 1: Secular trend in menarcheal age. Data from Bodzsar & Susanne 1998 and 4 Dutch 
national growth surveys mentioned in the text. 
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On the other hand there is a theoretical, yet disputed, increase in breast cancer risk as an 
effect of an earlier start of oestrogen exposure in women with a history of early menarche 
(32, 33). However, no data is available about the net effect on breast cancer risk when 
women with early puberty would ingest more phyto-oestrogens.The early onset of puberty in 
many adopted children from developing countries to Europe (34, 35) raised the question 
whether exposure to low levels of oestrogenic chemicals in the environment, xeno estrogens, 
may lead to higher expression of oestrogen regulated genes in children that were used to 
vegetarian diets (Mengarda, unpublished data). A possible role of intra-uterine growth 
retardation can be hypothesised in these children as well (36). With regard to diet however, 
data from the literature suggest that the composition of the diet is a less important 
determinator of pubertal events than is the attainment of a certain body size or fat mass at 
which pubertal onset is permitted (37-39) 
Another potential explanation for the decreasing age of onset of puberty might be the 
increasing prevalence of obesity both in the United States and Europe which seems to be 
related to earlier onset of puberty, as the hypothesised minimal body mass is reached at an 
earlier chronological age (40-42). 
CONCLUDING REMARKS 
During the last century an earlier start of puberty has been observed in most European 
countries. In the last decades, however, this decrease slowed down or came to a halt as 
illustrated by the very recent data from The Netherlands (8)_ 
The shift towards a younger age has also been obselVed for age at menarche and 
still continues in several European countries, albeit at a slower rate. Occasionally, during 
periods of socia-economic instability age at menarche was found to have shifted towards a 
later time. From several reports it became clear that the more recent decline of menarcheal 
age resulted mostly from a reduced frequency of late maturers. 
Improved socio-economic conditions, improved health service and hygienic 
circumstances, changes in nutrition, and growing urbanisation are among the most important 
factors influencing these secular changes. The observation that the earlier maturation slowed 
down, stopped, or even reversed may indicate either that environmental conditions have 
ceased to improve, or that these have already allowed the full expression of genetic potential 
(13). 
The striking decrease in age at onset of puberty and menarcheal age as reported 
from the United States, especially in African-American girls (33) has not been found in 
Europe. The magnitude of the decrease is in part due to the comparison with old references 
from Marshall and Tanner. The possible influences of substances that have oestrogen-
related effects have been mentioned and require further study (33). 
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ABSTRACT 
To test the activity of the hypothalamo-piluitary-gonadal (HPG) axis in girls with clinical signs of 
puberty a stimulation test can be performed with native Gonadotropin Releasing Hormone 
(GnRH) or with GnRH agonists (GnRHa). It has been suggested that GnRHa testing with 
leuprolide acetate is a better tool than GnRH testing for the early diagnosis of pubertal 
disorders, We compared the response to native GnRH and GnRHa leuprolide acetate (0,5 mg. 
s,c.) in 65 girls with early or precocious puberty. The correlations betw"een the gonadotropin 
peak values in both tests were 0.87 for LH and 0.80 for FSH. Using a cut off level of 10 lUlL for 
a LH peak as indicative for HPG activation, significantly more girls in Tanner stage 2 could be 
diagnosed by the GnRHa stimulation test compared to the test with native GnRH. The mean 
LH/FSH ratio was Jess than 1.0 after the GnRHa stimulation in girls in Tanner stage 2 and we 
suggest that this ratio has limited value in the decision with regard to initiating therapy. We 
conclude that GnRHa stimulation with leuprolide acetate demonstrates HPG axis activation in 
an early phase and can replace the standard iv GnRH stimulation test. 
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INTRODUCTION 
Several strategies have been proposed to assess central activation of the pituitary in children 
with a history of pubertal development at a young age or in other disorders of puberty (1). 
Stimulation tests with Gonadotropin Releasing Hormone (GnRH) all use the increased 
reactivity of the pituitary to hypothalamic GnRH as indication of central puberty (2-4). The 
luteinizing hormone (LH) response to GnRH is biphasic: first there is depletion of stores of 
gonadotrophins in the pituitary, and secondly the newly synthesised pool is released (5). The 
LH response to intravenously administered native GnRH seems to represent the readily 
releasable pool of pituitary LH, while the newly synthesised pool of LH may cause the 
response to GnRH agonist (GnRHa) (6-8). To release LH and follicle stimulating hormone 
(FSH) sufficiently, pituitary maturation is required. Prior exposure to GnRH is necessary for 
sufficient amounts of quickly releasable LH. The other aspect of maturation is the ability of the 
cells to produce de novo gonadotropins (5). Agonists of GnRH are able to produce larger LH 
peaks in comparison to native GnRH (6, 7): in rats this peak is 50 - 100 times greater (8, 9). 
One might therefore expect that in children with recent onset of puberty GnRH agonists are 
more capable in demonstrating pituitary activation than native GnRH. This may allow a 
diagnosis of central precocious puberty (CPP) in an earlier phase. 
Ibanez el al. demonstrated that pubertal LH peaks (> 8 lUlL) afier GnRH agonist 
leuproJide acetate administration correlated with progression of puberty during a mean follow-
up period 01 12.9 months (6). The authors suggested that for the early diagnosis of pubertal 
disorders GnRHa testing with leuprolide acetate is a better tool than GnRH testing. 
[n the present study the usefulness of the GnRHa test is further investigated: we 
compared the response of LH, FSH and estradiol (E2) following administration of native GnRH 
or GnRH-agonist leuprolide acetate. Special emphasis is put on patients in which pubertal 
development has progressed only to Tanner stage 2, as in our experience the standard test 
with native GnRH was often found to be non-discriminatory. We hypothesise that the 
stimulation test with GnRH-a leuprolide acetate would be able to demonstrate hypothalamo-
pituitary-gonadal (HPG) axis activation in an earlier phase of puberty than after stimulation with 
native GnRH. Furthermore, in case both tests are comparable, the GnRHa stimulation test is 
still less invasive and less time consuming and may therefore be cost-effective. 
PATIENTS AND METHODS 
In all girls with clinical signs of puberty, consecutively referred to our endocrinology unit 
between 1995 and summer 1999, a standard GnRH stimulation test with 100 micrograms 
GnRH intravenously (Relefact LH-RH, Hoechst AG, Frankfurt am Main) was performed. Blood 
samples for LH, FSH and E2 were taken at baseline and for LH and FSH at 30 and 60 
minutes. After a week (range 5 - 10 days) a GnRHa stimulation test was performed with 500 
micrograms leuprolide acetate (5 mg/ml preparation, 0.1 ml), given s.c. After 3 hours one 
single blood sample was taken and LH, FSH and E2 levels were measured. Laboratory 
assessments for LH and FSH were peliormed by monoclonal specific immuno radiometric 
assay (IRMA) (BioSource Europe SA, Nivelles, Belgium), sensitivity 0.2 and 0.1 mlUlml 
respectively. E2 was assessed by coated tube radio-immuno assay (RIA; Orion Diagnostica, 
Espoo, Finland), sensitivity 20 pmol/L. We calculated the LH peakiFSH peak ratio as a variable 
as this ratio was described previously to distinguish prepubertal from pubertal children based 
on the sharp rise in LH in early pubertal girls (4, 10-12). 
As the best availab[e standard to indicate pubertal activity we used an a priori cut off 
peak of LH in IRMA of 10 lUlL in the standard GnRH stimulation test (13). In some children 
both tests were performed more than once. This was done when both tests resulted in a 
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prepubertal response while clinical appearance suggested puberty. Then, pubertal develop· 
ment was monitored for 3·6 months and the child was retested. 
Values in the standard GnRH stimulation test and GnRHa test were non· 
parametrically tested with the Wilcoxon signed rank test for paired values. The Mann~ 
Whitney test was used to compare between groups. For bivariate correlations we used 
Spearman rho, as the distribution of the parameters was not normal. As the data were paired 
we used the McNemar test to compare the fractions of pairs that were discordant in LH peak 
after either standard GnRH or GnRH·a leuprolide~acetate. A significance level of < 0.05 was 
indicative for statistical significance. 
Patients were included based on their first clinical presentation, and divided in 2 
subgroups: group 1: precocious puberty: pubertal development (according to Tanner ~ 82 in 
girls before the age of 8 years); group 2: early puberty: pubertal development before the age of 
10). In table 2 some clinical data on a subg~oup of patients is presented. The description of 
further diagnostic tests is beyond the scope of this article. 
It was decided to treat patients when auxological or psychosocial indications were 
present and when the peak value of LH in the GnRH test was> 10 lUlL When the LH peak in 
the GnRHa stimulation test was> 10 lUlL progression of puberty was probable based on data 
in the literature (6), and in that case we regarded it unethical to postpone GnRH agonist 
treatment. 
RESULTS 
Central activation: LH and FSH 
Seventy-seven pairs of tests were performed in 65 girls (44 presenting with Tanner stage 2, 31 
with Tanner stage 3 and 2 with Tanner stage 4). Fifty-six tests were performed in group 1 (22 
with organic causes of precocious puberty) and 21 in group 2 (4 with organic causes of early 
puberty). No significant differences were present for mean LH, FSH and E2 values and 
LHfFSH ratio's in either test comparing children with or without organic reasons that could 
explain the early or precocious onset of puberty. No significant differences between the mean 
values of LH and FSH peaks with or without the repeated tests were observed. Therefore each 
test was used as independent test. 
Peak values of LH and FSH obtained in the GnRH stimulation test significantly 
correlated with values obtained after GnRHa stimulation: Spearman rho was 0.87 for LH and 
0.80 for FSH (both p < 0.001). In group 1 these correlations were 0.89 and 0.83, and in group 
2: 0.83 and 0.76 respectively (all p < 0.001). In figure 1a mean LH and FSH peak values and 
in figure 1b the LHfFSH ratios are shown for Tanner stage 2 and 3. 
Girls with Tanner stage 2 (n=44) were studied in more detail. Peak values for LH and 
FSH in both tests are plotted against each other in figure 2. In all children with prepubertal LH 
peaks in both tests the LHfFSH ratios were < 1. In Tanner stage 2 we found values of the 
LHIFSH ratio below and above 1.0, ranging from 0.15 to 10.3 in the GnRH test (median: 0.67) 
and from 0.11 to 8.9 in the GnRHa stimulation test (median: 0.61). The number of Tanner 2 
girls with LH peak> 10 in the GnRH test (n=14) and LHIFSH ratio < 1.0 is two. 
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Table 1: Summary of results of 44 pairs of GnRH and GnRHa stimulation tests in girls in 
Tanner stage 2; the number of patients is given. 
LH peak in GnRH test LH peak in GnRH test 
> 10 lUlL < 10 lUlL 
LH peak in GnRHa test> 10 lUlL 13 8 
LH peak in GnRHa test < 10 tU/L 1 22 
Figure 1 a: FSH- and LH -peak values in 2 different GnRH stimulation tests; • = p < 0.001 
" 
LH In GnRI-I LH in GnRHa FSH inGnRH FSH in GnRHa 
Figure 1 b: Peak LH I peak FSH ratio in girls after GnRH or GnRHa challenge according to 
Tanner stage; • p = 0.001; 
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When children were divided in 2 groups according to the LH peak in the GnRH stimulation test, 
the McNemar test for paired observations showed a significant difference (p<0.02) between the 
fraclions that are discordant for results of the test (8/30 and 1113 respeclive[y) (tab[e 1). 
Figure 2: Scatterp[ot of peak LH and peak FS values in GnRH test vs GnRHa test; 
Spearman rho: 0.87 for LH and 0.80 for FSH (both p < 0.001). 
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The children with discordant responses in the 2 tests were studied in more detail. Those with a 
pubertal response in the GnRHa test and no pubertal response in the standard test (n=8) are 
summarised in table 2. We added clinical signs of HPG axis activation in this table. In these 8 
girls, the patients with organic reasons for CPP (nrs 1, 2 and 6) all had LH peak values just 
above the cut off value. Mean E2 values in the 22 girls with 2 LH peaks < 10 [U/L ranged from 
< 20 to 86 pmoVL (mean: 31.7 pmo[!L) in the GnRH stimulation test and from < 20 to 109 
pmo[!L (mean 43.8 pmoVL) in the GnRHa stimulation test. 
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Table 2: Individual data of 8 patients with LH > 10 lUll in GnRHa test and LH < 10 lUlL in 
GnRH stimulation test. 
Nr Diagnosis Age GnRH test GnRHa test Clinical 
evjdence~ 
LH peak E2 LHiFSH LH peak E2 LHiFSH 
(lUll) (pmoI/L) ratio (lUll) (pmoI/L) ratio 
1 Brainlumor 3.5 6.3 80 0.72 10.2 123 0.88 A 
2 MMC 9.7 6.6 23 0.62 10.8 111 0.72 A 
3 ICPP 8.9 7.6 190 0.76 34.0 181 1.28 B,C 
4 ICPP 7.7 5.9 57 0.75 18.7 103 1.13 B,C 
5 ICPP 4.6 7.7 33 0.16 lOA 100 0.19 B 
6 Cranio 7.0 9.6 28 0.74 11.1 44 0.66 C 
7 ICPP 6.6 8.0 22 0048 15.2 19 0.61 B 
8 ICPP 8.8 7.4 70 0.81 17.2 160 0.69 A 
. for presence of HPG aXIs activation. A. pubertal E2 levels> 50 pmoVL (ref. (26), B. advanced (?: 2 
yr) bone age; C: pubertal ultrasound uterus. ICPP :;: idiopathic central precocious puberty; MMC = 
meningo myelocele; cranio = craniopharyngeoma 
Compared to these girls, the 8 patients presented in table 3 had significantly higher E2, LH 
peak and LHiFSH ratio values in both tests and higher FSH peak levels in the GnRHa test (all 
p < 0.05, for LH peaks: p<O.OOI). The only girl (age: 9 years) with a pubertal LH peak (10.7 
lUlL) in the standard GnRH test but not in the GnRHa stimulation test (8.8 lUlL) had an 
advanced bone age, low E21evels « 20 pmol/L in bolh tests) and ratio's below 1 in both tests. 
Table 3: Follow-up data of girls without pubertal LH peak in both stimulation tests 
Category Number 
Gonadotropin independent PP 6' 
Progression with central activation within 6 months 5 
Slow progression without central activation within 6 months 7 
Other 2 
No data on progression available 2 
Total 22 
#. ovarian cysts (n-4), obeSity (n-1), possibly McCune-Albright syndrome (n-i) 
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The LH/FSH ratio was < 1.0 in 4 of 14 girls with a LH peak> 10 lUll in the GnRH stimulation 
test and in 8 out of 21 girls with a LH peak> 10 lUlL in the GnRHa stimulation test. 
Gonadal activation 
In girls in Tanner stage 2 E2 values were studied in both tests. Median basal value was 35.0 
(range 6.60-190) pmollL in the standard test. Mean (SO) E2 in the GnRHa test, 3 hours after 
GnRHa administration, was 72.1 (50.7) pmollL. 
Spearman correlations betvv'een LH peak and E2 serum levels in the group girls with 
Tanner stage 2 were 0.49 in the standard GnRH test and 0.66 in the GnRHa stimulation test 
(both p< 0.01). For girls in Tanner stage 3 these correlations were 0040 (p<0.05) and 0.56 
(p<0.01) respectively. In the group of girls with' pubertal' LH peaks after GnRHa (n=21) only 3 
had E2 levels below 50 pmoUL, indicating that already 3 hours after a GnRHa stimulus the E2 
production is clearly activated. 
No activation of HPG axis (LH peak < 10 lUlL) in either test was seen in 29 pairs of 
tests, referring to 22 children (table 3). Five of these children demonstrated HPG axis activation 
during follow-up within 6 months when the tests were repeated. 
DISCUSSION 
The decision to start a dignostic procedure in children with precocious or early puberty is 
related to the age of the normal occurence of sexual characteristics in the population. In The 
Netherlands the age at onset of puberty in girls did not decrease dramatically over the last 20 
years (15, 16). Therefore, the adaptation of the age limit for the definition of precocious puberty 
recommended in the USA is not applicable for the Dutch population (17). Then, one would be 
certain about further progression of puberty in the near future in order to prevent unnecessary 
treatment. In some children there is rapid progression of sexual development, while in others 
there is only slow progression without marked acceleration of bone maturation and without 
decrease in final height, as Palmert et a/. showed (14). The children with slowly progressive 
puberty ali had low LH peaks in a GnRH stimulation test. The authors state that slowly 
progressive puberty in girls does not warrant therapy and it was advised to monitor girls with 
FSH predominant response in GnRH stimulation test and moderate bone age advancement for 
at least 6 months before initiation of therapy. It would be helpful when a single assessment of 
gonadotropins in serum could discriminate between prepubertal and pubertal girls. Recently. a 
sensitive immunofluorometric assay (IFMA) for basal LH and FSH was used for the diagnosis 
of CPP, but this method was able to diagnose CPP in only 62.7 % of the girls and has a limited 
availability in clinical practice (18). 
Thus, stimulation tests that challenge the HPG axis are still to be used to discriminate 
between prepubertal and pubertal girls. The classical test is performed with an iv. bolus of 
GnRH. Alternatively, agonists of GnRH could be applicable. The potent GnRH agonist 
Jeuprolide acetate was shown to be able to distinguish children with progression of puberty 
from those without (6). Apparently, the GnRH agonist is able to induce de novo synthesis of 
gonadotropins in the pituitary indicating the onset of puberty (19). Therefore, in our study we 
used the same GnRH agonist and used an even higher LH peak as cut-off to be sure that all 
children with a LH peak> 10 lUlL in the GnRHa stimulation test were indeed prone to 
progression of puberty. Comparing the tvv'o tests high correlations were found between the 
peak values of LH and FSH without differences between early or precocious puberty. 
We put emphasis on the subgroup of patients with early pubertal development (Tanner 
stage 2). In clinical practice we have often seen that the standard GnRH stimulation test does 
not substantiate central HPG axis activation: Sometimes there is hardly any rise in LH, FSH 
levels are higher than LH levels and the LH/FSH ratio shows a prepubertal pattern, although 
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puberty progresses in the following months. We have shown that application of the GnRHa 
stimulation test results in a considerable reduction of the number of these 'prepubertal 
responders' (8/30) now demonstrating the HPG-axis activation. This phenomenon was 
obseNed despite the highly significant correlations of the LH and FSH peak values obtained in 
the standard GnRH test and after GnRHa stimulation. The lower potency of natural GnRH 
compared to leuprolide acetate may explain the prepubertal· like response (20). It is not clear 
from the literature why GnRH agonist administration stimulates the de novo gonadotropin 
synthesis. A possible explanation is the longer duration of stimulation, due to the subcutaneous 
route of administration and sustained delivery to the circulation (2, 20). 
The data of Roger et al. in normat girls (5) suggest that the ratio LH/FSH is not 
consistently > 1 in healthy girls that have reached Tanner stage 2. We and others (21) 
showed the same for girls with early or precocious puberty. The use of the LH/FSH ratio with a 
cut-off of 1.0 to demonstrate pubertal onset in Tanner stage 2 might be of questionable value 
as we show ratio's ranging from values far below 1.0 up to 10 in both tests. Furthermore, in 
the GnRHa test, girls in Tanner stage 2 showed a mean value for the LH/FSH ratio below 1.0. 
Detailed analysis of the girls in Tanner stage 2 showed that the combination of a LH/FSH ratio 
> 1 and a pubertal LH peak was more frequently present in the GnRH stimulation test than in 
the GnRHa stimulation test. Thus, the usefulness of the LH/FSH ratio in distinguishing 
prepubertal from pubertal girls is debatable, and possibly limited to the GnRH stimulation test. 
This is a remarkable finding, indicating that GnRHa is able to induce an increase of both FSH 
and LH in recently started puberty. It is in line with the observations that FSH release after 
GnRHa stimulation is more gradual and has not the biphasic pattern as LH release. Therefore 
FSH peaks will be demonstrated on a later moment than LH peak (2, 22, 23). 
In patients without pubertal LH peak in either test, the decision not to treat was justified 
by the clinical course. No rapid progression was observed in these patients. In this study, the 
decision to treat patients was not used as a validation for the test under investigation. We 
already applied the results of earlier findings on the use of the GnRHa stimulation test (6) in 
our clinical practice. Thus, we make no recommendations regarding the predictive value of the 
GnRHa stimulation test for progression of puberty, because the study design does not allow a 
statement on this. 
We show that GnRHa induces E2 production even 3 hours after administration. An 
early rise in serum E2, described in adult females, was not observed by Rosenfield after 
nafarelin administration in girls with CPP (24). The normal response pattern of early pubertal 
ovaries to gonadotropin exposure is not known. One might speculate that the first LH pool 
could be responsible for the short term response. The maximum E2 level is probably not 
reached after 3 hours as it was shown that the time lag between LH and E2 was between 6 
and 9 hours due to the time required for aromatization (25). 
Based on our findings, we advise to test children with clinical development of secondary 
sexual characteristics with 500 microgram of leuprolide acetate s.c. and serum sampling after 3 
hours for LH, FSH and E2. The test has to be repeated after 3-6 months in case HPG axis 
activation can not be demonstrated. The benefit of our advice for the patients is a less invasive 
procedure and results in an earlier diagnosis to start the appropriate treatment. Secondly, the 
test 'IS less time consuming and less expensive. 
In conclusion: the GnRHa stimulation test with leuprolide acetate demonstrates HPG 
axis activation in an early phase of puberty, therefore improving the diagnostic process in 
children with early or precocious puberty. 
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ABSTRACT 
We studied the auxological effects of treatment with the GnRH agonist leuprolide acetate 
(Lucrin ® ) at 3.75 mg/28 days in 38 children with early or precocious puberty. We present 
our newly developed scoring system, the Puberty Suppression Score (PSS), in which clinical 
and biochemical parameters determine whether suppression was effective, Leuprolide 
acetate suppressed pubertal development in the majority of cases. During treatment there 
was a significant correlation between the number of times that PSS was 10 and gain in 
predicted adult height (PAH) compared to initial prediction at the start of treatment. After 6 
months of treatment, ineffective suppression measured by PSS was associated with the 
magnitude of gain in PAH. We conclude that a leuprolide acetate dosage of 3.75 mg every 
28 days effectively suppresses puberty. PSS is helpful in monitoring the suppressive 
capacity of a GnRH agonist. We recommend to start with leuprolide acetate at 3.75 mg/28 
days and to increase the injection frequency or dose in case PSS is 10 after 6 months of 
treatment. 
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INTRODUCTION 
For years, gonadotrophin-releasing hormone (GnRH) agonists have been used as potent 
therapeutic suppressors of gonadotrophin release from the pituitary (1-6). In children with 
early or precocious puberty, the depot formulations of GnRH agonists have made this 
treatment more acceptable. With the use of depot formulations, a large difference in dose per 
kilogram body weight is observed in daily practice (7). To assess whether this dose is 
sufficient for a particular child, clinical, auxological and biochemical evaluation of the 
suppression of pubertal development is demanded. In the recent literature, a suppressed 
peak level of luteinizing hormone (LH) in a GnRH stimulation test is regarded to be the best 
parameter to estabtish pubertal suppression (7-9). Cook ef al. (10) suggest that overnight 
monitoring of LH release is more sensitive than GnRH stimulation testing. These authors and 
others (11, 12) also stressed the importance of clinical regression of pubertal characteristics 
and decrease in skeletal maturation rate. 
So far, no scoring system has been developed which evaluates pubertal suppression 
during treatment. Such a scoring system should include clinical, auxological and biochemical 
parameters and should be applicable in clinical practice. Besides evaluation of the ongoing 
treatment in the individual patient, it may be useful for comparison of different treatment 
modalities or formulations. In the present study, the pubertal suppression of 38 children with 
early or precocious puberty is evaluated by a newly developed scoring system, the Puberty 
Suppression Score (PSS). We evaluate the usefulness and validity of the PSS and discuss 
possible clinical applications. 
PATIENTS AND METHODS 
Thirty-eight patients (33 girls and 5 boys) with early or central precocious puberty (CPP) 
treated with the GnRH agonist leuprolide acetate were studied in a retrospective analysis. 
Thirty patients had true CPP (signs of puberty before the age of 8 in girls and before the age 
of 9 in boys). In 8 children, puberty was early (signs of puberty before the age of 10 in girls 
and before the age of 11 in boys). Leuprolide acetate (Lucrin ®; Abbot, Amstelveen, The 
Netherlands) was given subcutaneously, 3.75 mg every 28 days, but the interval between the 
first 3 injections was 14 days. Thirty-eight children received treatment for 18 months, 32 of 
them for 24 months. Height was measured by a Harpenden stadiometer in an outpatient 
clinic. Height and body mass index (BMI) were compared to Dutch standards (13), and 
height standard deviation scores (H-SDS) for chronological age (CA) or bone age (BA) were 
calculated. LH and follicle-stimulating hormone (FSH) levels were assessed by 
immunoradiometric assay, estradiol (E2) and testosterone (T) were assessed by 
radioimmuno assay. At diagnosis, a GnRH stimulation test with 100 I-Ig LHRH intravenously 
was performed, and LH peak values> 10 lUll were considered to indicate central activation 
of the hypothalamic-pituitary-gonadal axis (14). In 13 children, an additional GnRH 
stimulation test was performed with 500 (J9 teuprolide acetate subcutaneously and blood 
sampling 3 hours after injection (15). During treatment, LH peak levels >5 lUll (7) in a GnRH 
stimulation test and basal E2 levels >50 pmolll or T levels >1.0 nmolll were considered to 
indicate effective suppression. BA was assessed by one observer with the method described 
by Greulich and Pyle (16). Prediction of adult height (PAH) was calculated with the Bayley-
Pinneau tables for average girls or boys (17). Skeletal maturation was expressed as 
I!.BNI!.CA. 
To evaluate pubertal suppression by the GnRH agonist, the PSS was developed with 
4 parameters: Tanner stage progression, growth, bone maturation and sex steroid level 
(table 1). These parameters were chosen because they reflect the major endocrine activity in 
CPP. 
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For each parameter, the score is 0 in case of effective suppression, while the score is 1 in 
case of ineffective suppression. The Tanner stage criterion reflects the clinical appearance of 
a child under treatment. In case of progression of Tanner B or G stage of more than 1 
compared to the start of treatment, suppression is clearly not effective. 
Table 1. Puberty Suppression Score 
Parameter Suppression effective Score Suppression not effective score 
Tanner stage .::: 1 stage progreSSion 0 > 1 stage progreSSion 1 
compared to start of treatment compared to start of treatment 
Growth IIH-SOS~ .:0 0.25/6 months 0 IIH-SOS~ > 0.25/6 months 1 
IIBA IIICA 
.:01 0 > 1 1 
Sex steroids E2 < 50 pmol/l; T < 1.0 nmolll 0 E2 > 50 pmolll; T > 1.0 nmolll 1 
Total PSS 0 14 
A progreSSion of 1 stage was considered to be due to inter~ or intra~observer variation. In a 
recent Dutch consensus statement (18), growth retardation or acceleration was defined as a 
change in height standard deviation score for CA (H-SOSCA) >0.25 SOS in 12 months. To 
assess accelerated grovvth during GnRH agonist treatment, we used this increase in H~ 
SDSCA for a period of 6 months. When the increase in H-SDS exceeded 0.25 SO in 6 
months, puberty was regarded to be ineffectively suppressed and the score was 1. Bone 
maturation is retarded during effective treatment (4), and therefore !J.8A1IJ.CA is <1. In the 
PSS, a ratio of >1 is regarded to indicate ineffective suppression and the score is 1. Basal 
values of sex steroids were considered to be prepubertal when the T level was ~1.0 nmolll or 
the E2 level was :s. 50 pmolll. When these basal levels exceeded these limits, suppression 
was considered to be ineffective and the score was 1. In a child with effective suppression, 
the PSS is 0 for each parameter. In case of ineffective suppression the PSS ranges from 1 to 
4, suggesting a sliding scale of ineffectiveness of suppression. 
Statistical analysis was performed using the Student Hest for paired observations. 
Values are expressed as means (± SO). Simple and multiple regression analysis was used to 
assess correlations between the PSS and gain in PAH. 
RESULTS 
Baseline parameters of the start of therapy are summarised in table 2. In 4 patients, LH peak 
values in a GnRH stimulation test with GnRH were below 10 lUll (9.6, 6.6, 7.7 and 3.1 lUlL); 
in 3 of them, LH peak values> 10 lUll (10.8, 34.0 and 27.9 tUII, respectively) were shown in 
the GnRH stimulation test with leuprolide acetate. The fourth one, a boy, had a LH peak 
value of 9.6 lUll, but his testes were bilaterally enlarged (10 ml) and his T level was 2.10 
nmoili. In a fifth patient with Tanner stages B4 P4, the E2 level was 188 pmolll and no GnRH 
stimulation test was performed. 
At baseline, the mean LH peak was 24.9 lUll (SO: 18.0); after 3 months of treatment, 
the mean LH peak level had decreased to 1.5 (0.8) lUll (range < 1.0-4.5 lUll), p < 0.001 
compared to baseline. The mean E2 level was 91.1 (65.1) pmolll at diagnosis; after 6 
months, all girls had an E2 level <50 pmolll, except for 1 girl (89 pmol/l) who had suppressed 
E2 levels on subsequent visits. H-SOS for CA significantly decreased from 0.79 (1.47) at 
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start to 0.68 (1.36) (p < 0.01). PAH increased from 155.6 (7.19) em to 161.4 (6.44) em (p < 
0.001) at 24 months of treatment. 
Table 2. Baseline characteristics (mean ± SO) of the study population 
CA, years 
BA, years 
Height, em 
H-SDSCA 
H-SDSBA 
Target H-SDS 
PAH, em 
Basal lH level lUll 
Peak lH, lUll 
Basal E2, pmol/l 
Basal T, nmol/l 
Girls (n=33) 
8.2 (1.9) 
10.3 (2.2) 
134.8 (11.5) 
0.72 (1.44) 
-1.37 (0.97) 
-0.23 (1.02) 
154.4 (6.7) 
1.7 (1.00) 
27.1 (18.8) 
91.1 (65.1) 
Table 3. Auxological data during treatment 
boys (n=5) 
8.7 (2.4) 
12.2 (2.5) 
140.5 (13.5) 
1.23 (1.76) 
-1.41 (0.28) 
-0.24 (0.87) 
164.8 (2.9) 
2.6 (1.9) 
13.4 (2.4) 
3.25 (1.95) 
treatment period (months) 
0-6 6 - 12 12 -18 
I!.BAII!.CA 0.75 (0.66) 0.56 (0.38) 0.42' (0.34) 
I!.H-SDS/6 mo -0.02 (0.20) -0.06 (0.15) -0.12 (0.13) 
HV (em/yr) 5.9 (2.2) 5.3' (1.8) 4.6'(1.6) 
18- 24 
0.56 (0.31) 
-0.10 (0.13) 
5.0' (1.7) 
HV ::: height velocity; * p ::: 0.05 compared to 0·6 months; # p < 0.05 compared to 0-6 months 
t p < 0.01 compared to 0-6 months 
The dose of leuprolide acetate decreased significantly (p < 0.001) from 111.3 (31.5) ~g/kg 
(range: 59.6-202.7 ~g/kg) between 0 and 6 months to 92.4 (24.1) ~g/kg (range 46.5-167.4 
jJglkg) between 18 and 24 months of treatment because of gradual increase in body weight. 
The BMI SDS significantly increased during treatment (p < 0.01) from 1.13 (1.11) to 1.39 
(1.11). In table 3 height velocity, skeletal maturation and growth during treatment are shown. 
To evaluate pubertal suppression, the PSS was calculated after 6, 12, 18 and 24 months of 
treatment. The results are given in table 4. In 6 children, the PSS was 10 on more than one 
occasion during treatment, and 13 patients showed signs of ineffective suppression at any 
moment. In children with a PSS > 0, the data of the GnRH stimulation test at 3 months were 
reviewed. None of these children had LH peak values indicating insufficient suppression: 
mean lH peak value 1.48 (0.65) lUll (range: 1.0-2.8 lUll). 
Because of signs of escape from treatment, the dose of leuprolide acetate was 
increased to 7.5 mg!28 days in 1 girl. Her PSS score was >0 in the period of escape because 
of accelerated skeletal maturation and an increased E2 level. In another child, at 22 months 
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of treatment, the frequency of injections was increased to 1 xl3 weeks because of alterations 
in behaviour at the end of each 4·week interval. The PSS was not >0 during the interval 
studied. In none of these two girls progression of Tanner stage >1 was observed. In the 
remaining 11 children with a PSS >0, ineffective suppression escaped clinical attention and 
no dose adjustments were made. 
Table 4. Number of patients with PSS > ° (ineffective suppression) during treatment with 
leuprolide acetate 
treatment geriod (months) 
6 12 18 24 
Tanner stage progression> 1 0/38 0/38 0/38 0/32 
H-SDS increase > 0.25/6 months 2138 0/38 0/35 0/29 
I!.BAlI!.CA>1 5/24 4/24 1/25 2125 
sex steroids (E2 > 50 pmolfl orT > 1.0 nmoVI) 2132 1/38 1/29 2122 
Total PSS > 0 9 5 2 4 
Table 5. Correlation coefficients of the correlation between BA at start (BAo), age at start of 
treatment (Age,) or PSSwm and gain in PAH in simple and multiple regression analysis. 
Figures in parentheses denote p value 
Regression variable Whole group Girls alone 
Simple regression, 18 months PSSc<.Jm -0.49 (0.007) -0.49 (0.01) 
Simple regression, 24 months PSSwm -0.37 (0.06) -0.40 (0.05) 
Multiple regression, 18 months BAo 0.09 (NS) 0.04 (NS) 
Age, -0.35 (NS) -0.34 (NS) 
PSScum -0.51 (0.01) -0.55 (0.01) 
Multiple regression, 24 months BA, 0.13 (NS) 0.28 (NS) 
Age, -0.38 (NS) -0.34 (NS) 
PSScum -0.37 (0.08) -0.35 (NS) 
The cumulative PSS during the treatment period (PSSwm) was calculated by adding the PSS 
of each 6-month PSS, resulting in PSSwm18 or PSSwm24 for 18 or 24 months of treatment, 
respectively. 
We studied the relationship between the PSSwm and gain in PAH during treatment (table 5). 
First, we performed simple regression between PSScum and gain in PAH at 18 and 24 months 
of treatment; correlation coefficients are given in table 5, separately for the whole group and 
for girls alone. Simple regression for the individual parameters in PSS did not show any 
consistent correlation, while PSScum - including aU these individual parameters together -
significantly correlated with gain in PAH at 18 and 24 months of treatment. Second, multiple 
regression was performed for PSS, corrected for SA and CA at the start of treatment, as it is 
known that these parameters may influence the magnitude of gain in PAH [3]. PSS was 
significantly correlated with gain in PAH at 18 months (whole group and girls alone, p = 0.01). 
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At 24 months of treatment, none of the 3 regression variables (SA at start, CA at start or 
PSScum) significantly correlated with gain in PAH. Calculations were performed for the 
association between PSScum and gain in PAH with and without the PSS of the first 6 months 
of treatment. Gain in PAH was plotted against increasing PSScum values during 18 or 24 
months of treatment (fig. 1 a). After 6 months of treatment, it appeared that there was a 
significant difference in gain in PAH between children with PSScum = 0 and those with PSScum 
>0 (p < 0.05). 
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Figure 1. PAH gain during treatment with GnRH agonist: relationship to PSScum18 or PSScum24 
(a) and without PSS of the first 6 months (b) .• P < 0.05 
DISCUSSION 
It was shown earlier that treatment of CPP with incomplete suppression of the pituitary~ 
gonadal axis leads to disappointing final height results, due to the rapid bone maturation 
compared to treatment modalities with complete suppression (3, 5, 6, 17, 19-22). We 
therefore consider complete suppression superior to partial suppression to achieve the 
auxo[ogical goals of treatment of CPP. However, complete suppression leads to very low 
height velocities in some CPP patients, possibly due to a decrease in GH secretion as a 
result of the decreased prepubertal E21evels (23-25). 
In order to evaluate to what extent pubertal development can be suppressed by a 
GnRH agonist, the PSS was developed. This scoring system is based on general[y accepted 
criteria for the evaluation of the effect of treatment and applicability in clinical practice. 
Although the cut-off values are arbitrarily chosen, we think that the criteria are appropriate to 
distinguish between effective and ineffective suppression. In this study, we showed that the 
combination of parameters correlates better with gain in PAH than any parameter alone. It 
might be questioned why we did not incorporate GnRH stimulation testing during treatment in 
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this scoring system. The first reason is that the applicability of GnRH testing in daily practice 
is limited because of the duration of testing and the intravenous route of administration of 
LHRH. Possibly, testing with leuprotide acetate subcutaneously (15) may be an alternative, 
but the value of this way of testing during treatment has to be established more extensively. 
A second reason is that GnRH testing is critically dependent on the moment of testing, while 
3 out of 4 parameters in the PSS reflect effects of treatment over a 6-month period. 
Thirdly, in this study we showed that it is possible to have a very well suppressed GnRH 
stimulation test while clinical suppression is clearly ineffective over a longer period. This 
limits the usefulness of the GnRH stimulation test as a marker of long-term suppression of 
puberty. 
Behavioural changes appearing at the end of the interval between injections may 
indicate ineffective suppression (26). Detailed psychological evaluation is required before 
these changes can be used as parameters of the effectiveness of treatment. 
During treatment with a GnRH agonist, height velocity decreased and bone 
maturation was halted. The mean PAH significantly increased from 155.6 to 158.9 and 161.4 
em after 18 and 24 months of therapy, respectively (both p < 0.001). The reported height 
gain based upon height predictions in other studies with the GnRH agonist leuprolide acetate 
varies between 3.4 and 5.5 em (8, 9). One should be aware that we used the average tables 
for PAH calculation [17] even when SA exceeded CA by 1 year or more. This results in a 
lower PAH at the start of treatment compared to PAH calculated by accelerated tables. 
Several theoretical explanations are possible for ineffective suppression during 
treatment: patient compliance, inadequate dose andfor way of administration. In general, 
compliance was not a problem, as the injections were given by the general practitioner every 
28 days. Inadequate dosage could be responsible for ineffective suppression. However, in all 
children the mean dose per month exceeded the minimally needed dose (30 ~gfkg) as 
calculated by Tanaka et al. ([27). In another study [7], it was also shown that in most children 
a dose of 3.75 mg resulted in a dose per kilogram that was largely above this minimally 
required dose. In Europe, most children are treated with 3.75 mg subcutaneously, while in 
the US 7.5 mg is the common dose, given as an intramuscular injection every 4 weeks. In 
our study, we increased the dose of leuprolide acetate in only 1 child to 7.5 mgf28 days 
resulting in better clinical suppression. A third reason for insufficient suppression could be 
the way of administration. In this study, leuprolide acetate was given subcutaneously, in 
other studies it was injected intramuscularly (8). No data are available on differences 
between subcutaneous and intramuscular administration. In our group, 1 child (2.6%) had a 
sterile abscess. Manasco et al. (28) described the occurrence of sterile abscesses in the 
subcutis during treatment with leuprolide acetate. The described percentages of this problem 
vary between 3-8% and 13% (7, 8,28). 
Our PSS data in this study suggest that a few children treated with the GnRH agonist 
leuprolide acetate 3.75 mgf28 days have an ineffective suppression measured by the PSS. 
These patients would not easily be detected without this scoring system because of the 
subtle changes over a longer period measured with the PSS. The usefulness of the PSS was 
studied in simple and multiple regression models. In the simple regression model, total PSS 
during the treatment period was correlated with gain in PAH at 18 and 24 months of 
treatment. In multiple regression analYSiS, SA at the start of treatment and CA at start were 
entered as important covariables for gain in PAH during treatment. The regression coefficient 
for PSScum was the most important variable in the equation for the whole group. In girls alone, 
this was also the case for gain in PAH at 18 months of treatment. It appeared that the 
combination of parameters in the PSS had a stronger correlation with any gain in PAH than 
one of the parameters alone. This suggests that the individual parameters can in part be 
considered as independent, while they are apparently not physiologically unrelated. In the 
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first 6 months of treatment, the PSS was >0 in a considerable number of children. We 
therefore calculated the difference in gain in PAH between children with and without 
ineffective suppression from 6 to 18 or 24 months (fig. 1b) to exclude the possible bias of 
enhanced skeletal maturation in the first 6 months of treatment. It appeared that there was a 
significant difference between the groups, indicating that when the PSS is >0 after 6 months 
of treatment, adaptation of the dose regimen is required. In our group, no clear progression 
of puberty according to Tanner was detected in any patient during treatment. It could be 
argued therefore that this parameter has to be left out. We think, however, that because of 
the clinical relevance of this parameter for the work-up of any patient during treatment with a 
GnRH agonist it should be included. Especially when Tanner stage assessment is per-
formed by one single observer, it can be useful. 
With ineffective suppression, it is unlikely to reach the auxo!ogical goals of treatment. 
Besides, there is a risk of vaginal bleeding and ongoing breast development in girls leading 
to emotional disturbances. On the other hand, the use of a standard leuprolide acetate dose 
of 7.5 mg/28 days has obvious financial consequences. With the use of the PSS, children 
with ineffective treatment can be detected and dosage can be adjusted from 3.75 to 7.5 mg 
every 28 days or by increasing injection frequency to once in 3 weeks. 
We conclude that thorough monitoring of the rate of suppression in children with CPP 
is essential. The PSS could serve as a useful tool to evaluate pubertal suppression during 
the treatment period. We advise to start treatment with leuprolide acetate 3.75 mg and to 
adapt the dose regimen in case of a PSS >0, especially after 6 months of treatment. Long-
term studies have to be undertaken to assess the effect of ineffective suppression during 
treatment on final height gain. 
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Final height after Gonadotrophin Releasing Hormone agonist treatment 
for central precocious puberty: the Dutch experience. 
o Mula, W Oostdijkb, BJ OUenc, C. Rouwed, M Jansen°, HA Delemarre-van de Waalf JJJ Waelkens9 
and SLS Dropa 
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ABSTRACT 
Final height (FH) data of 96 children (87 girls) treated with GnRH agonist for central precocious 
puberty were studied. In girls mean FH exceeded initial height prediction by 7.4 (5.7) em (p < 0.001); 
FH was significantly lower than target height, but still in the genetic target range. When treatment 
started < 6 years of age height gain was significantly higher than when started> 8 years of age. 
Bone age (BA) and chronological age (CA) at start of treatment, as well as SA advance at cessation 
of treatment were the most important variables influencing height gain in multiple regression analysis. 
BA advance at start of treatment was most important in simple correlation. In girls, GnRHa treatment 
seems to restore FH into the target range. A younger age and advanced bone age at start of 
treatment are associated with more height gain from GnRHa treatment. 
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INTRODUCTION 
When long-acting Gonadotrophin Releasing Hormone agonist (GnRHa) treatment became available 
for the treatment of children with central precocious puberty (CPP) in the mid-1980s, it was expected 
that long-term treatment would lead to substantial improvement of compromised final height (FH), It 
took many years to obtain FH data in children with CPP. Some authors reported on final height in 
relatively small samples or selected groups of patients, GnRH agonists were administ~!1~d as daily 
injections or in nasal spray, or even after a period of treatment with cyproteron acetate. Recently, 
results of larger study groups and of randomised trials have been described 11-14 revealing stronger 
evidence about the auxological effects of treatment. However, it is not yet clear which type of children 
will benefit from treatment with GnRH agonists. 15 ,16 In addition, questions about the appropriate 
chronological age (CA) or bone age (BA) to discontinue treatment remain unanswered. 
The interpretation of analyses that focus on parameters at the start or discontinuation of 
treatment which intenere with the gain in adult height is difficult for at least three reasons. Firstly, as 
the parameters used are closely interdependent it is not possible to identify one or more independent 
factors determining effect. Secondly, in the methods of calculating predicted adult heigh (PAH), the 
current models are possibly less accurate in CPP. 3 Finally, it is necessary to allow for the effect of 
regression towards the mean: children with very advan~~d bone age at start of treatment have an a 
priori chance of ending up with FH in the normal range. Furthermore, the question is how to define 
effect of treatment, as recent data on the natural course of CPP in untreated patients are not 
available. We present here results from a nation-wide analysis in The Netherlands of final height data 
in children with CPP uniformly treated with GnRH agonist triptoreHn, providing data on the state of the 
art in The Netherlands. 
PATIENTS & METHODS 
In this retrospective multi-centre study the clinical records and X-rays for BA of children treated for 
CPP were re-examined, The children (n=36) from a former analysis by Oostdijk et al.5 were included 
in Ihis group. CPP was defined as Ihe onsel of symploms of sexual development before the age of 8 
in girls (Tanner stage 2) and before the age of 9 in boys (testicular volume::: 4 ml), pubertal response 
of LH in a GnRH stimulation test and pubertal levels of sexsteroids according to the individual hospital 
laboratories, or advanced BA: BAJCA ratio> 1,0, When available, perinatal data and family history 
were obtained, as well as the eventual adoption status and MRI findings. 
A depol preparation of Iriplorelin (Decapeplyl CR®) was given 1M every 28 days for alleast 18 
months in a dosage of 3,75 mg. Eight patients were treated with depot preparations after a period of 
intranasal buserelin or cyproterone acetate. Both idiopathic and organic forms of CPP were included. 
Height data were gathered at start of treatment with depot triptorelin, at the end of treatment and at 
final height. Final height was defined as BA of > 15 yr. in girls and >17 in boys, or a growth velocity of 
less than 1 cm/yr. measured over a 6-month period, Height data were expressed as height standard 
deviation scores (H·SDS) eilher for chronological age (H·SDScA) or for BA (HSDSBA). Reference dala 
and equations for calculating target heights (TH) and H-SD scores were derived from the 1980 growth 
study in The Netherlands.18 
Suppression of puberty was monitored at 3 - 6 months' intelVals and escapes from treatment 
(for example vaginal blood loss or clinical progression of puberty) were recorded. The decision to stop 
treatment was based on auxological or psychological factors. After treatment age of menarche was 
note~ One experienced obselVer penormed bone a~e assessment with the method of Greulich and 
Pyle 1 , and the average tables of Bayley and Pinneau 0 were used as suggested by Kau!i3 to calculate 
predicled adull heighl 
Statistics included pairwise comparisons between PAH at start of treatment, PAH at the end of 
treatment, TH and final height (FH), and univariate correlations and multiple linear regression analysis 
(backward selection procedure). 
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Our objective was to identify pre-treatment or post-treatment factors influencing the main outcom 
parameter which is the gain in height between start of treatment and final height. Because of thi 
objective we only used 5 variables in the mUltiple regression analysiS that could have possibl 
influence on decision making in clinical practice: chronological age at start and stop of treatmen 
bone age at start and stop of treatment and bone age advance (BA - CAl at the end of treat men 
Because of the small number of boys multiple regression was not applied on them. A p-value of 
0.05 was considered to indicate statistical significance. 
RESULTS 
Ninety-six patients, 87 girls and 9 boys, were included in the analysis. Characteristics of the patlenl 
before treatment are shown in table 1. One or more signs of escape from suppression were note 
during reatmen! in ten girls: pubertal values in oestradiol levels were reported in five girls, four girl 
had temporary vaginal blood loss after the first 6 months of treatment, and in four girls clinical puberi 
had progressed -in 1 girl due to non-compliance. In case of biochemical proven escape the dos 
regimen was adapted. No serious side effects were observed, some children complained abol 
increase in body weight. 
Table 1: Patient characteristics before treatment (Rx); (mean LSD). 
Girls (n=87) Boys (n=9) 
CA at start of puberty (yr.) Median: 7.0 Median: 7.75 
Range: 0.8 - 8.0 Range: 4.0 - 9.0 
CA at start Rx (yr.) 7.7 (1.25) 8.3 (1.74) 
BA at start Rx ('yr.') 10.4 (1.17) 10.9 (1.99) 
BA advance (BA'CA) at start Rx (yr.) 2.8 (1.03) 2.7 (1.68) 
H-SDS for CA at start Rx 1.54 (1.28) 1.57 (1.96) 
H-SDS for BA at start Rx -1.14 (0.94) ·0.96 (1.12) 
Target height SDS ·0.05 (1.08) ·0.37 (0.79) 
Peak LH after GnRH stimulation (lUlL) 31.7 (25.4) 21.6 (15.2) 
Brain MRI or CT pertormed 61 8 
- Hamartoma 2' 0 
- Neurofibromatosis 1 2 
- Tumour 2 1 
Number of adopted children 13 0 
Type of CPP 
- Idiopathic 76 3 
- Organic 11 6 
PAH at start Rx (cm) 
-average tables B&P 155.3 (7.25) 171.5 (4.14) 
-accelerated tables B&P 160.6 (7.80) 180.0 (8.40) 
, both < 6 years of age al start puberty 
BA :=: bone age; CA :=: chronological age; H-SOS = standard deviation score for height; LH :=: luteinizin 
hormone; GnRH :=: Gonadotrophin Releasing Hormone; CPP :=: cenlral precocious puberty; PAH = predicte 
adult height; B&P = Bayley and Pinneau; MRI = magnetic resonance imaging; CT = computerised tomogram. 
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Mean treatment period was 3.4 (1.31) [mean (SO)] yr in girls and 3.8 (1.33) yr in boys. Sane age 
advance (SA-CA) was reduced to 1.3 yr in girls and 1.0 yr in boys at discontinuation. Mean period 
between cessation of treatment and the occurrence of menarche was 1.3 (0.8) yr, range: 0.1 to 4.3 yr. 
After treatment mean height increase was 9.7 (3.4) cm in girls and 12.9 (5.4) cm in boys. Mean FH-
SOS was 0.63 SOS below mean TH-SOS in girls and 1.30 SO below TH in boys (p< 0.001 and < 0.01 
respectively). Mean H-SOS for CA at start of treatment was 1.54 (1.28) in girls and 1.57 (1.96) in 
boys. It decreased to 0.70 (1.06) and 0.81 (1.37) in girls and boys respectively at discontinuation of 
treatment. 
Mean final height was 162.5 (7.26) cm in girls and 170.8 (7.16) cm in boys. Mean height gain 
in girls was 7.4 (5.71) cm and - 0.6 (5.94) cm in boys. Height increase in the subgroup of adopted 
girls was 6.3 (3.87) cm. Figure 1 shows PAH at start and discontinuation of treatment, attained FH 
and TH for girls. Mean height gain between girls with start of puberty < 6 (n~21) and> 6 years of age 
(n ~ 64) was not significantly different: 9.3 and 6.7 cm respectively. In both age groups FH was 
Significantly higher than pre·treatment PAH (both p<O.OOl) and FH-SOS was not significantly different 
between the two age groups. In boys there was a significant difference in FH-SDS between the older 
and younger boys (p < 0.05). In table 2 the girls are divided in 3 groups based on age at start of 
treatment and gain: the difference between FH·SOS and TH-SOS was calculated for each group. 
Table 2: Predicted adult height at start (PAH1), final height (FH) and target height (TH) data of girls 
divided in 3 subgroups based on chronological age at start of treatment: group 1: < 6 years, group 2: 
6·8 years, group 3: > 8 years (range: 8-9.8 years). 
Rx duration PAH 1 FH Height gain FH-SDS TH-SDS N 
(yr) (cm) (cm) (cm) 
Group 1 6.2 (1.1) 151.4 (8.05) 163.1 (8.54) 11.7 (8.03) -0.84 (1.38) 0.27 (1.02)b 8 
Group 2 3.8 (0.8) 154.3 (6.04) 161.9 (6.31) 7.9 (5.54) -1.03 (1.02) -0.11 (1.09)b 37 
Group 3 2.6 (0.7) 157.0 (7.75) 163.0 (7.90) 6.1 (4.97)' -0.85 (1.27) ·0.06 (1.10)' 42 
All girls 3.4 (1.31) 155.3 (7.24) 162.5 (7.26) 7.4 (5.71) -0.93 (1.17) -0.05 (1.08)d 87 
a = p < 0.05 compared to group 1: b = P < 0.01 compared to FH-SDS In paired Hest; c :=: p < 0.05 compared to 
FH-SDS in paired Hest; d = p < 0.001 compared to FH-SDS in paired Hest (66 pairs) 
Correlation and regression analysis 
The dilference between PAH at start of trealment and the attained FH (height gain) was considered to 
be the most important variable describing the effect of GnRHa treatment. Therefore this variable was 
analysed using simple correlations and multiple regression analysis as described above. Results of 
the simple correlations are given in table 3 for girls, in boys CA at discontinuation of treatment 
correlated significantly with height gain. 
In the multiple regression analysis a model with BA at start and stop of treatment, CA at start 
of treatment and with BA advance at stop of treatment could explain 48.9 % of the variance. This 
model is described in table 4. In girls treated at CA > 8 years we studied the role of SA advancement 
at start of treatment. In table 5 the results are shown. No statistical significance was demonstrated 
between the values of gain between the groups, possibly due to the small number of girls with SA 
advance> 3 years. Non-parametric correlation did not reveal significance. 
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It can be derived from tables 2 and 3 that age at start of treatment was one of the most importan 
variables determining the effect of treatment. Figure 2a shows a correlation plot with height gail 
against age at start of treatment in girls, and figure 2b growth after treatment against BA a 
discontinuation of treatment. 
Table 3: Simple correlation with height gain as dependent variable (girls) 
CorrelationJPearson) P value 
BA advance at start Rx 0.63 < 0.001 
CA at start -0.39 < 0.001 
Rx duration 0.38 < 0.001 
H-SDS for CA at start 0.34 < 0.01 
H-SDS for BA at start -0.34 < 0.01 
Ht at discontinuation of Rx 0.27 <0.05 
H-SDS for CA at discontinuation of Rx 0.23 <0.05 
Ax:::: treatment; SA :::: bone age; CA = chronologIcal age; H-SDS = standard devlal10n 
score for height 
Table 4: Total model of multiple regression analysis: dependent variable:::: gain; intercept:::: 12.5 
(SE: 12.07); explained variance = 48.9 %) 
Predictive factor Slope (standard error) P value 
BA at start of Rx 5.55 (0.86) < 0.001 
CA at start of Rx -4.89 (0.58) < 0.001 
BA advance at discontinuation of Rx -2.89 (0.92) < 0.001 
BA at discontinuation of Rx -1.77 (1.21) 0.15 
SA:::: bone age; CA :::: chronologIcal age; Ax = treatment 
Table 5: Height gain related to BA advance at start of treatment in girls with CA at start of 
treatment> 8 years. 
BA- CA (vr) Height gain (mean (SO) in cm Number of girls 
<2 4.5 (5.24) 13 
2-3 6.7 (4.58) 22 
>3 7.4 (5.78) 6 
SA:::: bone age; CA = chronologIcal age 
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Legend 
(Next page): 
Figure 2. 2A: Scatterplot of age at start of treatment and height gain, r = -0.39, P < 0.001 (girls only) 
28: Scatterplot of SA at discontinuation of treatment and growth after discontinuation of treatment in 
girls: r = -0.67, P < 0.001 
Figure 1. Predicted adult height (PAH) at start and stop of treatment, final height (FH) 
and target height (TH) .• = P < 0.001, ., = P < 0.01 
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DISCUSSION 
In our study GnRHa treatment in children with CPP results in a final height that is significantly higher 
than pre-treatment PAH, but significantly lower than target height. Using multiple regression analysis, 
a model in which CA and SA at start of treatment have significant influence explains nearly 50% of 
variance in height gain. However, children with onset of puberty below 6 years of age did not gain 
significantly more than children> 6 year old at onset of puberty. Both groups gain compared to PAH 
at start of treatment. Height gain is observed even after treatment started after the age of 8 in girls. 
Our study describes FH data in a large population of patients with CPP uniformly treated with 
GnRHa. KleUer and Kelch summarised data of several centres in different countries pertaining to 150 
patients, however with substantial variations in treatment regimens.4 The results of that study are 
frequently cited to support the statement that treatment in younger patients « 6 years of age at onset 
of puberty) result:fl in improvement of FH in contrast to children with onset from 6-8 years of age at 
onset of puberty. Because of the use of different outcome parameters and the composition of their 
control group it is difficult to assess to what extent their results can be compared with ours. In the 
study of Carel et aI, girls with onset of puberty between 6 and 8 years of age showed, as in our study, 
a positive height gain of 4.5 (5.3) em, resulting in a FH which was significantly different from PAH at 
start.
l1 Bouvattier et aI, showed that girls in advanced puberty (age of onset between 8.4 and 10 yr) 
14 
did not reach a final height significantly different from prediction at start, From our data it can be 
concluded that there is more likely to be a positive effect of treatment when age at start of puberty is < 
6 years of age. Cassia et al. showed that in girls with onset of puberty> 7,5 years old, GnRHa 
treatment does not improve auxological outcome,13 
With respect to the age at start of treatment, which can have a variable delay after onset of 
puberty, we conclude that even when treatment starts> 8 years of age it is possible to improve FH 
compared to initial PAH, as was described previously.12 
In our study, the gain in height, defined as the difference between PAH at start and FH was 
. 11 12 5 
7.4 (5.7) cm, other studies have reported 4.8 em ,2.9 or 3.4 em . We used the average tables of 
BP at start of treatment, resulting in lower PAH at start of treatment if compared to accelerated tables, 
We believe that this method gives a better indication of the effect of GnRHa treatment, as Kauli 
showed that predictions witr the average tables are more accurate in girls with CPP regardless of the 
advancement of bone age, We used the same method in girls and boys, although this method has 
not been used previously or validated in boys, 
Our results in girls show that FH~SDS, although in the genetic target rangel is significantly 
lower than TH~SDS, which was also found by Kletter and coworkers 4, whereas Carel1 reported a FH-
SOS close to zero, therefore not different from the midparental height SOS. All the above-mentioned 
reports suggest a restoration of FH within the target range. The results for the boys suggest no 
substantial height gain, as reported previously.11 
The best way to evaluate the effect of treatment of GnRH agonists would include the use of 
randomised trials with untreated controls, It is, however, considered unethical not to treat children with 
CPP. The use of a historical control group has its limitations as well because of the secular trend in 
age of puberty and adult height. One should also account for prediction errors in any method used. 
For example De Waal et aI, demonstrated that the prediction error in different prediction methods in a 
sample of tall girls 2 11 years of age was 3.3 (2.5) cm. 22 In our opinion gain of height between the 
PAH at start and attained FH is the best way to analyse effect in studies without a control group, In 
the literature FH jtself has also been used as measure of effect.5,11,12 
For analysis of predictive factors for effect, we used variables in a multiple regression model in 
girls with probable clinical implications, e.g. SA at cessation of treatment. Chronological age and BA 
appeared to be important variables in this model as well as BA advancement at discontinuation. In 
other stUdies many variables were shown to influence height gain. In analysing these studies it 
appeared that the difference between BA and CA at start of treatment has significant influence on 
height gain in multiple regression analyses,5,12 Taking together the results of simple and multiple 
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regression analysis one can conclude that the younger the girl, the more advanced bone age is at 
start of treatment, and the more BA equals CA at discontinuation, the more height gain from treatment 
with GnRH agonist can be expected. This conclusion is in line with the conclusion of Kaplowitz et al. 
that GnRHa treatment in children with slowly progressive puberty a2~d Jess bone age advancement 
has not been proven to have a significant effect in improving FH. No definite statement can be 
derived from our data as to when to discontinue treatment, while others did make 
recommendations. 11 ,12 
We suggest that children with CPP should be treated as early as possible and that children 
treated after the age of 8 years old can gain height especially when there is prominent BA advance at 
the moment of start of treatment, indicating progressive forms of CPP. In addition, apart from 
auxological considerations psychosocial aspects of precocious sexual development in children should 
be accounted for in the decision to treat or not to treat. 
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ABSTRACT 
The small number of boys present in most studies on final height (FH) after Gonadotrophin 
Releasing Hormone agonist (GnRHa) treatment for central precocious puberty (CPP) offers 
uncertainty on the effects of treatment on final height in males. We therefore combined final 
height data from The Netherlands, Italy and France to study the effect of GnRHa treatment in 
a large group of 29 boys with CPP. 
Mean chronological age at start of treatment was 7.9 (SO 2.1) years, BA was 11.0 (2.0) 
years. All boys were treated by the depot formulations of GnRH agonist triptorelin with 
established gonadal suppression for a mean treatment period of 4.6 (2.0) years. 
Final height was 172.6 (6.7) cm. Final height SOS was -0.68 (1.20), not significantly different 
from the target height SOS of -0.27 (0.75). FH-SOS was significantly lower in the subgroup 
of 12 patients with organic CPP compared to patients with idiopathic CPP (-1.34 (1.06) vs.-
0.21 (1.13) respectively, p< 0.01), but no difference in height gain was observed. Mean 
estimated height gain, defined as the difference between predicted and actual adult height 
was 5.8 (8.4) cm using the average tables of Bayley & Pinneau, and 0.3 (8.3) cm using the 
appropriate tables. Regional differences in height gain were observed between the different 
countries, reflecting different local practices in initiation of treatment. 
We conclude that GnRH agonist treatment in boys results in a FH close to TH. 
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INTRODUCTION 
In the studies published on the results of Gonadotrophin Releasing Hormone agonist 
(GnRHa) treatment for central precocious puberty (CPP), male patients are present just in 
small numbers (1-5). Comparisons between the effects of GnRHa treatment in boys and girls 
are scarce (6) also due to the low incidence of CPP in boys. The number of male patients 
with an organic substrate for the development of early puberty is relatively high compared to 
girls, and more often intracerebral pathology can be observed, further limiting the number of 
idiopathic CPP in boys (6, 7). 
Furthermore, the relevance to compare boys and girls is limited. In boys, although the 
importance of oestrogen is acknowledged (31) the pubertal growth pattern is mainly driven 
by testosterone that is aromatized to oestrogens and by increased growth hormone levels, 
thus different from that in girls (8). Pubertal suppression in boys may thus have different 
effects on growth compared to girls. Consequently, no conclusions from girls' results of 
GnRHa treatment can be inferred to boys. 
The small number of GnRHa treated boys offers uncertainty on the effects of 
treatment on final height (FH); uncertainty also persists on the issues when to start or stop 
GnRHa treatment in boys. Most studies were not able to thoroughly analyse the boys' data, 
suggesting that larger groups should be analysed. 
A further issue in the analysis of FH in boys with CPP is the reliability of height 
predictions. In untreated girls with CPP the Bayley-Pinneau (BP) method overestimates FH 
by 4-6 em (2). In tall boys a tendency to overestimate FH by the BP prediction method is 
present as well (9). In a small number of boys with CPP Zachmann ef a/. reported that the 
BP method was reasonably accurate (10). No final recommendation on the best method for 
height prediction can thus be given. 
In the present study we collected data from 3 different countries on boys with CPP 
that had been treated with similar GnRHa treatment protocols and had reached final height 
(FH). We thereby provide the results on the largest population of GnRHa treated boys to 
dale, 
PATIENTS AND METHODS 
Data from patient files were retrospectively collected in a standardised way. The patient data 
were gathered from The Netherlands, Italy and France and have been presented in part in 
earlier reports (2, 3, 5). 
All patients had reached FH after a variable period of treatment with the GnRH 
agonist triptorelin (Oecapeptyl®) as monthly 1M depot (3.75 mg); some (n = 5) were treated 
previously for a short period by cyproterone-acetate or intranasal GnRHa before start of 
GnRHa depot treatment. 
Pubertal development started before the age of 10 years with enlargement of testes 
(::: 4 ml) and elevated peak Luteinizing Hormone (LH) levels in a standard GnRH stimulation 
test, proving the central origin of the precocious development of secondary sexual 
characteristics. 
In the analysis height data at start and discontinuation of treatment, as well as FH 
data were used. Final height was defined as a growth velocity < 1 cm per year in a 6 months 
period and/or a BA > 17 years. Because of the different backgrounds of the children height 
data were standardised by using standard deviation scores (SDS) for height. For the Dutch 
boys we used the 1980 Dutch references (11), for the Italian boys the Tanner references 
from 1965 (12), which are suitable for the Italian population, and for the French boys the 
Sempe references from 1979 (13), which are quite comparable with the Tanner 1965 
references. Target heights were calculated by [(heightmother + heightfather) /2] + 6.5 in Italian 
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and French boys. In The Netherlands a formula is used that accounts for the secular trend: 
TH::: [(heightmother + heightfather +12) 12J +3. 
Bone age (BA) assessments using the Greulich and Pyle references (14) were not 
centralised in the French and Italian group. In the Dutch patients the SA assessment were 
performed by one observer. Predictions of adult height using the Sayley-Pinneau method 
were performed in two ways. First we used the method as initially described (15) using the 
appropriate tables (i.e. "accelerated" table when BA exceeds CA by more Ihan a year or 
"average" table when SA is within a year of CA); second, as suggested by Kauli in girls with 
precocious puberty (16), we used the "average" table irrespective of SA. 
Laboratory analyses were performed in the different hospitals using either RIA or 
IRMA. The diagnosis for CPP by GnRH stimulation test was made according to the local 
standards. Adequate gonadal suppression was assessed regularly by clinical and/or 
hormonal follow-up. GnRHa doses were adjusted to maintain complete suppression. 
Statistics: 
To describe the populations, the means (SO) were calculated. Comparisons between start 
and discontinuation of treatment and between start of treatment and FH were performed pair-
wise with the appropriate test for distribution of the variables. 
In order to assess the effect of treatment two different outcome variables were used: 
we compared the initial prediction with attained FH, which is called height gain; and 
secondly, we compared FH and TH, expressed as SO scores. 
Correlations were studied between the 2 outcome variables and several baseline 
variables at start of treatment in order to elucidate the effect of any factor on outcome. We 
performed a multiple regression analysis with the 4 variables that had the highest correlation 
in univariate correlation analysis. P values < 0.05 were considered to indicate statistical 
significance. 
RESULTS 
a) Descriptive 
Data of 29 boys were available for analysis: 9 from The Netherlands, 12 from Italy and 8 from 
France. Organic causes were present in 12 boys (e.g. neurofibromatosis (NF) n ::: 5, brain 
tumour, n ::: 4). All boys were treated for more than 1.5 years. Mean age at start of puberty 
was 6.7 (2.3) years. In table 1 the further patient characteristics at start of treatment are 
shown. 
Mean treatment duration was 4.6 (2.0) yr. At the end of treatment BA was 13.7 (1.0) 
'years'; the mean increase in SA was 0.57 (0.17) 'year' per year increase in CA The 
changes in H-SOS for SA and for CA as well as FH-SDS and TH-SDS are shown in figure 1. 
Final height was 172.6 (6.7) cm; FH-SDS was -0.68 (1.20) and was not significantly different 
from TH-SDS (paired t-test, 27 pairs, p = 0.08) 
In figure 2 predicted adult height at start and stop of treatment, the attained FH and 
TH are shown in cm. Both FH predictions with the average tables and FH predictions with the 
appropriate BP tables are shown. For comparison, FH data of untreated boys with CPP 
reported by Thamdrup, Sigurjonsdottir et al. and Paul et al. are represented as well (4, 17, 
18). Growth after treatment up to FH was 14.4 (7.7) cm (range: 4.3-43.7 cm), and correlated 
significantly with SA at discontinuation of treatment: Spearman correlation coefficient ::: -0.60 
(p = 0.001). 
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Table 1: Clinical characteristics of the patients at start of GnRHa treatment. 
Mean SO 
Chronological age (CA) (yr) 7.9 2.1 
Bone age (BA) ('yr') 11.0 2.0 
H-SOS for CA 1.88 1.78 
H-SOS forBA -1.39 1.04 
TH-SOS -0.27 0.75 
Predicted adult height (em) 
according to 
- Average tables (SOS) -1.54 1.19 
- Appropriate tables (SOS) -0.70 1.37 
- Average tables (cm) 166.8 8.5 
Appropriate tables (cm) 172.3 9.8 
CA: chronological age; BA: bone age; H-SDS- height standard 
deviation score; TH: target height. 
* see patients and methods for description of the use of BP tables. 
Figure 1: Height standard deviation scores (H-SOS) before and after treatment with GnRHa, 
final height SOS (FH-SOS) and target height SOS (TH-SOS) in 29 boys with CPP. 
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Figure 2: Predicted adult height before (PAHstart) and at discontinuation of treatment 
(PAHstop) using average or appropriate tables, attained final height (FH) and target height 
(TH) in 29 boys treated with GnRHa 
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For comparison the FH of untreated boys in the stUdies of Thamdrup, Sigurjonsdottir and Paul (cited in 
the text) are shown likewise. * p < 0.001 compared to FH. 
Final height was heigher than the initial height predictions. Mean height gain defined as the 
difference between predicted and actual final height was 5.8 (8.4) cm using the average 
table, and 0.3 (8.3) cm using the appropriate table. 
b) Comparisons between countries and subgroups 
In table 2 the data of boys are summarised for the individual countries [mean (SD)I, showing 
significant differences in FH-SDS and height gain. The percentage of boys with organic CPP 
was high in the Dutch subgroup. No significant difference in duration of treatment was 
present between the countries. In boys with age of onset of puberty below 6 years of age 
(n=8) gain with average tables was significantly higher (p<0.05) than in the other boys, while 
FH-SDS was not significantly different. 
FH in the 12 organic patients was 169.5 (5.1) cm, and FH-SDS was -1.34 (1.06), 
both significantly different (p < 0.05) from the FH outcome in Idiopathic patients where FH 
was 174.7 (7.0) and FH-SDS was -0.21 (1.13). In organic patients FH-SDS was significantly 
lower than TH-SDS (p<O.Ol). There was neither a significant difference in TH-SDS, SA or 
BA-CA at start of treatment, nor in height gain between idiopathic and organic patients. 
The subgroup of 5 patient with NF was compared to the remaining organic patients; 
FH-SDS and height gain (for both prediction methods) appeared to be significantly lower (p < 
0.01 and p < 0.05 respectively) in the NF group. 
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Table 2: Patient characteristics differentiated per country. 
Age start puberty (yr) 
Age start Rx (yr) 
BA start Rx (yr) 
Duration of treatment (yr) 
FH (cm) 
FH·SDS 
TH·SDS 
organic cause (%) 
height gain (av) cm 
height gain (appr) cm 
NL (9) 
7.1 (1.9) 
8.3 (1.7) 
10.9 (2.0) 
3.8 (1.3) 
170.8 (7.2) 
·1.67 (1.07}'# 
·0.37 (0.79) 
66.6 
·0.6 (5.9)@ 
·7.3 (5.1)@# 
Italy (12) 
6.2 (2.2) 
6.8 (2.2)# 
10.6 (2.3) 
5.2 (2.5) 
173.7 (6.9) 
·0.15 (1.02) 
0.02 (0.77) 
33.3 
12.7 (6.2) 
6.8 (6.1)# 
France (8) 
7.1 (3.0) 
9.2 (1.7) 
11.6 (1.7) 
4.7 (1.8) 
172.9 (6.4) 
·0.36 (1.06) 
·0.54 (0.63) 
25 
2.7 (6.0)' 
·0.9 (6.2) 
# p<O.05 compared to France; • P<O.01 compared to Italy; @p< 0.001 compared to Italy; SA: bone 
age; H-SDS- height standard deviation score; TH: target height; FH: final height; Ax: GnRHa 
treatment; av : average lable for heigh prediction; appr : appropriate table for height prediction 
c) Correlation and regression 
Height gain was correlated with several variables and the results are shown in table 3. The 
same procedure was performed for FH-SDS. 
Table 3: Univariate correlations of height gain and FH·SDS 
Height gain FH·SDS 
Average tables Appropriate tables 
CA slart symptoms ·0.60 (p<O.Ol) ·0.36 (NS. p-0.053) ·0.27 (NS) 
CA at start Rx ·0.72 (p<O.Ol) ·0.49 (p<O.Ol) ·0.26 (NS) 
SA at start Rx ·0.29 (NS) ·0.19 (NS) ·0.11 (NS) 
SA advance start 0.50 (p<O.Ol) 0.45 (p<0.05) 0.20 (NS) 
Duration of treatment 0.58 (p<O.01) 0.54 (p<O.Ol) 0.04 (NS) 
THSDS 0.28 (NS) 0.17 (NS) 0.28 (NS) 
CorrelatIOn coefficients With P value afe shown. CA. chronological age, 8A. bone age, TH-SDS: 
target height standard deviation score; FH: final height; Ax: GnAHa treatment; NS: not significant. 
Similar to other reports height gain was correlated with SA or SA advance at start of 
treatment. However. since SA is used to define height gain (by the SP method). this result 
should be interpreted with caution since the two variables were not obtained independently. 
Identical methodological considerations should be taken into account in the linear regression 
analysis that was performed with 4 variables: CA and SA at start of treatment, the difference 
between SA and CA, and duration of treatment, where height gain was the dependent 
variable. A model with a positive correlation coefficient for SA advance and a negative 
correlation coefficient for SA at start of treatment could explain nearly 60% of variation in 
height gain using average tables for height prediction (table 4). 
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Table 4: Factors associated with height gain; r' ~ 0.60; average tabes of BP were used 
Predictive factor Slope 95 % CI of slope P 
BA at start of treatment (yr) - 2.68 - 3.81 /- 1.56 < 0.001 
BA advance at start of treatment (yr) + 3.59 2.18/5.01 < 0.001 
DISCUSSION 
In this study we show that FH-SDS was not significantly below TH-SDS in a relative large 
group of 29 boys after GnRHa treatment for CPP. The estimation of the mean height gain 
varied between 0.3 and 5.8 cm depending upon the prediction method. 
Boys with advanced SA and early onset of CPP are expected to have the worse final 
outcome. We did not confirm this assumption suggesting that GnRHa treatment is effective. 
In this retrospective study we Observed regional differences in practices and effects of 
GnRHa treatment. The Italian boys had the highest estimated height gain, probably due to 
the relatively young age and the marked BA advance at start of GnRHa treatment. The 
differences in age at initiation of treatment reflects the use of more (or less) liberal criteria to 
start GnRHa treatment. In The Netherlands GnRHa treatment was used in boys entering 
puberty just before 10 years of age, whereas in Italy the mean age at start of treatment was 
lower. Another difference is the longer interval between onset of puberty and start of 
treatment in the French group. Combining data from several countries allowed the analysis of 
a wider spectrum of patients, since 'national data' reflect [ocal practices and prescription 
habits. 
The published studies on FH in GnRHa treated bays show variable results. In the 
study of Galluzi et a/. (using appropriate tables) idiopathic CPP patients had a FH exceeding 
initial prediction by 7.2 cm (6). In the studies of Oostdijk et al. and Paul et al. FH-SDS was -
1.6 and -1.7 respectively (1, 4). In the recent study of Bertelloni et al. FH was close to TH 
(5). In an older study, where daily deslorelin was used, FH was 168.0 (8.3) cm, 
corresponding with -1.3 SDS (19). Patients from the studies by Oostdijk and Bertelloni are in 
part included in this paper. These relative discrepancies reflect the heterogeneity of the 
patients treated and the difficulties in assessing "height gain", based on predicted height at 
onset of puberty. Indeed, very little data on the validity of BP prediction methods in boys with 
CPP is available. With this in mind, the apparently normal predicted height (172.3 (9.8) cm) 
in our large series of boys with marked CPP using the appropriate SP tables strongly 
suggests that this method overestimates the true FH if boys were left untreated. This is in 
line with the historical reports showing poor FH outcome in untreated boys with CPP (4, 17, 
18), see figure 2. It is also in accordance with the observation of a considerable 
overestimation of FH by the BP method in tall boys (9). Therefore, we also used the average 
tables as suggested in girls (16), although we could not validate this method in an untreated 
group of boys with CPP. 
Performing a randomised trial with untreated controls in boys with CPP would resolve 
the issue of height gain, but is not ethical, given the psychosocial objectives of treatment. 
The comparison with historical controls suggests that the improvement of FH after GnRHa 
treatment is about 15 cm, although the secular change in height (8 cm between 1955 and 
1997 for Dulch boys (20)) should be taken into account. Further, the difference in target 
height calculation should be taken into account. The correction of 3 centimetres for secular 
trend in the Dutch formula results in a higher TH of approximately 0.5 SDS compared to the 
TH resulting from the formula without this correction. Without the correction, TH in the Dutch 
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boys would have been about -0.9 SOS, explaining in part why the difference between TH~ 
SOS and FH-SOS in this subgroup was considerably higher than in the boys from Italy and 
France. Another part of the expanation could be the differences in duration of treatment and 
in the percentage of boys with organic CPP. 
Whether GnRHa treatment results in different effects in boys with organic and 
idiopathic forms of CPP has been debated as well. OUf analysis shows that boys with 
organic CPP have a lower FH-SOS than boys with idiopathic CPP. However, 5 of the 12 
boys with organic CPP had neurofibromatosis, a condition that may directly compromise FH 
(21-23). Accordingly, in NF patients height gain and FH-SOS were significantly lower 
compared to the remaining patients with organic CPP. 
As in other studies in girls, the younger age at start of symptoms of CPP was 
associated with more height gain compared to initial height prediction (3, 24) and is known to 
be associated with poor spontaneous outcome (17,18). Although this suggests that patients 
should be treated early, before irreversible SA maturation has occurred, strict criteria for CPP 
should be used. 
We found no correlation of FH with initial patient characteristics, suggesting that even 
boys with initially a poor prognosis ended up in the range of the genetic height potential. In 
linear regression analysis an association of height gain with SA and SA advance at start of 
treatment was described. Interpreting these data would suggest that a higher SA results in a 
smaller height gain, especially when the difference with CA is small. Prospective studies 
should address this issue formally. 
Several reports have shown that girls with non-progressive forms of CPP should not 
necessarily be treated at least for auxological goals (25). In boys the issue of progressive vs. 
non-progressive forms of CPP has not been clearly delineated as yet, probably because the 
assessment of a pubertal testicular volume and plasma testosterone are relatively robust 
criteria, unlike minimal breast development or plasma oestradiol. 
Criteria used to decide on discontinuation of treatment have been debated and can 
influence post-treatment growth and final outcome. In our study post~treatment growth was 
highly correlated with SA at discontinuation of treatment (r = ~O.60. p<0.01). Identical results 
were obtained in girls (2, 3). In normal children, peak HV occurs around a CA of 11.5 yr in 
girls and 13.5 yr in boys (26). In several studies in girls with CPP the average BA at 
interruption of treatment was> 12 yr (1,2,6,24) while it is close to 13.5 years in boys ( (6, 
2?) and this study). Therefore BA at discontinuation corresponds to early~mid puberty in boys 
and to late puberty in girls. Altogether, these differences may explain why boys grow an 
average of 15 cm after treatment while girls only grow 9-10 cm. Similarly, Galluzzi et al. have 
observed a more pronounced post~treatment growth~spurt in boys than in girls (6). Based on 
our study we cannot recommend a particular SA to discontinue treatment. 
In boys with pseudo precocious~puberty anti~androgens and aromatase inhibitors 
have been used, sometimes in combination with GnRHa when central puberty develops. The 
analysis of the relative contribution of the anti~androgenic effect and anti-estrogenic effect is 
difficult in these cases. It Was shown that Spironolactone and Testolactone were able to 
normalise the growth rate and rate of bone maturation (28). Further, observations of 
mutations in the estrogen~receptor gene (29) and of aromatase deficiencies (30) in males 
suggest that blocking the estrogenic effect would be enough to achieve the auxological goals 
in boys with CPP. However, blocking the androgenic effect in young boys with CPP is 
important as well. 
We conclude that in boys with CPP GnRHa is effective in obtaining a FH not 
significantly different from TH. 
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ABSTRACT 
Early onset of puberty is frequently observed in adopted children. During treatment with 
Gonadotrophin Releasing Hormone agonist (GnRHa) a decrease in height velocity (HV) 
precludes height gain. We studied the effect of the addition of growth hormone (GH) to 
GnRHa treatment in a 3~year randomised trial in 30 adopted children with early puberty. 
Mean age (SD) at start of treatment was 9.6 (0.9) yr in girls and predicted adult height (PAH) 
using a segmented bone age (BA) assessment method was 148.0 (5.3) em. HV decreased 
gradually in both groups wilh a higher HV in the group with GH addition (= group B). No 
significant difference between the rates of bone maturation (~BA I ~CA) of both treatment 
groups was observed. After 3 years of treatment PAH increase was 5.7 (3.8) cm in group A 
(GnRHa alone) and 10.1 (3.8) em in group B (P < 0.01). Insulin-like growth faelor I (IGF-I) 
levels were higher in group B. HV decreased slowly in both groups during treatment, unlike 
stabilisation of IGF~llevels. We conclude that after 3 years of treatment the addition of GH to 
GnRHa results in a higher HV and a significant increase in PAH compared to GnRHa alone. 
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INTRODUCTION 
In children adopted from developing countries the onset of puberty is often considerably 
earlier than in the countries the children originate from, resulting in compromised adult 
height(1-7). The occurrence of early puberty might be related to the improvement of 
nutritional status in early life (8, 9), possibly facilitated by an increase of [eptin secretion 
acting as permissive factor for the onset of puberty by interacting with several neuropeptides 
(10). 
In early or precocious puberty long-acting GnRHa treatment is currently considered 
the first choice of treatment. Data from recent literature suggest that adding growth hormone 
(GH) to GnRHa treatment is of benefit to improve final height (FH) (11). However, 
randomised prospective trials on the effect of combined treatment are scarce, especially in 
non-GH deficient patients (12). 
In children adopted from Eastern Asia or South America the parental heights are 
generally not known, thus making the analysis of any growth promoting therapy difficult. 
These difficulties are of even more importance as bone age (SA) assessments can only be 
compared by western world standards. It is not known how these standards compare to 
foreign-born children and how to account for possible effects of catch up growth on skeletal 
maturation. 
In this study we evaluate the effect of the addition of GH to GnRHa treatment in 
adopted children with early puberty. We compare initial height predictions at start of 
treatment with predictions after 3 years of treatment with an adapted bone age assessment. 
PATIENTS & METHODS 
Children in this study met the following inclusion criteria: (A) born in India, Sri Lanka, Colombia 
or South Korea; (B) pubertal development started between 7 and 10 years of age in girls with 
breast development andlor menarche; in boys, pubertal development with testicular 
enlargement (:=:: 4 mL) started between 8 and 11 years; (C) pubertal response of Luteinizing 
Hormone (LH) in a GnRH stimulation test (13); (D) bone age at start ~ 12.5 yr in girls and ~ 14 
yr in boys; (E) Predicted adult height (PAH) below the third percentile for the Dutch population 
(14), which is the nation-wide accepted cut-off value for the diagnosis of short stature; (F) 
passing of a psychological screening test before start of the study; (G) written informed 
consent from parents or guardians; (H) no abnormalities in endocrine and biochemical 
screening. 
Height was measured every 3 months by the same observer in the outpatient clinic 
using a Harpenden stadiometer. The mean of 4 measurements was used for analysis. Sitting 
height (SH) and weight were assessed at each visit as well. Pubertal staging was scored 
according to Tanner (15). 
Sone age (SA) was assessed by a segmented Greulich & Pyle (GP) score. This 
method consists of the scoring of 7 regions of the hand and wrist (radius, ulna, metacarpals, 
proximal, medial and distal phalanges and carpals), assigning a GP bone age to each segment 
and dividing the summarised score by seven. This method combines the advantages of 
detailed scoring with the use of the most appropriate method of BA assessment in early 
puberty (16). For adult height prediction we used the average Bailey & Pinneau tables even 
when SA was more than 1 year advanced over chronological age (17). 
Laboratory assessment at baseline included: a GnRH stimulation test with 100 119 
GnRH and sampling after 30 and 60 minutes and an arginine GH stimUlation test (0.5 g/kg 
body weight Lv. over 30 minutes) in order to exclude growth hormone deficiency. During the 
study GnRH stimulation tests were repeated after 12, 24 and 36 months to monitor pituitary 
suppression. Growth hormone, LH and FSH were assessed by time resolved 
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immunofluorimetric assay (Wallac, Turku, Finland); androstenedione by radioimmunoassay 
(DSL Sensheim (Germany) and DHEA sulphate by an in house RIA with tritiated DHEA-S. 
Estradiol and Testosterone levels were measured by RIA (Orion Espoo, Finland). IGF~I and 
IGFBP~3 were assessed and transformed to SO scores as described previously (18). 
Ultrasound measurements of uterine and ovarian volumes were performed regularly, and 
ovarian volumes were compared with normative data for calculation of SO scores (19). 
The children were randomised and treated for 3 years with either GnRH~agonist alone, 
group A (triptorelin (Decapeptyl®, Ferring and from 1998: Ipsen); dosage: 3.75 mg Lm. every 
28 days) or in combination with hUman recombinant GH: group B (Genotropin®, (Pharmacia & 
Upjohn) 4 lUI m' s.c. every day). 
In the original design of the study a third arm was included as a non~treated control 
group, but this design was discontinued when the parents of the children that were randomised 
for no treatment refused further participation, as GnRHa treatment would be available 
elsewhere. Before randomisation, children and parents underwent extensive psychological 
evaluations aimed at assessing their motivation for treatment and current psychological status. 
The results of these evaluations will be published separately (chapters 6.2 and 6.3). The study 
was approved by the local Ethics Committees and by the Dutch National Board on the Ethics 
of Medical Research (KEMO). 
Statistical analysis 
Results are expressed as mean ±. SO. The main outcome parameter of this study is height 
gain, defined as the difference between initial height prediction and height prediction at 
discontinuation of treatment. Differences between groups were analysed by Student's t~test. 
Comparisons between parameters within the treatment groups were performed pairwise. 
When appropriate non-parametric comparisons (Mann-Whitney) were used to compare 
group A and B. Univariate correlations were non-parametrically tested with Spearman rho in 
case of non-normal distribution. 
Changes in variables during the study period between treated patients and controls 
were analysed by repeated measurement analysis. The changes during the course of 
treatment between groups and changes in the course of treatment for both groups together. 
A p value of <0.05 was considered to indicate statistical significance. 
RESULTS 
Auxology 
Thirty patients were randomised for treatment, 27 girls and 3 boys. Children originated from 
Sri Lanka (10 girls, 2 boys), India (9 girls), Colombia (6 girls, 1 boy) and South Korea (2 
girls). They had arrived in The Netherlands at a median age of 4.5 months (range 1.0 - 84). 
Fourteen girls were randomised for group B and the other girls as well as the three boys for 
group A The children from each country were equally divided in group A and B. 
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Table 1: Patient characteristics at start of treatment (median and range). 
Group A Group B Boys (n=3) 
(13 girls) (14 girls) 
Chronological age (yr) 9.8 (7.3/10.7) 9.7 (7.6/10.6) 10.8 (10.6/11.6) 
Age at arrival (months) 3.0 (1.0/84.0) 7.0 (1.0/51.0) 2.0 (1.5/14.0) 
Height (cm) 133.9 (116.8/148.1) 134.6 (126.6/145.2) 131.4 (129.6/135.1) 
H-SDS forCA -0.85 (-2.88/0.82) -0.63 (-2.24/0.60) -2.40 (-2.521-2.33) 
Bone age (Yrl 11.0 (8.5112.1) 11.5 (10.0/12.6) 10.4 (9.1/11.9) 
H-SDS for BA -1_68 (-3.071-0.74) -2.32 (-3.121-1.18) -1.48 (-2.971-1.35) 
Predicted adult height (cm) 150.3 (140.7/159.2) 145.5 (141.1/155.2) 169.9 (158.1/170.3) 
lH peak value (lUll) in 35.5 (1.0/60.0) 22.7 (1.6/51.8) 26_0 (18.4/39.5) 
GnRH stimulation test 
GH peak (mUll) in GH 29.4 (9.0/106.7) 44_1 (15.8/126.6) 23.7 (21.3126.6) 
stimulation test 
In table 1 patients characteristics at start of treatment are shown. The mean difference 
between carpal and phatangeal 'BA' appeared to be 0.5 yrs (range 0.1 - 1.1) at start of 
treatment. Height-SDS for SA (H-SDSBA ) for girts in group A stabilised after an initiat 
increase, whereas group B showed a continuous increase (figure 1). The differences 
between the two groups did not reach statistical significance. The change in H-SDSsA from 
start to 3 years of treatment was significantly different between group A and S: 0.39 (0.41) 
and 0.83 (0.38), respectively (p=O.Ol). Significance was also present during the course of 
treatment between group A and B in repeated measurements analysis (p < 0.001). 
H-SOS rorBA 
-, -"~--,, -'~ 
ILl Irc= 
., 
treatment pellod (months) 
Ffgure 1. Growth during treatment: H-SDS for SA. significant differences 
between groups in course of treatment (p<O.OOl). 
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Silting height SDS did not change significantly during treatment in group A and B and no 
significant differences were present between group A and B. Sitting height I height ratio SDS 
slowly increased during treatment with a significant difference in both groups between start 
and at 36 months (p = 0.001) but without significant differences between group A and B in 
the course of treatment. 
Height velocity (HV) calculated over the consecutive 12-month periods was 
significantly higher in group B in the first year of treatment: 5.4 (1.15) and 6.7 (1.59) cm I yr in 
group A and B respectively (p < 0.05). HV gradually decreased to 3.6 (1.00) and 4.1 (1.67) 
cm Iyr respectively in the last year (figure 2a). In table 2 the bone maturation, defined as 
flSA I fleA shows that SA maturation was < 1.0 during the whole treatment period and was 
not significantly different between the groups. SA at discontinuation of treatment was 12.3 
(SD 0.9) yrs in group A and 13.0 (0.6) in group B. 
Table 2: Bone age maturation in girls and boys (mean, SD) 
ABA I ACA period (months) Group A Group B 
0-12 0.64 (0.18) 0.64 (0.17) 
12-24 0.54 (0.19) 0.46 (0.16) 
24-36 0.54 (0.19) 0.42 (0.22) 
The resulting parameter (PAH) is shown in figure 2b. In both group A and B the increase in 
PAH between start and 3 years of treatment was highly significant (p < 0.001), the change in 
PAH in time between group A and B was significant during the treatment period (p< 0.001). ). 
In figure 2c the gain in PAH compared to initial prediction is shown at different moments. The 
gain in PAH was significantly different between group A and B at 36 months of treatment: 5.7 
(3.8) and 10.1 (3.8) cm respectively (p < 0.01). In group B gain in height prediction was 
negatively correlated with BA at start of treatment (rho = -0.60, P = 0.02). In 13 girls actual 
height at discontinuation of treatment already exceeded initial height prognosis, 11 of them 
belonging to group B. 
A temporary increase in Body Mass Index (BMI) SDS was observed in group A, while 
in the girls with combined treatment BMI-SDS increased from 0.58 (0.97) at start to 0.99 
(0.81) at discontinuation of treatment (p<0.05). The change in BMI-SDS between start and 
Legend to Figure 2: height velocity and changes in height prediction. 
2a: Height velocity per treatment year. 2b: Absolute values of PAH; significant differences 
between groups in time (p<O.OOl); 2c: cumulative height gain compared to start of treatment; 
asterisks indicate differences between group A and S. ~: p<0.05, **: p<0.01 
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discontinuation of treatment was not significantly different between group A and B. The 
number of girls with BMI·SOS > 2 did not change in group B. BMI·SOS was not different 
between the 2 groups during the treatment period. 
Hormonal data 
Suppression of puberty was monitored by a GnRH stimulation test. During treatment mean 
LH peaks for all patients were 0.95 (1.16), 1.18 (2.09) and 0.62 (0.43) at 12, 24 and 36 
months respectively. Mean estradiol level in girls at start of treatment was 67.5 (45.6) pmollL 
(range 39-203). Estradiol levels were suppressed during treatment and mean values did not 
exceed 40 pmollL except for 1 girl in group B at 6 months of treatment with an E2 value of 50 
pmol/L. No significant differences were seen between group A and B. 
Serum androstenedione and DHEA-S levels in girls were not significantly different 
between group A and B during the course of treatment When taken group A and B together, 
the difference between levels at start and at discontinuation of treatment were significantly 
different for both androstenedione and OHEA·S (p < 0.001, table 3) 
Table 3 Main changes in serum DHEA-S and androstenedione levels in girls; see text for 
detailed description. 
(mean; SO) Group A Group B 
OHEA·S at start (~moIIL) 1.81 (1.20) 1.80 (0.85) 
OHEA-S at 6 months (~mollL) 2.04 (1.29) 2.26 (1.33) 
OHEA-S at 36 months (~moIIL) 3.34 (1.80)' 3.32 (1.29)' 
Androstenedione at start (nmollL) 3.48 (2.21) 2.69 (1.46) 
Androstenedione at 6 months (nmoIIL) 1.85 (0.93)# 1.71 (0.89)# 
Androstenedione at 36 months (nmoIIL) 2.75 (1.72) 2.82 (1 AS) 
Paired t-test: • p < 0.001 compared to start # p < 0.05 compared to start 
In girls, at start of treatment IGF-I SOS was 1.14 (1.02) when corrected for CA and 0.67 
(0.90) when corrected for BA, both significantly higher than 0 (p ,,-0.001). IGF-I was higher in 
group B than in group A, both the serum levels (figure 3) and the SO scores for CA and BA 
In the longitudinal analysis between groups, there were significant differences between group 
A and B for the IGF-I serum levels and for the so scores (all p < 0.01). In group A IGF·I -
SDBA scores gradually decreased during treatment while the SD scores for group B stabilised 
at values significantly higher than in group A at 24, 30 and 36 months (p < 0.05). 
No significant changes during the course of treatment, between groups or between 
group A and B during treatment were present for IGFBP-3 levels or IGFBp·3 SO scores. 
Mean IGFBP-3 SD scores for BA remained < 0 and showed only small variations within 1 
SOS. The ratio IGF·IIIGFBP-3 remained stable in group B, whereas the values in group A 
were significantly lower in the second half of the treatment period. 
In group B significant correlations were present between lGF-I-SDSBA and HV at 0, 
12 and 24 months of treatment, where IGF·I SOSBA correlated with HV in the following year 
of treatment (Pearson correlation coefficients: -0.62, -0.63 and -0.67 respectively, p < 0.05 or 
< 0.001). 
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Figure 3: IGF-I and IGFBP-3 levels during treatment; 3a: absolute values of IGF-I in nglml; 
differences between group A and B: at 12 and 24 months: p<O.05 and at 36 months: p<O.01; 
the change between group A and B in time is significantly different (p < 0.01) 
3b: absolute values of IGFBP-3 in mg/L. No significant changes between groups and/or in 
time 
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Laboratory evaluation of renal and hepatic function did not reveal any abnormalities. In group 
B mean and maximal HbA1c levels remained equal or below initial values and did not exceed 
6.6 % during the treatment period. 
Ultrasound 
Ovarian ultrasound measurements revealed a decrease in ovarian volumes, from 2.6 (1.1) ml 
at start to 1.5 (0.7) mt at 36 months (p < 0.01). Neither the absolute values nor the calculated 
SO scores were significantly different between group A and B in the course of treatment. 
In both groups, the uterine volumes decreased, with higher values in group B, the 
difference reaching significance only at 24 months: 2.5 (1.83) ml and 4.0 (3.37) ml in group A 
and B respectively, (p < 0.05). During treatment, no significant difference was observed 
between the treatment groups. 
Boys 
In the 3 boys mean increase in PAH was 5.9 (1.46) cm. Height SOS for SA increased from-
1.93 (0.90) to -0.89 (0.83) after 3 years of treatment. In this treatment period BA increased 
from 10.5 (1.4) to 12.1 (1.54) years and mean HV was 6.5 (0.71).4.8 (0.27) and 4.3 (0.17) 
cm/yr in the first, second and third year respectively. 
Side effects 
No serious side effects were observed during treatment. One girl in group B had local 
erythema after the triptorelin injection. Treatment was continued after 15 months of triptorelin 
with leuprolide acetate in a comparable dosage given s.c. whereafter effective suppression 
was established. One girl in group A dropped out 15 months after start of treatment. 
DISCUSSION 
In this randomised trial comparing the effect of GnRH agonist treatment alone or in 
combination with GH in adopted children with early puberty we show that the addition of GH 
to GnRHa treatment results in a significant increase in PAH after 3 years of treatment. Our 
results are in line with the data of Tuverno et al. who also showed beneficial effects after 2 
years of GH addition in adopted girls in a comparable study design using Buserelin nasal 
spray as the GnRH agonist (9). 
The best way to perform our study would have been a design with an untreated 
control group. However, we did not succeed in performing such a trial as explained above. 
Thus, children treated with GnRH agonist alone served as the best possible controls and 
historical data of untreated adopted children will be gathered for final height analysis. 
The importance of effective suppression of the hypothalamo-pituitary-gonadal axis to 
reach the auxological goals of GnRHa treatment is well-established (20). Effective 
suppression was ascertained in this study allowing proper analysis of the additive effect of 
GH. 
The rationale for the addition of GH to GnRHa treatment is based on the clinical 
observation that after some period of GnRHa treatment height velocity decreases below 
even normal prepubertal levels (21,22). In our study, HV decreased during treatment in both 
treatment groups, with a higher HV in group B at any time point although the difference was 
only small in the last 6 months of treatment. The IGF-I SDS corrected for BA also showed a 
gradual decrease during treatment. However, mean serum levels remained in the normal 
range in both groups, thus not providing a final explanation for the decrease in HV. 
Walvoord, reviewing the current literature on the combined treatment concluded that 
the influence of GnRHa treatment on the GH-IGF-axis is not clear (23). Our data 
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demonstrate higher IGF-I levels and SO scores in the group with combined treatment, and 
both in group A and group B a decreasing trend over time is present. Thus, addition of GH is 
able to maintain IGF-I levels in a higher range during GnRHa treatment. These higher IGF-I 
levels seem to result in higher HV in group 8. However, despite the stabilisation of IGF-I 
levels in the last year of treatment, HV shows a decline, suggesting that the amount of IGF-I 
alone is not sufficient to maintain the previous HV, neither on a rate appropriate for 
prepubertal girls nor appropriate for the the relative high SO scores for IGF-1. The 
explanation for reduced growth despite adequate GH and IGF-I levels is not clear. There 
might be a direct effect of severe sex steroid deficiency on skeletal growth or an involvement 
of local factors (22). In rat, the oestrogen withdrawal by GnRHa caused increased apoptosis, 
and no direct role of GnRHa itself could be demonstrated inhibiting growth (24). IGFBP-3 
values did not change during treatment, in line with other reports in GnRHa treated children 
(25) but in contrast to an earlier report on IGFBP3 levels in children on combined treatment 
(26). The changes in the ratio between IGFBP-3 and IGF-I in group A may have resulted in 
higher binding of circulating IGF, thus limiting the free fraction. This may raise the question 
whether further GH dose increments during GnRHa treatment would result in higher HV, 
such as described in Turner syndrome (27). 
From our study it can be concluded that the addition of GH to GnRHa results in higher 
IGF-I levels accompanied by higher HV in the first years of treatment. Thus GH is able to 
prevent the negative effects of GnRHa on the IGF-I or GH secretion. However, it is known 
that the results of GH testing do not adequately reflect growth characteristics during GnRHa, 
and one should account for the changes in BMI (22, 28). The absence of a difference in 
change in BMI-SOS between group A and B does not support the hypothesis that a decrease 
in GH dependent growth factors would lead to an increase in fat mass (29). On the other 
hand it should be realised that BMI is not the optimal parameter to assess body fat mass in 
children (30) and that the changes in BMI-SDS in our study were relatively small. 
The difference between group A and B in height gain in our study is mainly explained 
by the higher height velocity during treatment in group B, occurring in the first 2 years of 
treatment, since the addition of GH had no significant effect on the rate of skeletal 
maturation. A similar observation was made by others (22, 26, 31). In the study of Tuvemo et 
a!. the rate of maturation was considerably higher (dBA IdCA =1) compared to our study, 
and height gain was considerably smaller. This may be due to the use of Buserelin as nasal 
spray that may have had a less suppressive effect on the hypothalamo-pituitary-gonadal axis 
when compared to suppression with depot preparations (32). However, in their study LH 
values in GnRH stimulation tests during treatment revealed suppressed pituitary activity with 
a comparable assay. These contradictory findings could be explained by the different 
methods of SA assesment and height prediction. 
As pointed out by Carel et al. several methodological questions arise in the evaluation 
of the effect of treatment in CPP (33). The Greulich & Pyle (G&P) method is most often used 
in CPP, but the disadvantages of any method with regard to height prediction are well known 
(34). In 1997 Kauli et al. described that the use of average tables of BP prediction method in 
girls with CPP results in more reliable height predictions than when the accelerated tables 
are used as commonly done in children with CPP. As we described earlier, using this 
prediction method makes it difficult to compare our data with earlier reports, that may have 
overestimated initial height prediction (20). In our study we used an adapted G&P method for 
BA assessment, which is close to the original recommendations made by Greulich and Pyle 
(35): the "point scoring system" of BA results in smaller intra-observer variations than an 
"atlas matching" method such as the way the G&P method is used in daily practice (16). 
The next issue is the reliability of western world standards for adopted children. 
Prakash studied skeletal maturity in well-off children in India and showed that the RUS 
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maturity score for girls reflected a parity with the British standards. The carpal scores ran 
from the 50th to the 25th percentile after 10 years in girls and after 11 years in boys (36). The 
influence of malnutrition or catch-up growth on skeletal maturation has been described (37, 
38) but the effect of the transition to favourable circumstances is not known. One might 
hypothesise that catch-up growth of children coincides with an increased rate of skeletal 
maturation, resulting in advancement of BA compared to standards. Whether this is followed 
by a normal maturation rate after the period of catch-up growth is not known. In clinical 
practice we and others (2, 8) have seen that in some children, especially those who were 
adopted at an older age, catch-up growth after arrival in Europe passed into a pubertal 
growth spurt. The reported data on adopted children with early puberty led to the suggestion 
that increased growth rate during recovery from nutritional deprivation in a critical period 
could result in early onset of puberty. This was confirmed in an animal model where the role 
of increased IGF-I as an important mediator is suggested in the accompanying paper (8). 
Proos et al showed in Indian girls adopted in Sweden that there is a correlation between the 
rate of catch up growth and age of menarche in children that had arrived after 3 years of age 
(2). Catch up growth will not only increase IGF-I levels but leptin levels as well due to the 
increase in body fat mass. In girls with precocious puberty serum leptin levels were modestly 
increased compared to girls matched for pubertal stage and a negative correlation between 
leptin SOS and BMI was obseNed (39). 
In girls adopted at a younger age another mechanism must be present. In those 
children catch up growth is present and is followed by a period of normal prepubertal growth. 
The mechanism for the early onset of puberty is not clear, and might be comparable with 
catch up growth in children after intrauterine growth retardation. There may be environmental 
factors in the pre- or postnatal period having long-term effects on the hypothalamo-pituitary 
action (40), for example on the hypothalamic control of LH release (41). 
The hesitation observed around the decision to treat adopted children with early 
puberty and low predicted adult height may be influenced by the assumption that early 
puberty is normal for these children. However, the available data from the countries of origin 
show that the normal age of menarche is higher than the normal age of menarche in The 
Netherlands, thus indicating an effect of the transition to Europe (1, 6, 42, 43). In our view 
treatment is justified to limit the negative effects of early closure of the epiphyseal plates and 
offering the children an adult height as close as possible to their genetic potential. Our results 
imply that addition of GH could be considered not only in adopted children but also in non-
adopted children without GH-deficiency with early puberty and treated with GnRHa. 
However, with respect to the high costs of GH treatment a balance should be found between 
cost and benefit. Further, it was described in CPP that height gain at FH was less than 
expected from the height prediction at the end of treatment, due to poor post-treatment 
growth (44). 
We conclude that the addition of GH to GnRHa treatment in adopted girls with early 
puberty results in a significant increase in PAH after 3 years of treatment. Follow up until FH 
is required to assess the ultimate results. 
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ABSTRACT 
Early puberly is frequently obseNed in adopted children. We treated 30 adopted children with 
early puberty and short stature in a randomised trial with either a Gonadotrophin Releasing 
Hormone agonist (GnRHa) alone or in combination with growth hormone (GH) for 3 years. In 
this trial the children and their parents underwent a psychological evaluation before start of 
treatment (T1) and at discontinuation (T2). At start of treatment the children did not have 
increased levels of behavioural or emotional problems as assessed by the Child Behaviour 
Checklist (CSCl). During treatment the CSCl scores did not increase. Self-perception of the 
children appeared to be normal, and after 3 years even a significant higher score for 
acceptance by peers was observed. At T1, in 80% of the children and in 17% in the parents an 
overestimation of future height was present. Lower family stress was observed at T1 and T2 
compared to reference values. We discuss the findings with reference to the reported levels of 
behavioural and emotional problems in adopted children and psychosocial effects of 
precocious puberty. We conclude that in adopted children with early puberty the psychological 
evaluation did not reveal any consistent abnormality. The treatment with GnRHa with or without 
GH does not increase emotional and behavioural problems nor decrease their self"perception. 
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INTRODUCTION 
Ear[y puberty is frequently seen in foreign-born adopted children (1-4). No dear explanation is 
available to understand the occurrence of early puberty. [t can be hypothesised that the 
improvement of nutritional status and socio-economic situation compared to the country of 
origin results in an accelerated maturation of neure-endocrine structures, especially during a 
specific critical period after birth. 
The effects of early puberty are well known: psychosocial distress and emotional 
problems (5-8) in addition to a decreased final height (7, 9, 10)_ Psychosocial evaluation in 
adopted children has revealed increased parent-reported emotional and behavioural problems 
compared to non-adopted peers (11,12). It may be assumed therefore that adopted children 
with early puberty are specifically at risk for emotional and behavioural problems. These 
problems could be attributed to early pubertal development, short stature and the adoption 
status. 
Currently the pubertal development in central precocious puberty or early puberty can 
be arrested effectively by Gonadotrophin-Releasing Hormone agonists (GnRHa) 
administration (13). We studied the effect of puberty-delaying treatment with GnRHa alone or 
in combination with recombinant human growth hormone (GH) to promote growth in adopted 
children with early puberty. The aim of the study was to evaluate the psychological effects of 
early puberty and short stature itself and of the treatment given. In this paper we describe the 
results of psychological assessments before treatment (T1) and afler treatment (T2). The 
evaluation of motivation for treatment and the effects of treatment on growth and puberty will 
be reported separately. 
PATIENTS AND METHODS 
Children in this study originate from India, Sri Lanka, Colombia and Korea and were adopted 
by Dutch parents. The children developed early puberty, defined as pubertal development 
between 7 and 10 years of age in girls and between 8 and 11 years in boys. In girls, the onset 
of puberty was characterised by breast development and/or menarche, in boys by testicular 
enlargement (~ 4 ml). In both the physical signs were accompanied by a pubertal rise in 
gonadotropins in a GnRH stimulation test. To assess bone age (SA) an X-ray of the left hand 
was obtained. The predicted adult height (PAH) was calculated on the basis of height and SA. 
For inclusion in the study PAH had to be below the third percentile of Dutch children for sex 
(14). 
The children in this study were treated for 3 years with either the GnRH-agonist 
triptorelin (Decapeptyl®) alone (group A) or in combination with recombinant human growth 
hormone (Genotropin®) (group B). A physician or nurse gave GnRH agonist every 28 days by 
an intramuscular (1M) injection; growth hormone was administered every day by subcutaneous 
(SC) injection at home by the patient him-/herself or one of the parents. 
The study schedule is depicted in figure 1 . 
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Figure 1: Study schedule 
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,.. Change in design 
In the original study design a third arm with untreated children was scheduled as a control 
group. It was decided to leave this control group out of the study design after it appeared that 
the parents of all patients who were randomised in the untreated control group refused further 
participation in the study as GnRHa treatment could be obtained elsewhere. This article 
describes the results of the patients entering into the treatment protocol. 
~ T1 data collection 
Before randomisation for group A or B, a psychological assessment (T1) was performed. The 
instruments used are shown in table 1. 
Child Behaviour Checklist (CBCL): The CBCL is a standardised instrument to obtain parents' 
reports of competence and problem behaviour of their child (15). It consists of 20 competence 
items and 120 problem items. Competence ratings were scored on three competence scales: 
activities, social and school and also on a total competence score. The problem items that 
describe the child are summarised in a score for internalising (e.g. withdrawn, anxious 
Idepressed), externalising (e.g. aggressive, delinquent) problems and a total problem score. 
The reliability and discriminative validity of the Dutch translation has been established (16). 
Reference values for adopted children in the Dutch population were used for comparison (17). 
The Teacher Report Form (TRF) is the CBCL version to be completed by the child's teacher. 
Reference values for the Dutch population are available (18). 
Self-perception profile for children (SPPC): Harter developed this self-reported 
instrument for measuring self-esteem or perceived competence in children (19). Self-
competence in different domains is measured (scholastic and athletic competence, social 
acceptance, physical appearance and behavioural conduct), as well as an independent 
assessment of global self-worth. A Dutch translation was validated by Van Dongen-Melman et 
a/. (20). The SPPC has been used in several studies on short stature (21, 22). For this study 
we analysed data on social acceptance and physical appearance as children with early puberty 
might be less socially accepted and do not feel comfortable with their physical appearance. 
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Table 1: Psychological inslruments at Tl 
Parents Child 
Standardised structured interview on signs of Standardised structured interview on signs of 
early puberty early puberty 
Standardised structured interview on expected Standardised structured interview on expected 
aspects of treatment aspects of treatment 
Silhouette Apperception Technique (SAT) Silhouette Apperception Technique 
Child Behaviour Checklist (CBCl) and Self Perception Profile for children 
Teacher Report Form (TRF)@ 
Questionnaire on family stress (NVOS) Wechsler Intelligence Scale lor children 
(WISC)# 
@: CBCL version to be completed by the teacher; #:short form: 'block deSign' and 'information' (39) 
Silhouette Apperception Technique (SAT): This test describes the accuracy of 
estimation of current and future height and was developed to study expectations of treatment 
with recombinant growth hormone (23, 24) 
NVOS: The "Nijmeegse Vragenlijst voor de Opvoedings Situatie" is a validated Dutch 
questionnaire evaluating family stress. It is to be completed independently by the father and 
the mother of a child. With the NVOS many aspects of famity functioning and family stress 
are evaluated. We limited our analysis to 4 main items that we regarded to be of specific 
importance: first to what extent the family functioning is accepted or should be changed, the 
presence of problems (2nd) and whether the parents are able to deal with problems (3rd). 
For these items a higher score indicates increased family stress. A general assessment of 
family functioning is expressed in the 'satisfaction' item (4th): the higher the score, the more 
satisfied the parent is. The NVOS was used in earlier studies in children with precocious 
puberty and was validated for the Dutch popUlation (25, 26). 
Standardised structured interview on signs of early puberty and expected aspects of 
treatment In the structured interviews issues on the duration of pubertal signs and the impact 
on the child as weH as expected difficulties or problems with treatment or injections or with 
endurance were addressed. 
~ Data collection during and after treatment 
The T2 data collection was pertormed at the end 01 the 3-year treatment period. Except for the 
structured interviews we used identical instruments as were used in the T1 assessment. 
During treatment there was an evaluation of the treatment using a structured questionnaire for 
parents and the child, asking about endurance and burden of treatment and the perceived 
meaningfulness of the treatment. 
Statistics 
Comparisons from the observed data with known normative data were periormed by one 
sample t-test. Non parametric (Wilcoxon signed rank) tests with paired data were used for the 
comparison between T1 and T2 values. Because of the small numbers of patients no extensive 
statistical methods were applied on the data. 
The protocol was approved by the local medical ethical committees and by the Dutch National 
Board on Medical Research (KEMO). Written informed consent was obtained from all 
participants in this study. 
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RESULTS 
After the assessment of motivation for trealment, 30 patients (27 girls) were eligible candidates 
for the study and entered into the treatment protocol, 12 from Sri Lanka, 9 from India, 7 from 
Colombia and 2 from South Korea. 
We report results on the girls, unless stated otherwise. Mean age at start of treatment 
was 9.6 (SO: 0.90) years, mean height was 134.4 cm (7.0) cm and predicted adult height was 
148.0 (5.3) cm (6 cm < P3). There was a wide range in age at adoption: from 1 to 84 months 
(median: 6 months). Thirteen girls were randomised to group A, 14 to group B. No significant 
differences were present between group A and group B at baseline. 
During treatment, one girl dropped out from group A. The data collection was not 
complete for all parents as some of them refused participation in completing the 
questionnaires, mainly as they believed that there were no problems with the child to be 
reported or as they judged their family situation as being without problems. 
The results of the height data are described separately (Mul e/ a/; chapter 6.1). In 
summary, a mean increase in predicted adult height was observed in both groups, with a 
significant higher increase in group B compared to group A (10.1 vs. 5.7 cm). 
1. Emotional and behavioural problems 
We compared the CBCl scores from the study group with the known age matched norms for 
Dutch girls as well as with the findings in adopted girls in The Netherlands. Furthermore, 
scores on T1 and T2 were compared. Results are shown in table 2 (mean (SO». There were 
no Significant differences between the mean values at T1 and T2 when compared to either 
the norms of adopted or non-adopted children in The Netherlands. The decrease in total 
problem score and internalising and externalising scores did not reach statistical significance. 
Table 2. CBCL results 
T1 T2 Adopted children. Dutch norm 
N=25 N=23 (girls 10 and 11 yr. (girls 4·11 yr. 
. 
. n= 235) n = 593) 
Total problem 18.64 (17.49) 15.22 (13.01) 18.14 (17.12) 19.18 (14.82) 
score 
Internal ising score 5.68 (5.36) 4.22 (4.98) 4.98 (5.49) 5.16 (5.02) 
Externalising score 5.72 (5.98) 4.70 (5.16) 5.48 (6.35) 6.04 (5.57) 
Total problem score in group A (GnRHa alone) was significantly higher than in group B 
(GnRHa + GH) at T1 assessment; 25.31 (19.98) and 11.42 (11.08) in group A and B 
respectively (p<0.05). All other measurements at T1 and T2, described in table 2, did not 
significantly differ between group A and group B. 
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In group B the total problem score was significantly lower than for the Dutch girls (T1: 11.42 
(11.0B), T2: nOB (B.30) vs.19.1B (14.B2), n=12, both P < 0.05), but not compared to the 
adopted girls. No significant correlations were present between changes in the CBCl scores 
and the increase in predicted adult height during the study period. In 14 girls T1 and T2 scores 
of the TRF were available. No significant differences were observed between T1 and T2. Total 
problem score, internalising and externalising scores decreased according to the age-specific 
pattern. 
2. Self-perception 
The mean scores at T1 and T2 for girls for general self-worth scores were not significantly 
different from those of the Dutch references (20). Mean scores for physical appearance 
decreased from T1 to T2, and social acceptance values increased. The score for social 
acceptance at T2 was significantly higher than the reference population (p <0.01). 
Table 3: HSPPC scores, n =23, mean (SO) 
T1 score In=23) T2 score (n=23) Norm Igirls) 
General self-worth 3.34 (0.72) 3.25 (0.69 3.19 
Physical appearance 3.12 (0.62) 2.B1 (0.B5) 3.03 
Social acceptance 3.22 (0.71) 3.43 (0.49) •• 3.02 
.. p < 0.01 compared to norm 
There was no significant difference between the T1 or T2 scores for general self-worth, 
physical appearance and social acceptance between children with and without GH addition. 
No significant correlation was present between the change in SPCC variables and the increase 
in predicted adult height. 
3. Expectations of treatment 
The Silhouette Apperception test before start of treatment showed that the parents did not 
expect an increase in height percentile from the estimated actual height to adult stature. The 
children however expected an increase from about the 30th percentile to about the 60th 
percentile at the time they would have reached adult stature (p<0.001). 
At T2 assessment however, the expectations for future height were less optimistic in 
the children than at start of treatment, but the p value was still < 0.01 when compared to the 
estimation of present height. Data are summarised in table 3 for boys and girls. 
When a score of.::: P50 is assumed to indicate overestimation of height the percentage 
of children overestimating future height is 80 at T1 and 72 at T2; for parents the percentages 
are 17 and 15, respectively. 
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Table 4. Estimated actual and future height expressed in height percentiles in the 
study group for child and parents 
T1 T2 
Child (n=30) Parent (n=29) Child (n=29) Parent (n=26) 
Actuat height 
P3 12 14 5 11 
P25 8 9 13 8 
P50 4 6 8 4 
P75 4 - 2 3 
P97 2 - 1 
Future height 
P3 1 10 1 9 
P25 5 14 7 13 
P50 10 4 6 2 
P75 10 1 15 2 
P97 4 - -
4. Family stress 
The NVOS scores from the mothers were used and studied for the whole group as a 
considerable number of fathers did not fill out the questionnaire. A summary of the main 
parameters is given in table 5. 
Table 5: NVOS scores 
T1 (n=26) T2 (n=22) Norms Dutch . 
Acceptance 1.11 (0.18). 1.22 (0.33), 1.40 (SD-0.49) n=234 
Able to deal with problems 1.38 (0.33). 1.52 (0.31)# 1.71 (SD=0.56) n=234 
Havinq problems 1.45 (0.41). 1.55 (0.39). 1.94 (SD=0.60) n-234 
Satisfaction 4.09 (0.65) 3.80 (0.79) 3.86 (SD=0,58) n-167 
• p < 0.001 ; .. = p < 0.05; # :::: p < 0.01, all compared to norm 
The 3 first mentioned items out of 4 listed in the table show lower values in the study group 
than in mothers from the general Dutch population. The higher the score on 'satisfaction' the 
higher the mother is satisfied about the rearing situation in the family. With respect to the 
studied NVOS items no significant differences were found between children with and without 
the addition of GH 
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5. Intelligence 
The IQ levels for the whole group decreased significantly, but clinically not relevant from 100.2 
(12.7) at Tl to 93.1 (10.5) at T2 (p=0.002). A comparable significant decrease was present in 
both groups. There were no significant differences between group A and group B at T1 or T2. 
Tabfe 6 Result of fQ subtests; 25 paired observations (mean SO) 
Verbal score Performal score Total fa 
Whole group Tl 9.08 (2.96) 11,48 (4.04) 100.2 (12.7) 
Range: 3 -19 6-26 77 -138 
Whole group T2 8.04 (1.92) 9.28 (3.08) 93.1 (10.5) 
Range: 5 - 14 5-15 80 - 123 
Difference Tl-T2 NS 0.001 0.002 
6. Structured interviews 
Eighty % of the children reported that their classmates did not treat them differently from 
others, while in 13% (4 children) the child reported that she was bullied for any reason. With 
regard to the treatment, at Tl 20% (6/22) of the children expected that it would be difficult to 
continue the monthly injections during the whole treatment period, while the parents 
expected only minor or no problems. 
When the children (n=21) were asked to estimate pain from injections (scale: from 
much pain to no pain) the majority expected 'some pain', only 1 child expected 'pain' or 'much 
pain'. In parents (n=22) the distribution was shifted towards pain: 8 times: 'some pain' and 11 
times 'pain' or 'much pain'. 
The answers of parents to the question regarding the additive effect of GH 
administration indicated that they expected more gain from GH administration than the children 
did. 
DISCUSSION 
When discussing and interpreting the results of this study we should acknowledge the 
limitations of the study with regard to sample size and the lack of an untreated control group. 
Furthermore, the several factors involved, for example the adoption status, early puberty and 
short stature make the interpretation even more difficult. 
In contrast to our initial hypothesis, adopted children with early puberty and low 
predicted adult height did not differ markedly from adopted or non-adopted children with regard 
to emotional and behavioural problems or self-perception. Their parents did not exhibit higher 
scores on variables of family stress. 
The results on the parents at T1 reveal that they are generally competent and realistic 
people, able to cope wilh the presence of early puberty in their adopted child. This is in line 
with the literature on families with adopted children or children born after reproductive 
techniques in which the quality of raising was shown to be better than in children born after 
normal conception (27). Explanatory factors for this quality could be the relatively high socio-
economic status of adoption parents and the fact that they are selected on parenting capacities 
before adoption. 
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When the CBCL data are compared to normative data on Dutch adopted children we see 
that in our study population the children did not show more behavioural or emotional 
problems than their age and sex matched peers. The reason for this may be that most 
children in our study group had only a short period experiencing their secondary sexual 
maturation characteristics, e.g. breast development, not yet giving rise to shame or bullying. 
Due to a pubertal growth spurt the actual height can even be experienced positively by the 
child as it may bring the child's height more close to its peers. Another reason might be the 
positive attitude of the parents to their children emphasising that being different from peers 
can be labelled positively. Moreover, many people estimate the early pubertal development 
as normal for a child adopted from developing countries. Thirdly, the children are strongly 
supported by their parents in coping with their early pubertal development. Similar factors 
could be used to explain the results from the HSPP social acceptance subscale 
demonstrating that adopted children feel themselves accepted by their peers, even now in 
the presence of signs of early puberty making them more different from their peers. 
In the longitudinal analysis CBCL scores showed decrease in the total problem score 
and subscales for internalising and externalising problem scores. The decrease is comparable 
with the lower scores in older children in the reference population. Apparently, the treatment 
does not contribute to increase in problem behaviour or emotional problems as one might 
expect when accounting for the intenSity of treatment. This can be explained by the positive 
attitude of parents and the fact that a lot of attention is paid to the children in the research 
setting. Furthermore, the relationship between parents and the adopted child was described by 
the parents as close (28). The major intervention of suppressing the pubertal development, 
causing regression or arrest of pubertal development may decrease problematic behaviour (5) 
or at least prevent a further increase. 
It is known from the literature that early or precocious puberty leads to elevated CBCL 
scores on the internalising syndrome (withdrawal and anxious Idepressed) up to 2 years after 
start of treatment (5). We did not confirm this observation which may be explained in part by 
the age at start of treatment that was relatively high compared to reports in children with 
precocious puberty_ No association was found between idiopathic precocious puberty and 
long-term severe psychopathology. However, it was reported that precocious puberty in girls is 
associated with a long-term risk of minor psychopathology (6, 29, 30). With respect to 
psychosexual development, early pubertal development was associated with earlier, but not 
extremely advanced psychosexual development (6, 29). During treatment with GnRH agonist 
problematic behaviour and functioning decreased slightly, particularly in the girls showing 
regression of breast development (5). In our population in all patients regression of the signs of 
puberty was observed. 
The most remarkable finding in the longitudinal assessment of HSPP was the relative 
increase in the score for social acceptance. Several factors could playa role: the regression of 
pubertal signs brings the child back into the age matched peers, children may feel that 
treatment makes them more 'normal' now and in the future and maybe the decreasing trend in 
emotional or behavioural problems improves acceptance in the peer group. 
It is difficult to demonstrate quantitatively to what extent children suffer from the early 
puberty or short stature due to the lack of standardised instruments. Therefore the indication 
for growth promoting treatments such as performed in this trial is hard to sustain as was 
demonstrated in the case of children with short stature (31). On the other hand we have to deal 
with parent's and children's expectations of treatment. In the SAT we studied the perceived 
current height and the expected height after treatment. The development of the scores from the 
SAT show that the expectations of the children with regard to future height are still positive at 
the end of treatment, while those in the parents did not change in the treatment period. This 
points to the limited capacity of the children to predict and estimate figures in the future, while 
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they are able to estimate their own current height in comparison to their peers. Parents did not 
have unrealistic expectations of the effect of treatment, probably due to the thorough 
information procedure before the informed consent was given. On the other hand, the children 
expected to be considerably taller at the end of treatment than they were at the moment 
starting treatment. In children with short stature about 60% of the girls had unrealistic 
expectations of their future height (::: p50), compared to about one~third in parents (32). 
With respect to the family stress the presence of early puberty and expected short 
stature does not increase family stress to levels above normal. On the contrary, family stress 
is even significantly [ower on the studied sub items. We show that the treatment does not give 
rise to family stress above the limits of normal. Probably, we have to do with stable families, 
already used and able to handle difficulties (33). Thereby, in general the socia-economic and 
educationalleve[ of parents of adopted children is relatively high. One can conclude that, as in 
children from IVF or KID procedures, the parents are competent in dealing with the problems of 
their children. On the other hand it was described in IVF parents, 1 year postpartum, that they 
reported lower self esteem and IVF mothers saw their children as more vulnerable and 'special' 
compared with controls (34). They often mentioned that their motivation was based on the idea 
of precluding future regret on not having tried every possible treatment option available. This 
might theoretically lead to some kind of overprotection with possible adverse effects on the 
child. In a quantitative analysis of motivation for treatment we concluded that the parents were 
in the fast majority of cases adequately motivated (Mul et al. chapter 6.3). 
In our study population the delay between start of pubertal development and start of 
treatment was not as long as in the study of Xhrouet et al. which was interpreted as a result of 
a cultural taboo on sexuality and pubertal development. Our experience does not indicate such 
a taboo being present in our population. Probably, the early occurrence of puberty in adopted 
children is regarded as normal for this group of children. 
The role of background variables for the adjustment of adopted children was described 
in the early seventies by Bohman (35) as relatively independent from each other. Verhulst et a/. 
however found that several background parameters placed the child at increased risk for later 
maladjustment, but even in case of the presence of such variables the majority of adopted 
children function quite well (36). The results of the psychological assessments we performed 
suggest normal functioning of the children. Early puberty andlor short stature does not seem to 
influence this negatively; however, they still have to go through puberty and adolescence which 
is known to be a vulnerable period for some adopted children with respect to identity and 
relations to parents (12). Secondly, when puberty progresses in peers, the feeling of being 
short may be enforced by the magnitude of the growth spurt in Dutch boys and girls. 
The results on IQ measurements in children with precocious puberty showed elevated 
IQ scores, with higher verbal than performal scores, and this was interpreted as a possible 
effect of sex steroids especially on the left hemisphere (5, 30, 37). The initial total IQ score in 
our group is not different from normal ~ comparable with the data of Xhrouet et al. (5) and a 
decrease of about 7 points is observed in the treatment period. Although significant, one might 
have doubts about the clinical relevance of this decrease. An interesting hypothesis on the 
decrease in verbal IQ scores is that withdrawal of sex steroid exposure to the brain brings the 
child back into a more age~appropriate IQ range. The lower verbal scores in our group, which 
was in contrast to what was known in CPP girls, could be explained by the adoption status of 
children, from which it is known, as in other children from foreign background, that verbal 
intelligence is lower than children born in their own country. In adopted children it was 
described that in primary school mathematics, which is part of verbal 10, was problematic, 
especially in boys (38). The authors concluded that a deficient development of visual~spatial 
organisation and to a lesser extent the lower concentration was due to the lower prestations in 
mathematics rather than intelligence or fluency. 
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The observation that there are no consistent differences between group A and B suggests that 
in early puberty the addition of GH does not contribute to development in either a protective or 
negative direction and that pubertal arrest is the main intervention in children with early 
puberty. 
We conclude that in adopted children with early puberty and predicted short stature the 
levels of emotional and behavioural problems, self-perception and family stress do not 
significantly differ from the population means, The treatment with either GnRHa alone or in 
combination with GH does neither increase emotional and behavioural problems or family 
stress nor decrease self-perception of the child. 
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III TREATMENT WITH GNRHAAND GH 
Chapter 6: Study of the effect of treatment with GnRH·agonist (Decapeptyl) alone or in 
combination with biosynthetic human growth hormone (Genotropin) in adopted 
children with early puberty. 
6.1 Gonadotrophin Releasing Hormone agonist (GnRHa) treatment with or without 
recombinant human growth hormone (GH) in adopted children with early puberty 
6.2 Study of the effect of treatment with GnRH (GnRH)-agonist alone or in combination 
with recombinant human growth hormone in adopted children with early puberty: 
Psychological assessments before and after treatment 
6.3 Motivation for treatment and psychological evaluation in adoptive families 
when a child presents with early puberty 
submitted 
Chapter 7 
A randomized controlled lrial of three years of growth hormone (GH) and GnRH agonist 
treatment in children with Idiopathic Short Stature and Intra-Uterine Growth Retardation. 
Chapter 8 
The effect of pubertal delay by GnRH agonist in Growth Hormone Deficient (GHO) children 
on final height 
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Chapter 6.3 
Motivation for treatment and psychological evaluation in adoptive 
families when a child presents with early puberty 
D. Mul', H.J.M. Versluis-den Bieman', W. Oostdijk"', J.J.J. Waelkens', S.L.S. Drop' and FME 
Slijper" University Hospital Rotterdam/Sophia Children's Hospital, Departments of 
Endocrinologyl 
and Child and Adolescent Psychiatry', Leiden University Medical Centre, Department of 
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ABSTRACT 
In internationally adopted children early puberty is frequently obselVed. In a clinical trial on 
hormonal treatment of early puberty the motivation of parents and child to participate was 
studied. The fast majority of parents and children were adequately motivated for treatment. No 
indication was found suggesting overmotivation in parents. Psychological assessment revealed 
no increase in emotional or behavioural problems in the children compared to reference values 
of adopted children in The Netherlands. We discuss the societal bias with regard to the role of 
adopted parents in clinical research and to growth promoting treatment in adopted children. 
We conclude that there is no reason to view adoptive parents differently from parents of non-
adopted children in the context of clinical research or medical treatment. 
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INTRODUCTION 
In The Netherlands about 25.000 international adoptees are part of society (anonymous, in 
(1)). It was described by Oosldijk et al. Ihat despite the catch-up growth after arrival final height 
in adopted children did not exceed that of the country of origin, due to early onset of puberty 
(2). In other European countries this phenomenon has been observed as well (3~7). 
An early onset of puberty may lead to a decrease in final height by early closure of the 
epiphyseal growth plates of the long bones mediated by the sex steroids. Furthermore, 
precocious sexual development may cause adjustment problems (8, 9). In children with 
precocious puberty treatment with Gonadotrophin Releasing Hormone (GnRH) agonists has 
been shown to improve final height to some extent (10,11). 
To study the effect of the addition of growth hormone to GnRHa treatment to further 
improve final height we designed a study in adopted children with early puberty. In the 
process of approval the Dutch national board on the ethics of medical research (KEMO) 
demanded a psychological study to evaluate the motivation for treatment of parents and 
children and of the psychological development during treatment. This was remarkable as in 
other growth studies in non~adopted children such a requirement was never pointed out. One 
of the concerns was that adverse motives of the parents could harm the child, or at least that 
contrasting interests between parents and the child in participation or refusing participation 
would be present. This concern could be based on the fact that many adoptive parents are 
rather persistent in their demands for help. This attitude may be enforced when the child has 
a medical problem. Thus in the medical profession a biased view on adoptive parents may 
have developed. 
Sharav points out the importance of a healthy motivation for adoption, which mainly 
consists of a deep wish to raise a child (12). The biological wish for a child has been given up 
(about 90% of parents of adopted children do not have biological children), and adoption is 
their conscious choice. This kind of motivation for adoption can be regarded as protective. 
The conscious choice of parents for adoption may lead to greater involvement in their 
children, even more than in mothers with biological children (13). In general, great 
involvement can also be viewed as a protective kind of motivation. 
Hoksbergen has the opinion that motivation for adoption generally consists of external 
and internal motives (14). Parents with external motives prefer adoption to complete or extend 
their family or to help a child that is in distress. Those with internal motivation adopt a child 
primarily to satisfy their own needs. The latter may be harmful because of great hopes the 
parents nourish towards their adopted child, which can not always be answered by the child. 
Thus, too much involvement or strong internal motivation of the adoptive parents may be a 
burden for a child and could result in developmental problems. Combined with a longstanding 
and intensive treatment for early puberty serious problems may arise. From the point of view of 
the adopted child, it might be difficult to refuse a treatment proposed by the parents, based on 
feelings of loyalty, dependency and an unconscious feeling of gratitude. These feelings may 
also result in a difficulty to express anger and fear, which may contribute to an increase in 
behavioural problems. 
The concept of motivation for treatment is not widely described in medicine, let alone in 
paediatrics. One study in adults addresses the factors affecting the decision to participate in a 
clinical trial (15). In that study the belief that the proposed treatment could improve or help to 
maintain the patients' condition was an important reason to participate in the trial. Many stUdies 
do discuss the ethics of participation of children in research trials mainly from the point of view 
of the right to consent (16). No literature is available on motivation for treatment in adopted 
children, whereas some studies were published on expectations of growth promoting treatment 
in non-adopted children (17, 18). 
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We studied the motivation for treatment and performed a psychological evaluation of parents 
and their adopted children who had volunteered for treatment of early puberty. 
The aims of the study were to investigate whether parents and adopted children are 
adequately motivated for treatment of early puberty, to evaluate psychosocial development 
before start of treatment and to assess tolerance of treatment of early puberty. 
PATIENTS AND METHODS 
Children in this study originate from India, Sri Lanka, Colombia and Korea and were adopted 
by Dutch parents. The children developed early puberty, defined as pubertal development 
between 7 and 10 years of age in girls and between 8 and 11 years in boys. The onset of 
puberty was characterised in girls by breast development andlor menarche, in boys by 
testicular enlargement (~ 4 ml); in both the physical signs were accompanied by a pubertal rise 
in gonadotrophin hormones in a GnRH stimulation test. To assess bone age (SA) an X-ray of 
the left hand was obtained. The predicted adult height (PAH) was calculated on the basis of 
height and BA (19). For inclusion in the study PAH had to be below the third percentile of 
Dutch children for sex (20). 
Detailed characteristics of the patients and the study design as well as the growth data 
are presented elsewhere (21). In brief: The children in this study were treated for 3 years with 
either the GnRH-agonist triptorelin (Decapeptyl®) alone (group A) or in combination with 
recombinant human growth hormone (Genotropin®) (group B). A physician or nurse 
administered GnRH agonist every 28 days by an intramuscular (im) injection; in group S the 
patient him-Iherself or one of the parents administered growth hormone every day by a 
subcutaneous (sc) injection at home. An untreated control group was incorporated in the 
original study design, but this part of the design was abandoned when parents who 
randomised for no treatment all left the study, 
The study was announced to adoptive families by means of the periodicals of adoption 
societies and we informed the parents orally during the procedure of informed consent 
Many parents were interested in the study and phoned for information. Because of the strict 
inclusion criteria only a few children were eligible candidates for the study. Before 
randomisation and start of treatment a structured interview was performed with parents and 
child separately to assess motivation for treatment. 
Instruments 
Motivation study 
An experienced psychologist (HJMV-dB) interviewed both parents and children. The 
interviews were recorded on videotape and scored by WO independent raters, The general 
motivation score was composed of the ratings on four parameters: 
(I) motivation for treatment, (/I) expectations of treatment, (/II) evaluation of psychological 
suffering from early puberty and short stature by the child and (IV) psychological strength of 
the child. 
For the parents wo more parameters were added: "expectations of treatment by the 
parents" and "psychological strength of the parents". The rating was performed in 2 steps: 
first, a qualitative judgement was given on an adequate versus inadequate range; 
subsequently, a quantitative score was applied. The cumulative score of parents and child 
ranged from 0-10 (table 1). 
I Motivation for treatment was assessed in parents by asking the ways they had used 
to reach our clinic and how they felt about the randomisation and treatment. The children 
were separately asked what they knew and felt about the treatment and how they felt about 
the randomisation procedure. 
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II Expectations of treatment of the child was assessed by asking the parents how they 
evaluated the psychological 'burden' of treatment for their child. The children were asked 
how easy or difficult they thought the treatment would be for a long period. 
III Psychological suffering of the child: the parents were asked how much they thought 
their child sullered from early puberty, short stature and the different appearance. The 
children were asked the same questions. 
IV Psychological strength of the child was estimated by rating the parents' answers on 
the question how they had been coping with difficulties in raising their adopted child and how 
the child had been coping with difficullies in life. 
When the total score was lower than 6, the observers rated motivation as inadequate (either 
from the parents or the child). In that case, participation in the study was not allowed. 
Table 1: Composition of the motivation score 
Child score Parent score 
Motivation for treatment 1 motivation for treatment 1 
Expectations of treatment 1 expectations of treatment 1 
Evaluation of psychological suffering 1 evaluation of psychological sullering 1 
from early puberty and short stature from early puberty and short stature by 
by the child the child 
Psychological strenglh of the child 1 psychological strength of the child 1 
expectations of treatment by the parents 1 
psychological strength of the parents 1 
MOTIVATION SCORE 4 + 6 
range 0-10 
< 6 = inadequate, 9 = good enough, 
10 = optimal 
T1 study 
After the motivation study and before randomisation and treatment the psychological 
assessment (T1) was performed. This study was repeated after discontinuation of treatment. 
The psychological assessment was performed to evaluate behavioural and emotional 
problems, self-perception, expectations of treatment and intelligence levels of adopted 
children. This psychological part of the study and the repeated assessment after 3 years of 
treatment is described in detail in a separate article (Mul et aI, chapter 6.2). In this article we 
describe the psychological assessment of a slightly different study population. The difference 
between the groups is due to the fact that some parents did not agree to enter into the study 
protocol after they were randomised to the control group. These parents were included in this 
paper. 
The following instruments were used: Child Behaviour Checklist (CBCL): The CBCL is 
a standardised instrument to obtain parents' reports of competence and problem behaviour of 
their child (22). The problem items that describe the child are summarised in a score for 
internalising (e.g. withdrawn, anxious/depressed), externalising (e.g. aggressive, delinquent) 
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problems and a total problem score. Reference values for adopted children in the Dutch 
population were used for comparison (23). 
Seif-perception profile for children (SPPC): Harter developed Ihis self-reported 
instrument for measuring self-esteem or perceived competence in children (24). Self-
competence in different domains is measured, as well as an independent assessment of global 
self-worth. For this study we analysed data on social acceptance and physical appearance as 
children with early puberty might be less socially accepted and do not feel comfortable with 
their physical appearance. 
Silhouette Apperception Technique (SA 7): This test describes the accuracy of 
estimation of current and future height and was developed to study expectations of treatment 
with recombinant growth hormone (18. 25) 
NVOS: The "Nijmeegse Vragenlijst voor de Opvoedings Situatle" is a validated Dutch 
questionnaire evaluating family. We limited our analysis to 4 main items that we regarded to 
be of specific importance: first to what extent the family functioning is accepted or should be 
changed, the presence of problems (2nd) and whether the parents are able to deal with 
problems (3rd). For these items a higher score indicates increased family stress. A general 
assessment of family functioning is expressed in the 'satisfaction' item (4th): the higher the 
score, the more satisfied the parent is. 
During the 3-year course of treatment a questionnaire was sent three times, at 6, 18 and 30 
months of treatment, to be completed by the parents (F1, F2, F3). The questionnaires 
contained items concerning psychosocial development of the child and their experience with 
medical treatment and injections in particular. 
RESULTS 
Before start of treatment: Motivation study 
Thirty-five parent-child couples entered into the motivation study. Data of 5 couples were lost 
because of inadequate tape-recording, so 30 tapes were available for analysis and described 
in this article. 
The interrater reliability of the 30 recordings was significant and high (ro O.95) for total 
scores of parents-child couples. Separately, the interrater reliability of the parents (6 
parameters) or of the child (4 parameters) was also satisfactory and significant, r:;: 0.83 and 
0,79 respectively. Agreement concerning the scores of the adopted children is lower but still 
satisfactory. 
In total 29 adopted children and their parents were accepted for treatment, 1 was not 
accepted (Table 2) because of a score of 4 on the motivation parameters. This means that 
the parents were rated as inadequate on all but one parameter ('burden of the child') and the 
child scored inadequate on 1 parameter (,motivation for treatment'). 
Table 2: Results of motivation study 
Group 1: optimal motivation 19 
Group 2: motivation 'good enough' 10 
Group 3: not accepted for treatment 1 
Total 30 
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In the interview with the child it became clear that she was very afraid of being treated, 
especially with regard to the injections, but did not dare to tell her parents. 
A score of 10 was considered to indicate optimal motivation (group 1), and a score of 
9 was labelled as good enough motivation (group 2). 
Of the 29 accepted couples 19 obtained a score of 10 and 10 a total score of 9. In group 2 
more children than parents were inadequately motivated, they had significantly more unrealistic 
expectations of the effect of treatment (p=0.01). These children "could not think any problem to 
happen" and were significantly more inadequately motivated (p=0.05) compared to children in 
group 1. 
In group 2, significantly more parents (p = 0.01) had unrealistic expectations concerning 
treatment as well, suggesting that they did not expect any problem to occur during treatment 
for their child or for themselves. 
We compared the group with optimal motivation and the group with 'good enough' 
motivation using the instruments of T1 measurements. No significant difference was present 
between both groups in GaGl scores, SPPG scores, family stress or expectations of treatment 
with SAT. 
Before treatment: psychological evaluation (T!) 
The sample for the psychological evaluation consisted of 27 girls and 3 boys. To avoid a sex· 
effect the results in this section only concern the girls. The adopted girls in our sample did not 
significantly differ from adopted girls in the general Dutch population (23) with regard to 
behavioural and emotional problems, measured by GacL. This holds for the internalising and 
externalising subscales as well for the total problem score. Compared to age-matched girls 
from the general population, the girls in our study had the same level of self-perception on all 
subscales of the Harter self perception profile. The expectations of the future height was 
overestimated by 80% of the children and 17% of the parents, when future height was defined 
as height> 50th percentile of the Dutch population. The mean IQ level measured by the WISC-
subtest was 101.0, not different from the population mean of 100.0. The NVOS scores 
revealed that general satisfaction with the rearing situation was higher than in the normal 
population and that the family was significantly more able to deal with problems compared to 
the reference group. 
During treatment 
Thirty children entered into the treatment protocol, as some accepted couples did decide not to 
continue as they were allocated in the control group that was incorporated in the original study 
design. Three couples were admitted based on the psychologist's decision alone since 
independent rating of motivation could not be obtained due to loss of tape recordings. 
At the F1 evaluation 6 months after start of treatment the parents reported that their 
children were doing well. In the children treated with GnRHa alone (group A) 96% of the 
children could stand the painful intramuscular injections well, 64% of the parents judged the 
treatment to be a little burden for their child and 36% a burden for themselves. The burden of 
treatment with GnRHa could be the painful and unpleasant injections, the stress before having 
an injection, the monthly visit to a physician and the loss of school time for the children 
because of these visits. 
In group 8 where monthly GnRHa and daily GH injections were combined, 85% of the 
children tolerated the injections well, whereas the other 15 % found it annoying. The parents in 
this group reported the treatment to be a little burden for their child in 23%, and for themselves 
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in 15% of the cases. Forty-six percent of the children injected themselves with grolNth 
hormone. 
Combined data in both groups revealed that 96% of the parents and 56% of the 
children thought the treatment was very advisable; and 68% of the parents reported a 
favourable psychological effect of treatment for their children. With regard to these last 
mentioned items no significant differences were present between group 1 and 2. 
At the 6, 12 and 30 months assessments no significant differences were demonstrated 
between the group with optimal motivation and that with good enough motivation with regard to 
tolerance or experienced burden of GnRHa or GH treatment in parents and child. A non-
significant tendency was observed that the judgements of parents in group 1 were more 
differentiated compared to group 2. 
The results from F1, 2 and 3 suggest that the burden of treatment for the child due to 
GnRHa injections decreases over time: the percentage of problems with injections decreases 
from 64% at F1 to 38% at F3. The burden of treatment from the daily GH injections shows 
some increase from 23 to 31 % at F1 and F3 respectively. 
DISCUSSION 
In contrast to the initial presumption we found in this study that the motivation of parents for 
treatment of their adopted child with early puberty is adequate in the fast majority of cases. 
Only one out of 30 patients was not accepted to enter into the treatment protocol due to a 
disagreement between the refusal of the child to partiCipate and the desire of the parents to 
obtain treatment. The differentiation in 'optimal' and 'good enough' motivation did neither 
predict the level of behavioural or emotional problems or self-perception of the child during 
treatment, nor the way parent and child perceived treatment. 
In clinical research in children, the process of decision-making is a balance between 
the interests of the child, the parents and the clinical researcher. Legally, it is the child that 
decides provided that he or she has sufficient understanding and intelligence to understand 
what is proposed. In that case the consent of the child and not of its parents is required. Thus 
" a reasoned refusal by a child to partiCipate in research is likely to be taken as evidence for 
such understanding, and it would be unwise to rely on parental consent in such 
circumstances" (26). Only in case of severe disagreement between parents and child the 
child's well~being might be threatened. 
As in many studies including therapeutic research in children, the distinction between 
motivation for participation in research and motivation for treatment is difficult to make. Van 
Sluijvenberg et al. studied participants of a randomised trial regarding febrile seizures. They 
found that the major factors in parents' approval to partiCipate were the contribution to clinical 
science (in 51%) and benefit for their own child in 32% of the parents (27). It is likely that the 
way the researcher informs the parents influences parental motivation. Highly educated 
parents - and most adoptive parents in our study belong to this group- may on the contrary 
be less influenced by the researcher's information, as they might be able to address more 
specific questions to him or her. 
One should assume a biased view towards adoptive parents, as only in this study, 
concerning adopted children, an evaluation of potential candidates was demanded. Such a 
prejudice towards adoptive parents that might be the basis for the demand of a motivation 
study is difficult to explain. In the introduction of this article we pOinted to the biased view on 
adoptive parents possibly present in the medical profession. The interacUon between the 
assertive, inspired and highly educated adoptive parents and the people that surround them 
may result in various feelings, maybe even resistance, in the latter. From a psychoanalytical 
point of view, one can think of unconscious hostile fantasies towards adoptive parents. 
These serve as a defence mechanism against feelings of guilt with regard to adopted 
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children that is felt in the interaction with adoptive parents. Alternatively, the good intentions 
of adoptive parents may be denied by unconscious feelings that adopted children should not 
get as much good as Dutch children. It is true that, as in other parents, adoptive parents 
have to deal with internal problems, and that these may concentrate around issues of 
defectiveness and restoration (28). However, in the literature no data have been published 
that report on adoptive parents who harm their child in dealing with these conflicts. Hoopes 
refers to literature from the nineteen sixties in a clinical sample in which adoptive mothers 
tended to overprotect their children as a result of feelings of inadequacy on childbearing (29). 
Our study shows that motivation in adopted parents is adequate. The evaluation of 
motivation for treatment could eventually be advisable, but should at least not be restricted to 
adoptive parents. Whether it is advisable at all for any trial with a major intervention in 
paediatric research might be questioned, as it might discard the parental autonomy and 
responsibility. 
Questioning growth*promoting therapy in adopted children is a relevant issue. Many 
people reason that adopted children are short in their countries of origin and thus should not 
be subjected to any growth promoting treatment at all. However, this reasoning overlooks 
that the expected increase in final height, as a result of catch*up growth and improvement of 
socia-economic circumstances, may not be attained due to early puberty. A further reason 
for growth promoting treatment is to compensate for the possible growth inhibition of GnRHa 
treatment in children with early puberty (30). 
The general picture derived from the psychological evaluation is described in a 
separate article (Mul et ai, chapter 6.2). In summary it is described in that article that for the 
child no elevation of CBCL scores for emotional or behavioural problems, normal self-
perception and acceptance by peers has been demonstrated. For parents it describes that 
no increased level of family stress and realistic expectations of treatment were shown. The 
latter may be due to the relative high socio*economic status in the group of adoptive parents 
(80 % in the highest category), that may contribute to the understanding of the information 
given before entering the study. Another possible bias to account for is that in The 
Netherlands parents go through an extensive selection procedure before being accepted as 
adoptive parents. 
Once treated, children seem to get used to the monthly injections. Probably the 
recurrent and repeated character of the daily injections, especially when the effects of 
treatment are not clearly visible for a child, causes an increase in burden (31), while the 
effects of the monthly injections for suppression of puberty is visible. 
We conclude that motivation for treatment in adoptive parents when their child enters in 
to puberty at an early age is adequate. The refusal of 1 out of 30 families to enter into the study 
can not be seen as a specific feature of the group of adoptive parents. They should be seen as 
normal parents. 
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ABSTRACT 
We assessed the effectiveness and safety of three years combined growth hormone (GH) 
and Gonadotrophin Releasing Hormone agonists (GnRHa) treatment in a randomized 
controlled study in children with Idiopathic Short Stature (ISS) or intrauterine growth 
retardation (lUGR). Gonadal suppression, GH reserve and adrenal development were 
assessed by hormone measurements in both treated children and controls during the study 
period. 
Thirty-six short children, 24 girls (16 ISS/8IUGR) and 12 boys (8 ISS/4 IUGR) with a height 
SOS <-2 in early puberty (girls: B2-3 and boys: G2-3), were randomly assigned to treatment 
(n=18) with GH (Genotropin 4 lU/m'lday) and GnRHa (Triptorelin, 3.75 mg/28 days) or no 
treatment (n=18). At start of the study mean (SO) age was 11.4 (0.56) or 12.2 (1.12) years 
whereas bone age was 10.7 (0.87) or 10.9 (0.63) years in girls and boys, respectively. 
Ouring three years of study heighl SOS for chronological age (CA) did not change in both 
treated children and controls, whereas a decreased rate of bone maturation after treatment 
was observed (mean (SO) 0.55 (0.21) 'year'/year versus 1.15 (0.37) 'year'lyear in controls, 
p<0.001, girls and boys together). Height SOS for bone age and predicted adult height 
increased significantly after 3 years of treatment; compared to controls the predicted adult 
height gain was 8.0 cm in girls and 10.4 cm in boys. Further, the ratio between sitting 
heighUheight SDS decreased significantly in treated children, whereas body mass index was 
not influenced by treatment. 
Puberty was effectively arrested in the treated children as was confirmed by physical 
examination and prepubertal testosterone and estradiol levels. GH dependent hormones 
including serum IGF-I, IGF-lI, Plep, PIiINP, alkaline phosphatase and osteocalcin, were not 
different between treated children and controls during the study period. Thus, a GH dose of 4 
IUlm2 seems adequate for stabilization of the GH' reserve and growth in these GnRHa 
treated children. 
We conclude that 3 years treatment with GnRHa was effective in suppressing pubertal 
development and skeletal maturation, while the addition of GH preserved growth velocity 
during treatment. This resulted in a considerable gain in predicted adult height, without 
demonstrable side effects. Final height results will provide the definite answer on the 
effectiveness of this combined treatment. 
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INTRODUCTION 
Since puberty initiates the process of epiphysial fusion that determines final height, the first 
signs of puberty are often perceived as an alarming signal in short children (1), and the 
question whether therapeutic options exist to improve final height is often asked. If initiated 
years before the onset of puberty, GH treatment may have beneficial effects on final height in 
children with Idiopathic Short Stature (ISS) and intrauterine growth retardation (IUGR) (2, 3). 
Once puberty has started, however, GH treatment in these short children has limited value; 
GH may stimulate a rapid progression through puberty, which is expected to reduce the gain 
In final height (4-6). The addition of Gonadotrophin Releasing Hormone agonists (GnRHa) to 
delay puberty has therefore been considered. GnRHa were initially used in children with 
central precocious puberty (CPP), with beneficial effects on adult height (7-9). Recent trials 
with GnRHa in short children showed an increment in adult height of 0.5 - 3.3 em (10, 11). 
No controls were included except for one study with 4 years treatment with GnRHa versus 
placebo, showing a height gain of 7.6 cm compared to initial prediction in the GnRHa treated 
children and of 10.3 cm compared to placebo group. The study population, however, was 
very heterogeneous and therefore the results are difficult to interpret (12). More recent 
studies, using the combined treatment of GH and GnRHa in children with ISS or IUGR, 
report a gain in final height prediction between -0.5 to 10 em (1, 13-17), but none of these 
studies used randomized conlrols. 
To answer the question whether GH and GnRHa treatment may improve final height 
in pubertal children with ISS and IUGR we designed a randomized controlled study with 3 
years treatment with combined GH and GnRH agonist treatment in 24 girls and 12 boys with 
ISS or IUGR. We verified the effectiveness of gonadal suppression by physical examinations 
and by measurements of sex steroids in all children. To assess the GH reserve during 
treatment we yearly measured IGF~I, IGF~II, IGF8P~3, and markers of collagen and bone 
metabolism, all GH dependent hormones (18). Adrenal hormones were measured to search 
for a possible effect of treatment on adrenal development. In this report we present data 
obtained during the first 3 years of the study. 
PATIENTS & METHODS 
Forty children were randomized for either combined treatment with growth hormone (GH) 
and Gonadotrophin Releasing Hormone agonist (GnRHa) or no treatment. GH, 
(Genotropin®, Pharmacia & UpjohnAB (Stockholm, Sweden)) was given in a dose of 4 
IU/m'lday sc, which is equivalent to 0.14 IU (0.05 mg) Ikg body weighVday. GnRHa 
(triptorelin (Decapeptyl® Ferring); since Decapeptyl® was withdrawn by Ferring in 1998 we 
used the same preparation from Ipsen) was given in a dose of 3.75 mg i.m. every 28 days. 
The randomization was performed separately in children with a known history of intrauterine 
growth retardation (IUGR), defined as a birth length <-2 SDS (19). Directly after 
randomization, two patients randomized for treatment refused treatment and 2 controls 
refused follow~up. Additionally, one ISS boy and one IUGR girls, both controls, became drop· 
outs. We report 3 year-data of 18 treated (12 ISS, 61UGR 16 boys, 12 girls) and 16 controls 
(11 ISS,S tUGR 15 boys, 11 girls). 
The protocol was reviewed and approved by the medical ethiGS committees at the 
four partiCipating centers (Catharina Hospital Eindhoven (n=12), Wilhelmina Children's 
Hospital Utrecht (n=12), Free University Hospital Amsterdam (n=10), and Sophia Children's 
Hospital Rotterdam (n:::2), and the parents of all children gave written consent for the study. 
When appropriate, the consent of the children was also obtained, 
Inclusion criteria were G2 or G3 in boys (testicular volume of ~ 4 and ::::10 ml) and 82 
or B3 in girls, an actual height < -2.0 SDS (20) or between -1.0 and -2.0 SDS with a 
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predicted adult height < -2.0 SDS (according to Bayley & Pinneau (21», and a chronological 
age and bone age less than 12 and 13 years in girls and boys, respectively. Furthermore, a 
maximum serum GH level> 10 ugll (1ug = 21U, The First International Reference 
Preparation of hGH, MRC London, code 66/217 was used as standard) after provocation 
(exercise, arginine, clonidine, L-dopa or glucagon), and a normal ratio of sitting 
heighUsubischial leg length (between P3 and P97) (22) were established. At time of 
inclusion, screening blood tests and urinanalysis were normal, and none had evidence of 
malnutrition or hormonal or systemic disease. 
All children were evaluated at baseline. Then, the children of the treatment group 
were followed every 3 months during treatment and at least once a year thereafter. Children 
in the control group were followed on a yearly basis. Evaluations included measurements of 
height (mean of 4 measurements performed by the same observer (LV) at the same hour of 
day on a Harpenden stadiometer), sitting height (mean of two measurements (LV)), and 
weight. Pubertal staging was assessed by one investigator in all children at all visits (GAK), 
according to the method of Tanner. The Prader orchidometer was used to determine 
testicular size in boys 
Height was expressed as SDS for chronological age (CA) and for bone age (BA) 
according to Dutch references (20). Body Mass Index (BMI) was calculated (weighU(height')) 
and expressed as SDS (23). Sitting height and sitting heighUheight were also expressed as 
SDS (22). Target height was calculated [father's height + mother's height + or - 12 cm for 
boys and girls, respectively) I 2] + 3 cm (for the secular trend) and expressed as SDS (20). 
Bone age radiographs were measured yearly in all children and were determined according 
to the method of Greulich and Pyle by one independent investigator (24). To evaluate the 
effect of treatment we used the gain in predicted adult height (PAH), defined as the 
difference between the height prediction at start and after 3 years of treatment or follow-up. 
In girls, a yearly ultrasound of uterus and ovaries was performed. We measured the volumes 
and examined the occurrence of OVarian cysts. 
Hormone anafys;s 
Laboratory tests at baseline and at yearly visits inCluded full blood count, serum FT 4, TSH, 
LH, FSH, estradiol in girls and testosterone in boys, blood HbA1c, fasting blood glucose, 
serum fasting insulin, IGF-I, IGF-II, IGFBP-3, leptin, DHEA, DHEAS, androstenedione, PICP, 
PIIINP, alkaline phosphatase and osteocalein. Plasma levels of IGF-I, IGF-II and IGFBP-3 
were determined in one assay in the endocrine laboratory of the Wilhelmina Children's 
Hospital, Utrecht on samples that had been stored at -20°C for a maximum of 4 years. These 
assays have been described previously (25). The levels of IGF-I, IGF-II and IGFBP-3 were 
expressed as ngfml and compared with references based on measurements in 906 healthy 
individuals. Smoothed references for three plasma parameters and three ratios were 
constructed using the LMS method (26). This method allows to find the best transformation 
of data which lack a normal distribution (as do all these parameters) yielding a smoothed and 
statistically valid fUnction. Serum leptin (ngtml) was measured by RIA (Unco Research inc., 
St Charles, Missouri, USA). PICP (normal range 200-1000 ~g/l (mean ± 2SD), decreases 
with age from 2-16 years) and PIlINP (normal range 5-18 ~g/l (mean ± 2SD), decreases with 
age from 2-16 years) were measured with RIA kits (Orion Diagnostics, Finland). Serum 
alkaline phosphatase (lUll) was measured with the VITROS analyser and osteocalcin 
(normal range 1.8-6.6 ~g/l (mean ± 2SD)) with a RIA kit (DiaSorin, Stillwater, USA). Serum 
LH (lUll) and FSH (lUll) were performed with a solid phase, time resolved 
immunofluorometric assay ((IFMA), Wallac, Turku, Finland). Serum testosterone (nmoI/L) (in 
boys), DHEA (nmoI/L) and androstenedione (nmoI/L) were measured with solid phase RIA's 
(DPC, Los Angeles, CA, USA). Serum estradiol (pmoI/L) (in girls) was also measured with a 
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sensitive solid phase RIA (Orion, ESPO, Finland) and DHEA-S with an in house developed 
RIA (Leiden, Department of Clinical Chemistry (MF)). All samples were measured in one 
assay on samples that had been stored at -20°C for a maximum of 4 years. 
Statistics 
Results are expressed as mean ± SEM or SO. The statistical analysis comprised a paired t-
test for comparisons between data at baseline and after three years, and when appropriate 
for non-normal distribution we used the Wilcoxon signed rank test. Differences between the 
treated children and controls were tested by Student t-test or Mann Whitney tests. 
Correlation analysis was performed appropriate for the distribution of the variable. 
Changes in variables during the study period between treated patients and controls were 
analyzed by repeated measurement analysis. Reported are the changes in time between 
groups and changes in time for both groups together. 
RESULTS 
Aux%gy 
Table 1 shows the auxological data at baseline and after 3 years of study for ISS girls, ISS 
boys, IUGR girls and IUGR boys separately. There was no significantly different pattern 
between these four subgroups in changes in bone age (BA), height velocity (HV), height SDS 
for chronological age (H-SDS CAl, height SDS for BA (H-SDS BA), BMI-SDS, or in predicted 
adult height (PAH) in cm or SDS. Combined auxological data of treated and control children 
are shown in figure 1-3 and in table 2. 
Table 2. Changes (mean ± SEM) in predicted adult height in cm between start and after 3 
years of study. 
N Control GH+GnRHa 
Girls 23 2.4 (1.69) 10.4 (1.24) 
Boys 11 -3.9 (2.09) 6.5 (0.87) 
IUGR girls 7 0.3 (5.87) 11.1 (1.72) 
ISS girls 16 3.1 (1.27) 10.1 (1.68) 
IUGR boys 4 -3.6 (2.40) 6.5 (0.30) 
ISS boys 7 -4.1 (4.50) 6.6 (1.58) 
Bone age advanced significantly less in GH+GnRHa treated children compared to controls 
(0.55 (0.05) 'year'/year versus 1.15 (0.09) 'year'/year, p<0.001, all girls and boys together). In 
subgroups, a significant difference in SA was seen in treated compared to control ISS boys 
after 3 years of study (table 1). Height velocity (HV) decreased significantly (p<0.001) in the 
GH+GnRHa treated children from 7.0 (0.32) cm/year during the first year of treatment to 5.4 
(0.24) and 4.9 (0.30) cm/year during the second and third year, respectively. In the control 
group HV was 7.4 (0.51), 7.0 (0.53) and 4.7 (0.4) cm/year during the first, second and third 
year of study, respectively (third year HV compared to the first year HV: p < 0.05). Height 
SDS for CA did not change during 3 years of study in all groups (see figure 1 A for 
GH+GnRHa versus controls, and table 1 for subgroups). 
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Table 1. Auxological data at baseline and after 3 years of study for ISS girls, ISS boys, IUGR girls and IUGR boys 
Start 
• 
. 
ISS girls ISS boys IUGR girls 
N- 16 8 8 
CA 11.5 (0.1) 12.2 (0.5) 11.3 (0.3) 
BA 10.9 (0.2) 10.9 (0.2) 10.2 (0.4) 
H-SOS CA -2.01 (0,14) -2,66 (0.20) -2.29 (0.14) 
H-SOS SA -1.63 (0,14) -1,83 (0.34) -1.30 (0.41) 
BMI-SOS -0.39 (0.23) -0,24 (0.36) ·0,64 (0.22) 
PAH (em) 151.8 (1.0) 168,4 (2,6) 154.3 (3.3) 
PAH SOS -2.65 (0.16) -2.02 (0.39) -2.24 (0.53) 
Birth weight (gr) 3084 (121) 2734 (301) 2338 (177)" 
TH·SDS -0.81 (0.20) -0.82 (1.27) ·0,08 (0.39) 
. p < 0.01 compared to girls with ISS 
+ P < 0.05 between control and treatment group 
+ p < 0.05 compared to start 
IUGRboys 
4 
12.2 (0.2) 
11.0 (0.4) 
-2.76 (0.19) 
-2.07 (0.37) 
-0.34 (0.77) 
165.9 (3.2) 
-2.40 (0.48) 
2341 (513) 
-0.93 (0.69) 
After 3 years 
. 
ISS girls ISS boys IIIUGR girls 
Co: 8 Rx:8 Co: 3 Rx:4 Co: 3 
14.4 (0.23) 14.6 (0.14) 16.4 (o.n) 14.5 (0.38) 14.8 (0.22) 
13.7(0.4) 12,7(0.2) 14.8(0.7) 13.1(0.1)+ 13.3(0.8) 
-2.22(0.19) -1.97(0,31) -2.02(0.11 ) -2.00(0.36) -2,20(0.18) 
-1.78(0.30) -0.86(0.31 )+ -1.04(0.42) -0.98(0.65) -1.25(0.61) 
-0.36(0.4) 0.18(0.25) -0.35(0.44) 0.19(0.82) -0.57(0.45) 
155.4(1.9)+ 161.1(2.4)+ 175.9(6,3) 171.3(5.6) 158.6(3.5) 
·2.06(0.30)+ -1.14(0,38)<- -0.92(0.94) -1.59(0.83) -1.55(0.57) 
. . 
IIIUGR boys 
Rx:4 Co: 2 Rx: 2 
14.0 (0.48) 14.9 (0.30) 15.6 (0.02) 
12,3(0.1) 15.4(0.4) 12.9(0.1) 
-1.68(0.21) -2.02(0.91) -2.99(0.03) 
-0.57(0.39) -2.46(0.32) -0,590.10) 
-0.06(0.36) 0.99(0.96) -1.75(1.50) 
163.3(3.0) 159.4(4.2) 175.4(1.5) 
-0.79(0.49) -3.38(0.62) -0.99(0.22) 
Table 3 Hormonal data (Mean ± SEM) at start of study and after 3 years for control and GH+GnRHa treated children. 
Start After 3 years Difference in ~ Difference i,n time, 
time, between whole group 
. I arOUDS 
control Rx Control Rx 
Leptin(ng/ml) 3.8 ±0.5 4.2 ±2.5 6.1 ± 1.1 7.7±1.1 NS P<0.001 
DHEA (nmoVL) 4.9 ± 0.7 7.3±1.2 10.3 ± 3.7 13.1±5.9 NS P<0.001 
DHEA-S (~mol/L 1.7±0.3 1.7±0.3 2.7±1.3 3.2 ± 0.3 NS P<0.001 
Androstenedione 1.5±0.1 2.2 ± 0.4 2.9 ± 0.7 2.8± 0.3 P = 0.01 P<0.001 
(nmoI/L) 
PICP (~g/L) 275.4 ± 22.0 321.5 ± 30.6 251.3 ± 40.5 272.2 ± 14.7 NS P<0.01 
PIJlNP(~g/L) 8.8 ± 0.8 9.0 ±0.7 8.1 ± 0.8 10.0 ± 0.8 NS P = 0.Q1 
Osteocalcin (~g/L) 5.8±0.7 5.8 ± 0.6 7.9 ± 1.2 8.1±0.7 NS P<0.01 
Alkaline Phosphatase 250.3 ± 17.0 210.2 ± 10.4 179.5 ± 23.6 183.4±21.9 NS P<0.01 
I (lUlL) 
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Height SOS for SA improved significantly in GH+GnRHa treated children compared to a 
decrease in controls (p<0.001, n = 30, figure 1 B). In subgroups, in ISS treated girls height 
SOS for BA was significantly different between start of study and after 3 years (table 1). The 
changes in predicted adult height (PAH) in cm or SOS were Significantly higher in 
GH+GnRHa treated children compared to controls (p<0.001); the change in PAH SOS is 
shown in figure 1C. The absolute values for changes in PAH (cm) between start of study and 
after 3 years are summarized in table 2. 
There was no significant difference between ISS and IUGR children or between boys 
and girls in change in predicted adult height. In treated children, age, SA, height SOS for 
CA, height SOS for BA, BMISOS, or pubertal stage at start of treatment, IGF-I, IGF-II, 
IGFBP-3 at start of treatment, birth weight or target height SOS did not significantly correlate 
with the change in PAH after 3 years of treatment (univariate non-parametric correlations). 
Body mass index SOS (BMISOS) did not change during the study period, in both 
groups. There was a significant change in sitting height SOS (SHSDS, p=0.05) and in the 
ratio sitting heighUheight SOS (SHHh p=0.016) in treated children compared to controls. After 
3 years of study, SHHt changed -0.33 (0.77) SOS in the treated group (having relatively 
longer legs after 3 years of treatment) compared to +0.43 (0.83) SOS in controls (figure 2). 
Puberty 
At start of the study period no significant differences were present between treated children 
and controls with regard to Tanner stage. Pubertal development was effectively arrested in 
the children treated with GH and GnRH agonist, while puberty progressed in the control 
group. Figure 3 shows the Tanner breast stage in relation to estradiol levels in girls and the 
mean testicular volume in relation to testosterone levels in boys. Ultrasound evaluation of 
uterus volume and ovarian volumes in girls showed reduction in ovarian volumes in the 
treated girls. We did not observe any abnormalities in the ovaries (indicative for the 
development of polycystic ovaries) or uterus by ultrasound in the children on combined 
treatment, 
Hormonal data 
Serum FT4, TSH, blood HbA1c, fasting blood glucose, and serum fasting insulin remained 
within the normal range in all children during the study period. Figure 4 shows the serum 
IGF-I, IGF-II, and IGFBP-3 levels (ng/ml) for treated children and controls. Serum IGF-I and 
IGFBP-3 levels were approximately 0 SOS, while serum IGF-lIlevels were around ~1 SOS. 
Serum IGF-I (ng/ml or SOS), or IGF-II (ng/ml or SOS) were not different at start of study or 
during three years of follow up between treated children and controls, while IGFSP-3 (ngfml 
or SOS) levels in controls decreased significantly in comparison to treated children during 3 
years of follow-up (p=0.01). With the exception of androstenedione, OHEA, OHEAS, PICP, 
PIIINP, osteoalcin and alkaline phosphatase levels were also not different 
Figure 1: Height SOS for CA (fig 1a) and for BA (fig 1b) during the study period. H-SOS for 
CA does not change in time; HSDS for SA data show significant differences in time and 
between groups (p<O.001) Fig 1 c shows the increase in PAH-SDS compared to the initial 
height prediction. * = p < 0.05; *** = p<0.001 
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Figure 3: Suppression of 
puberty during the study 
period. 
3a: Tanner breast stage in 
girls; 
3b: serum estradiol levels 
in girls; 
3c: mean testicular volume 
in boys and 
3d: serum testosterone 
levels in boys. Statistical 
differences are not shown 
in this panel. 
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Figure 4: IGF-I, IGF-II and IGFBP3 levels during the study period (mean ± SO). 4.: IGF-I 
levels (nglml) increase significantly in both groups during in time (p<0.001); 4b: IGF-II levels 
(nglml); 4c IGFBP3 levels (nglml), showing a significant difference in time (p< 0.001) and 
between groups (p=0.01). 
between treated and control children during three years of follow~up. All hormone levels 
increased significantly with age in both treated and control children (table 3). 
Serum lepUn levels did not significantly differ between controls and treated children. 
Pearson correlations between BMI~SDS and serum lepUn levels showed no consistent 
patttern: significant correlations were found at start and at 2 years in girls (p < 0.05) and at 1 
and at 3 years in boys (p<0.01). Obesity defined as BMI-SOS > 2 was only present in 1 boy 
in the GH+GnRHa group at 1 time point. 
DISCUSSION 
Combined treatment with GH and GnRH agonist in short children with ISS or IUGR in a 
randomized controlled trial resulted in an unchanged height SDS for chronological age and a 
decreased rate of bone maturation. Thus, height SDS for bone age and predicted adult 
height increased significantly after 3 years of treatment. Compared to controls the predicted 
height gain was 8.0 cm in girls and 10.4 cm in boys. Further, body proportions changed in 
favor of relatively longer legs in treated children, and body mass index was not influenced by 
treatment. 
Previous studies using the combined trealment of GH and GnRH agonist show 
considerable variability in gain of predicted adult height, ranging from -0.7 to 10.5 cm (1,13, 
14, 16, 17, 27). Results of two of these studies seem comparable to our study (16, 27): The 
gain in predicted adult height of 9.3 cm in a group of 7 girls reported by Saggese and 
coworkers was reduced to 6.3 em after comparison with a historical control group (27). The 
same pattern was observed in our study in 23 girls, with a reduction of 10.4 to 8.0 cm when 
compared to randomized controls. Pasquino et at. also reported a gain of 10.5 cm in girls, but 
no controls were included (16). A recent randomized controlled study of the effect of the 
addition of GnRHa to GH treatment in 7 GH deficient individuals showed a gain in near final 
height of 1.4 SOS or 9 cm (28). After comparison with randomized controls the gain in 
predicted adult height in our 11 boys increased from 6.5 to 10.4 cm. The decrease in height 
prediction in non-treated short boys shows that this prediction method is overestimating final 
height in boys. This finding is in line with the overestimation of final height in untreated ISS 
boys, as we suggested earlier (29). Contrasting our expectations based on findings from 
previous reports, a relative young bone age or an early pubertal stage were not predictive for 
a relative large gain in adult height. This finding may have clinical applications for future 
treatment of older children in whom puberty has progressed substantially. Thus, after 3 years 
of study our results are encouraging. However, the gain in final height will provide the definite 
answer on the effectiveness if this combined treatment. The final height gain may be 
probably less than 8 to 10 cm, as we have learned from experience in previous studies in 
CPP (7). 
The sitting height SOS and the ratio of sitting heighUheight SOS decreased 
significantly in both treated girls and treated boys during the study period. This indicates that 
delaying puberty in our study has resulted in relatively longer legs. This result is in 
accordance with the observation in hypogonadotropic hypogonadism, who provide a natural 
experiment of pubertal delay. These men also have relatively longer legs compared to their 
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trunk at final height (30). At final height some change in body proportions may also be 
present in treated children, but we expect that the trunk/leg ratio will remain within the normal 
range. Our data on body proportions are in contrast with the findings at near final height in a 
recent study on GH deficient children where the addition of GnRHa resulted in no change in 
body proportions (28). 
The clinical observation that treatment with GnRHa may lead to obesity could not be 
confirmed by changes in BMISDS or leptin levels in our study (31), Moreover, we could not 
identify a consistent pattern between changes in BMISOS and changes in leptin. It has to be 
emphasized that a BMI-SOS change is not a good marker of change in fat mass, particularly 
during puberty. Another explanation for the absence of obesity in our treated children may be 
the result of the combined treatment of GnRHa and GH we used. The probable effect of 
GnRHa on induction of fat mass which is usually reflected by increased leptin levels (32), 
may have been counterbalanced by the anabolic effect of GH on muscle mass in our treated 
children. 
The therapeutic efficacy in terms of suppressing puberty and the good compliance to 
treatment were shown by the absence of progression of puberty at clinical assessments. This 
Was further confirmed at the biochemical level by prepubertal levels of serum estradiol in girls 
and serum testosterone in boys during treatment. The development of polycystic ovaries, a 
previously suggested side effect of GnRHa treatment (Hindmarsh, personal communication), 
was not observed in the ultrasound studies in our treated children. 
The decreased growth rate after GnRHa treatment without GH, as was observed in 
previous studies, may be explained by a reduction of pituitary GH secretion after withdrawal 
of sex steroids (33). The unchanged height SOS for chronological age after treatment in our 
study suggests that the addition of GH treatment seems to counteract this mechanism. 
Therefore, the combined treatment resulted in preservation of growth during treatment while 
a delay in bone maturation was accomplished. Assessments of IGF-[, IGF-II, IGFSP-3, Plep, 
PIlINP, alkaline phosphatase and osteoca[cin, suggest that a GH dose of 4 IU/m'lday is 
needed for replacing the GH secretion in puberty in these GnRHa treated children. The 
assumption that adrenal development is not altered by GnRHa treatment was confirmed by 
the measurements of OHEA and DHEAS. All androgens increased with age in both groups. 
Androstenedione levels, however, increased significantly less after 3 years of study in treated 
children compared to controls. 
We conclude that 3 years treatment with GnRHa was effective in suppressing 
pubertal development, while the addition of GH preserved the growth potential during 
treatment. This resulted in a considerable gain in predicted adult height, without 
demonstrable side effects. Final height results will provide the definite answer on the 
effectiveness of this treatment regimen. 
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Chapter 6: Study of the effect of treatment with GnRHragonist (Decapcptyl) alone or in 
combination with biosynthctic human growth horrnone (Genotropin) in adopted 
children with early puberty. 
6.1 Gonadotrophin Releasing Hormone agonist (GnRHa) treatment with or without 
recombinant human growth hormone (GH) in adopted children with early puberty 
6.2 Study of the effect of treatment INlth GnRH (GnRH)-agonist alone or in combination 
with recombinant human growth hormone in adopted children with early puberty: 
Psychological assessments before and after treatment 
6.3 Motivation for treatment and psychological evaluation in adoptive families when a 
child presents with early puberty: 
Chapter 7 
A randomized controlled trial of three years of growth hormone (GJ-l) and GnRH agonist 
treatment in children with Idiopathic Short Stature and Intra-Uterine Growth Retardation. 
Chapter 8 
The effect of pubertal delay by GnRH agonist in Growth Hormone Deficient (GHD) 
children on final height 
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INTRODUCTION 
Several strategies can be applied to optimize GH treatment in growth hormone deficient 
(GHD) children during puberty (1). In a recent issue of this journal Mericq and coworkers 
reported their results of a prospective, randomized trial on the effect of growth hormone (GH) 
alone or in combination with Gonadotrophin Releasing Hormone agonist (GnRHa) in 
pubertal GHD patients (2). They concluded that delaying puberty by GnRHa led to a near 
final height SD score (SDS) of -1.3 +/- 0.5 compared with -2.7 +/- 0.3 in the group treated 
with GH alone. 
However, in this study the patients had been untreated up to the age of 12-18.5 
years, which is not the usual situation in western countries. In addition, in several cases the 
growth retardation was less severe than would be expected in classical GHD patients without 
treatment. 
Although a randomized controlled trial in a large and representative sample is 
certainly the best design to study the efficacy of a therapeutical regimen, a patient series with 
matched controls is a good second. We report on a retrospective analysis of the effect of the 
addition of GnRHa to GH treatment in GHD children, treated at a younger age and smaller 
stature with GH, in which GnRHa was added. Matched controls with GH treatment were used 
for comparison. The children were younger as well as shorter for age compared to the 
subjects in the randomised trial (2). 
PATIENTS AND METHODS 
From the nation-wide database of GH treated children (Dutch Growth Foundation! Advisory 
Group on Growth Hormone) we selected 21 patients with GHD who had been treated with 
the combination of GH and GnRHa (Triptorelin or Leuprolide acetate, 3.75 mg per month), 
after a variable period of GH therapy alone. All patients had reached final height (FH). The 
GnRHa was given soon after entering into puberty at a relatively early age and!or low height 
for age. 
Thereafter the database was screened for matched controls who were only treated 
with GH, consecutively taking as matching criteria: age at start of puberty, H-SDS and age at 
start of GH treatment, GH dosage, sex, BMI-SDS at start of treatment and type of GHD. 
These criteria were chosen, because they best predict the growth response to GH (3). For 10 
patients on the combination therapy (group A) suitable matched controls were found (group 
B). For the remaining 11 patients (group C) no suitable controls were available. 
RESULTS 
Selected clinical data are shown in the table [mean (SEM)]. In group A the mean age at start 
of GnRHa treatment was 11.9 (SE 0.5) yrs and mean treatment period was 3.0 yrs 
(range:1.2 - 5.6 yr). 
DISCUSSION 
We conclude that patients who are at risk of not attaining their genetic growth potential by the 
onset of puberty when height has not sufficiently caught up, can reach a final height close to 
their genetic target by the addition of GnRHa to GH substitution therapy. This effect was 
seen in both groups A and C. In contrast, continuing GH therapy alone, as in group B, leads 
under these circumstances to a final height of 1 SOS below target. 
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The efficacy of the combination therapy is also shown by other relevant parameters such as 
the greater mean (SO) change in height SOS from the onset of puberty, and to a lesser 
extent the change in height SDS since the onset of GH treatment. 
Table: Summary of patient data 
Groug 
A B C 
Number (M/F) 218 7/3 3/8 
Diagnosis 
multiple I isolated GHO 7/3 8/2 6/5 
idiopathic I organic GHO 6/4 7/3 5/6 
GH peak (mUll) 10.9 (1.4) 8.5 (2.1) 7.6 (1.5) 
MPH-SOS -1.44 (0.40) -0.93 (0.31) -1.68 (0.30) 
Age start GH (yr) 7.6 (1.0) 7.6 (1.2) 10.2 (1.4) 
H-SDS start GH -3.08 (0.58) -3.22 (0.61) -4.23 (0.48) 
Age start puberty (yr) 10.7 (0.6) 11.5 (0.5) 11.5 (0.8) 
H-SDS start puberty -2.17 (0.39) -1.78 (0.39) -3.39 (0.58) 
GH dosage during puberty' 16.0 (0.9) 14.7 (1.4) 17.0 (1.2) 
FH-SDS -1.31 (0.39) -1.77 (0.34) -1.66 (0.16) 
FH-SDS - MPH-SDS 0.13 (0.37)' -0.85 (0.36) 0.04 (0.31) 
FH-SDS - H-SDS start puberty 0.86 (0.48) 0.01 (0.36) 1.73 (0.58) 
GH: growth hormone; MPH: mid parental height; SDS: standard deviation score; FH: final height; #GH 
dosage: average in pubertal period (IU/m2Iweek); ~ p=O.05 compared to group 8; in other variables no 
signif. differ between group A and 8 
If the difference between FH SDS and MPH-SDS is taken as the most reliable outcome 
parameter, the effect of GnRHa addition on final height can be estimated at 1 80S 
(approximately 6-7 cm). 
The literature on the final effect of the addition of GnRHa to GH in GHD children is 
limited. Adan et al. reported that the combined treatment resulted in a normal adult height, 
albeit somewhat below target height (4). Hibi et al. reported in 24 GHD children treated with 
GH and cyproterone-acetate (CPA) andlor medroxyprogesterone acetate (MPA) for 4.4 
years that FH-SDS was about 1 SOS higher than in a group children on GH alone. The final 
height 80S was -2.2 in boys and -1.9 in girls, probably somewhat lower than in the more 
recent studies due to less effective gonadal suppression by CPA or MPA (5). 
In summary, in spite of the uncertainty about the representativeness of the patient 
sample studied by Mericq et al. (2), their data and those of other investigators discussed in 
their paper, as well as our retrospective analysis, all point in one direction: adding GnRHa in 
early puberty to GHO patients who have been treated with GH, or in whom GH and GnRHa 
are started simultaneously, enables the patients to reach their genetic target, while final 
height of patients on GH alone is about 1 SOS below MPH-SOS. This result is of similar size 
as the efficacy of GnRHa in idiopathic short stature (6). 
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ABSTRACT 
The indications for growth hormone (GH) treatment in non-GH deficient short children are in 
debate. Some argue that it does not belong to the medical domain. We describe three 
different approaches to this issue. We argue that a disease oriented or client oriented 
approach are not sufficient. Both lead to withdrawal of medical interventions or to undesired 
application. An approach that focuses on suffering as an indication for treatment of short 
stature is the most appropriate. The challenge is to develop proper tools to evaluate suffering 
and the efficacy of GH treatment in these children in order to relieve or prevent suffering. 
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INTRODUCTION 
Height seems to be extremely important; studies show that height has a significant impact on 
salaries of men (1), people with short stature are liable to societal bias (2), and famous 
models are tall (3). Taking into account the association of power, status and height, it is no 
wonder parents like to have tall children or at the least are concerned if their child seems to 
have growth problems. 
Synthetic growth hormone (GH) is used in the treatment for short children with growth 
hormone deficiency (GHD). Growth hormone treatment (GH treatment) is also advocated for 
those with non-growth hormone deficient short stature, e.g. idiopathic short stature (ISS), 
intrauterine growth retardation (lUGR), Turner syndrome, and during GnRHa treatment for 
early and precocious puberty. The use of GH in children with short stature has led to serious 
discussions amongst the medical discipline as well as amongst phHosophers and ethicists (4, 
5, 6). GH treatment in idiopathic short stature, for example, may be seen as an 
enhancement, a treatment done for the sake of appearance just like breast enlargement for 
women or eye surgery for children with Down syndrome. This raises questions such as 
'should GH treatment be covered by health care insurance' and 'how should the danger of 
medicalization and stigmatisatlon be valued'? 
We will focus on the question, whether or not the use of GH in short children belongs 
to the medical realm. Three different lines of reasoning will be sketched. The first line 
contains that GH treatment should only be administered to those with a disease or disability 
(if treatment is proven to be efficacious). The second line of reasoning holds that medicine 
should focus on complete physical, mental and social wellbeing. This argumentation will 
imply that almost any wish for a medical intervention belongs into the medical realm. In this 
article we will analyse and apply both lines of reasoning and suggest a third that rests on the 
notion of prevention and elevation of suffering. 
THE PROPER GOAL OF MEDICINE: THE DISEASE APPROACH 
Some define health as the absence of disease and argue that the proper goal of medicine is 
the prevention and the cure of diseases and disabilities. This view on the proper aim of 
medicine clearly involves a distinction between disease and health, treatment and 
enhancement. 
According to Daniels the general function of health care is Uta maintain, restore and 
compensate for the loss of functioning that is normal for a member of our species" (7). 
Normal functioning of an organism may be disrupted or lost by diseases and disabilities. 
Disease and disability are seen as "departures from species-typical normal functional 
organization or functioning" (7). Daniels' view does not imply that health care should restore 
a situation in which individuals are equal: he emphasises that individuals differ with respect to 
natural endowments. There is human variation with respect to skills and talents such as 
creativity, intelligence and sports. Health care should not make people equal competitors but 
normal competitors. Health care should restore normal functioning in order to provide people 
with an equal opportunity to, for example, schools and jobs. 
Daniels refers to the biostatistical theory of Boorse (8). His theory holds that health as 
the absence of disease is a value~free theoretical notion. "Health is normal functioning, 
where the normality is statistical and the functions biological." A function is in Boorse's view a 
contribution to a goal. Eventually the goals are individual sUlVival and reproduction. The 
goals of an organism can be determined by averaging a large sample of that kind of 
organism (differentiated to age and gender). On the basis of this study a species design can 
be discerned. This species design selVes as the basis for health judgements: the physician 
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can establish whether someone is healthy by determining whether the functioning of the 
body matches with the design of the species. 
Reasoning along this line leads to the following conclusions. According to Daniels GH 
for idiopathic short children would be an enhancement rather than a treatment, and therefore 
not acceptable (7). If Sue has short stature due to GHD and Mary due to familial short 
stature, Sue would receive treatment while Mary would not. For Sue has a subnormal 
functioning organ while Mary seems not to suffer a disease from a biostatistical perspective. 
In the case of IUGR there seems to be no clear answer. The etiological factors in individual 
children are often unknown. Although some cases will be undisputed (e.g. the Silver-Russell 
syndrome (9» it is difficult to determine the cause of growth retardation in the majority of 
cases. These practical difficulties are absent in the case of Turner syndrome. A clear 
chromosomal disorder can be found with growth retardation as one of the clinical symptoms. 
Moreover, recent studies have proven that growth hormone treatment is efficacious (10, 11). 
From Daniels' line of reasoning the administration of GH treatment therefore seems to be 
justified in the case of Turner syndrome. 
In Sweden and The Netherlands studies are conducted on the effect of the addition of 
GH to GnRHa in adopted children on growth (12, 13). These children are studied because 
they have an early puberty, their predicted adult height is short and during treatment with 
GnRHa decrease in height velocity may be observed. Suppose clinical trials show that 
additional GH treatment results in a considerable increase in height compared to GnRH 
agonist alone. According to the disease-oriented model of Daniels, GH should not be 
prescribed. If these children after GnRHa treatment do not differ from children in their native 
country with respect to the normal functioning ability and the mean height, one should 
abstain from GH-treatment. The short stature is, in this view, part and parcel of the ethnic 
background of the adopted children. From a bio-statistical perspective nothing is wrong with 
these children. Some would argue that early puberty in these children is a disorder and the 
possible decreasing height velocity during its treatment needs intervention. However, the 
early onset of puberty seems to be related to the transition to the western world countries 
and does not belong to the normal functioning in the countries of origin. It is therefore 
doubtful whether the administration of GnRH agonist (with or without addition of GH) would 
pass Daniels' disease-oriented model. 
Daniels' line of reasoning has serious practical and moral problems. The case of Sue 
and Mary illustrates one of the problems of his treatment-enhancement distinction. The short 
stature of Sue can be ascribed to a subnormal functioning organism but in our view the 
cause of her short stature is not an ethically relevant characteristic. When it does not 
interrupt her total functioning, the subnormal functioning does not really matter. 
The above-mentioned criticism concerns Boorse's concept of normal functioning 
ability. Some phenomena would be categorised by this concept as healthy or normal while 
the medical literature defines these as a disease that can be prevented, e.g. arteriosclerosis 
or dental caries (14). The biostatistical concept would categorise phenomena as normal that 
are categorised as diseases in medical textbooks. Boorse therefore extends his definition of 
disease: °a disease is a type of internal state that is a limitation on functional ability caused 
by environmental agents". The extended definition and these examples, however, illustrate 
that a cultural context should be understood in order to determine what is normal. In order to 
determine what normal or good functioning means, information is needed about the 
circumstances in which functioning takes place. A biostatistical concept will not do because 
biology gives too little guidance of what is normal or abnormal. 
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THE PROPER GOAL OF MEDICINE: THE CLIENT APPROACH 
The second line of reasoning would define health in a broader sense as u a state of complete 
physical, mental, and social well-being~, which is the well-known definition of the World 
Health Organisation. In this view the proper goal of medicine is to contribute to the physical, 
mental and social wellbeing of people. Provided people pay for it themselves nothing is 
wrong with medical interventions to change appearances Le. short stature. Medicine may 
respect all these diverse wishes and desires, and its task may be making everyone happy. 
As long as the subjects are properly informed and are aware of both benefits and risks, the 
choice of parents and their children should be respected. This line of reasoning would imply 
that GH treatment should be given to children with a disease or disability such as GHD and 
to children with idiopathic short stature as well as to internationally adopted children (with or 
without treatment for early puberty). Moreover, if parents request GH treatment for their 
children in order to give them a better chance of being a college athlete, these parental 
requests should be respected. 
This line of reasoning could imply that all differences between individuals should 
belong to the medical realm; differences between height, weight and skin colour. Too short, 
too fat, too black, too old, it has no end. Some would see no objections, provided that people 
pay the costs themselves. There may, however, be serious problems. If medicine would 
respect all these wishes this could lead to medicalisation and stigmatisation. Zola introduced 
the concept of medicalisation to criticise the increase of medical control over private and 
social life (15). Medicalisation is the process in which more and more phenomena in human 
life are governed by a medical perspective. As Verweij stated one should analyse the rather 
vague intuitions that underlie this concept and make explicit what is wrong with 
medicalisalion (16). 
One of the dangers of medicalisation is that it could turn healthy individuals into 
patients. Children who are under medical treatment may have more problems than non-
referred children (17, 18). Treatment itself may give rise to feelings of inferiority or 
unacceptability. The child may become self-conscious or worried about her/his height (19). 
More studies are needed to determine the effects of the treatment on the psychosocial 
development. With respect to these negative effects, parental requests should be restricted. 
Secondly, the unrestricted use of medicine for the sake of appearance may reinforce existing 
social norms of privileged groups (20). Medicine would support the negative attitudes 
towards stigmatised individuals: persons who are unable to conform to standards which 
society calls 'normal'. Height prejudice, so-called 'heightism' may and should be countered 
by restricting extreme and ill-motivated requests (21). 
THE PROPER GOAL OF MEDICINE: THE SUFFERING APPROACH 
There is a third perspective that may more or less circumVent the problems linked with the 
above-mentioned approaches. According to this Hne of reasoning suffering is the real issue 
and the medical intervention may relieve or mitigate it. This view attaches great importance 
to subjective suffering: suffering as experienced by the individual. Not all existential and 
psychological suffering due to such diverse circumstances can or should be remedied by 
medicine. The suffering approach is based on the assumption that the suffering of the 
individual subject may (to a certain extent) be understandable to others, Le. the doctor. 
Suffering is a condition that can not be objectified but the human condition makes it possible 
to understand that some conditions involve suffering. Maybe it is not possible to understand 
how someone experiences it, but it may be appreciated that somebody is hurt and is 
suffering. In medical practice physicians have to form a notion of the degree of the patient's 
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suffering. In complex cases like euthanasia and assisted suicide the physician is even 
required to determine whether the person involved is really suffering unbearably. 
This approach implies firstly that not only the parents, but also their child and the 
physician try to determine whether the treatment may prevent or relieve the child's (present 
and future) suffering. Although most children will be too young to decide for themselves, their 
perspective should be included as well. Secondly, gain in stature is not a sufficient criterion 
to decide whether or not to start with GH treatment. Efficacy is an important but not sufficient 
aspect. Essential is whether or not the subject suffers and the treatment will prevent and 
relieve the suffering. Several studies emphasise the adverse effects of short stature on 
psychosocial wellbeing and educational attainment (2, 22, 23). Studies, however, also 
dispute the assumption that short stature is associated with psychosocial maladjustment and 
a reduced quality of life (18, 24, 25). The advantages of shorter statute have even been 
emphasised (26). The results of these latter studies seem to imply that not all categories of 
people with short stature may benefit from GH-treatment. Whether or not some categories 
(or individuals within a category) may derive more benefit from adequate coping techniques 
should be investigated thoroughly. Finally, children and adults with an average height will not 
be confronted with problems due to their height. A 'taller' stature will more likely create 
advantages than cause suffering. From the suffering perspective there are good reasons to 
withhold GH to these children whether or not the parents pay for it themselves. 
If we try to apply the suffering criterion to the above-mentioned categories, the 
following conclusions can be drawn. In the case of growth hormone deficiency GH treatment 
would be accepted for it was described that adults with GHD were satisfied with their height 
after GH-treatment (mean height close to P3) (24). Moreover patients with GH deficiency 
suffer from other physical and psychological problems (e.g. lack of energy); GH treatment 
may mitigate these problems. Children with IUGR could benefit from GH treatment; 
psychosocial problems may be relieved by GH treatment (26). More studies to prove the 
benefits of GH-treatment, however, are necessary before conclusive, more reliable answers 
can be given. In Turner syndrome, where a reduction in quality of life in adults was 
demonstrated (24), GH treatment is effective and improves body image and results in greater 
self-esteem (28). With respect to ISS the cause of short stature is unknown. From the 
suffering perspective this is not relevant. At this moment there is little knowledge about 
whether GH treatment improves their psychological and social wellbeing. According to Van 
Busschbach et ai, quality of life was not affected for a group of normal short adults (mean 
height close to the P3), while short adults with a medical history of shortness appeared to be 
negatively affected in their social functioning. But even here the impact of short stature on 
the quality of life was small. The complaints of patients with ISS may be the result of 
unsuccessful coping strategies. Thus the offer of GH treatment should take place in a 
research setting with adequate selection criteria and evaluation of psychosocial wellbeing. 
Our last example concerns the use of GH to internationally adopted children during 
GnRHa treatment. From a suffering-perspective it matters that early puberty may have a 
negative influence on the emotional and cognitive development of these children (self-image, 
development of identity etc.). Medical intervention may be beneficial to these children. It 
seems reasonable, therefore, to offer it to them. There is, however. no unanimity about the 
negative effects of early puberty (29). With respect to short stature the adopted children 
possibly reach an adult height that is considerably lower than children in the country in which 
they grow up due to an early start of puberty and this may cause serious problems. More 
research is needed to determine how serious these problems are and whether GH-treatment 
can solve these problems effectively. 
At this moment discussion about quality of life and degree of suffering is still taking 
place. Medical practice should be based on good (clinical and psychological) research. 
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Empirical science is therefore needed to determine whether suffering due to short stature is 
the case and whether GH treatment is the most appropriate intervention (6, 30). In case of 
demonstrating that GH treatment is not such an appropriate intervention one should decide 
not to treat these children with GH, thus reducing high costs and preventing unnecessary 
treatment. From a suffering perspective a clinical trial may therefore be justified on condition 
that psychosocial wellbeing is evaluated extensively and for a long time. 
CONCLUSION 
Different lines of reasoning can deal with the justification of GH-treatment. Some try to solve 
the issue of short stature by applying notions of disease or disability. others state that the 
proper goal of medicine is to contribute to physical, mental and social wellbeing of people. 
We have pointed to the weaknesses of both approaches and argued that a suffering-
perspective is more appropriate, i.e. it focus on a better personal and social functioning and 
may minimise the dangers of medicaUsation and stigmalisation. According to this approach 
the suffering of a person from his or her short stature is essential. Empirical science is 
needed to evaluate suffering and to evaluate whether GH treatment is a proper means to 
prevent or relieve serious suffering. 
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Chapter 10 
General discussion and recommendations 
This thesis deals with several aspects of the treatment of early puberty in children, either 
adopted or non-adopted. In this section the results of the various studies will be integrated 
and put into the perspective of current knowledge. Recommendations for clinical practice will 
be made at the end of this section. 
NORMAL PUBERTY 
In chapters 2.1 and 2.2 trends in normal pubertal development have been described 
extensively. We reviewed the European situation and concluded that in most countries the 
age of onset of puberty and the age of menarche still decrease. The role of environmental 
factors is discussed. In some countries a stabilisation in the decreasing trend is observed. 
Since 1980, in The Netherlands no further decrease was observed in the age of occurrence 
of the first signs of puberty in girls and boys. The mean age at onset of puberty in girls is 10.7 
years and 11.5 years in boys. In boys, the observed age of G2 stage was higher than in 
1980, raising questions on the description of this stage. Only a slight decrease in age of 
menarche was observed, from 13.28 to 13.15 years between 1980 and 1997. 
The observed relationship of menarcheal age and weight and height suggests that in 
countries with increasing height and weight menarche will occur earlier. Indeed, in the USA 
the age of onset of puberty is remarkably reduced, in parallel with increased obesity 
observed in children (1, 2). However, despite the ongoing secular change of increasing adult 
height as well as the increase in the number of obese children (3) no dramatic decrease was 
observed in the age of menarche nor in the age of onset of puberty in the Netherlands. 
We conclude that in The Netherlands the decreasing trend in age of pubertal 
development has been stabilised between 1980 and 1997 and that only a slight decrease in 
the age of menarche was observed. There is no need to change the age limit for the 
definition of precocious puberty in The Netherlands. 
" GONADOTROPHIN-RELEASING HORMONE AGONIST TREATMENT 
Diagnosis and follow-up 
In chapter 3 we analysed the gonadotrophin response to the GnRH or GnRHa stimulation 
test in children with clinical development of puberty. 
We concluded that the GnRHa test was able to demonstrate HPG axis activation in 
children with early puberty more precisely than the GnRH stimulation test. Once HPG axis 
activation is demonstrated by GnRHa stimulation we expect further progression of puberty, 
as was also demonstrated by Ibanez et al. (18). The absence of pubertal LH peaks in a 
GnRH or GnRHa stimulation test was shown to predict a slow course of puberty (12). For the 
decision whether to treat patients with GnRHa HPG axis activation has to be demonstrated. 
We conclude that HPG axis activation is more efficiently demonstrated by the GnRHa 
stimulation test. As HPG axis activation indicates the onset of puberty, this test may be the 
decisive factor in the decision whether to treat children with signs of pubertal development 
with GnRHa (see section VI). 
In order to reach the optimal auxological goals of treatment careful follow-up is 
demanded during treatment with GnRHa. We showed that in the Puberty Suppression Score 
(PSS), incorporating auxological and biochemical variables, signs of incomplete suppression 
during treatment correlate with less height gain during treatment compared to children who 
were effectively suppressed. With leuprolide-acetate in a dosage of 3.75 mg per 28 days 
efficient gonadal suppression was achieved with only a limited number of side effects or 
escapes. Triptorelin showed comparable efficacy and tolerability in the same dosage. In 
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several reports up to FH long-term safety of triptorelin has been demonstrated by normal 
resumption of puberty after discontinuation of treatment (chapter 5.1 and ref (4, 5)). After 
GnRHa treatment for precocious puberty normal pregnancies were reported (5, 19). 
We conclude that the PSS can be used to monitor children under treatment with 
GnRHa for early or precocious puberty. 
Precocious puberly 
After long-term follow-up until final height a general conclusion can be drawn about the 
efficacy of GnRHa treatment for central precocious puberty. As described in the introduction, 
several studies reporting final height show a height gain of about 5 cm compared to the 
prediction at start of treatment. In most countries this is comparable with about 1 SOS. 
It is also relevant to compare the achieved FH with the genetic potential expressed by 
the midparental height or target height. In some studies the results of GnRHa treatment show 
that FH is in the target range (4, 5). In other studies FH is significantly lower than target 
height (6, 7). It should be recognised that in Thamdrup's series of untreated children with 
CPP FH was 16 cm below midparental height (MPH) in girls and about 11 cm below MPH in 
boys (8). 
In table 1 we present the data of the 6 largest studies, including our study, reporting 
on FH after GnRHa treatment in girls with CPP. In 4 of them a significant difference is 
present between TH and FH, either in cm or in SOS. 
Table 1: Gain in FH in girls after GnRHa treatment for precocious puberty 
First author N= CAslart BAslarl Rx (vrl FH minus 
(vr) (vrl PAHstaft (em) 
Mul' 87 7.7 10.4 3.4 7.4 
Arrigo 71 7.0 9.8 4.0 2.9 
Carel 58 7.5 10.1 3.7 4.8 
Heger 50 6.2 9.3 4.4 5.9 
Oostdiik 31 7.7 10.8 3.4 3.4 
Galluzzi 22 7.3 10.3 4.0 3.2 
• sIgnIficant dIfference between FH and TH eIther In em or In SOS 
a see chapter 5.1 of this thesis; b p < 0.001; 
FH mlnus-
TH (in 50S) 
·0.88" 
-0.48 c. 
+0.15 d 
·0.6 
_1.026 • 
·0.84" 
Refer. 
. 
(9) 
(7) 
(4) 
(5) 
1(6) 
(10) 
C TH-SDS was not shown in the paper; calculated from raw data: TH -SOS ::: -0.12. When expressed 
in em FH was significantly < TH; 
d TH-SDS was not shown in article; calculated from raw data: TH-SDS = -0.55. When expressed in 
em FH was not significantly different from TH; 
e The difference between FH and TH expressed in cm: p < 0.01; I P < 0.01 
Several factors may have contributed to differences in the outcome parameters shown in 
table 1, e.g. the method of adult height prediction, the different BA or CA at start of treatment, 
treatment duration and the difference between SA and CA. In univariate and multlvariate 
analyses different factors appeared to be correlated with one of both outcome parameters, 
i.e. gain in height between initial prediction and final height or final height itself. Height gain 
was negatively correlated with SA at discontinuation of treatment (4) and positively correlated 
with BA advance at start of treatment (5, 7). Final height was positively correlated with target 
height (4, 6, 7) and treatment duration (6, 7). 
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In our study we found height gain to be positively correlated with BA at start of treatment and 
negatively correlated with CA and with BA advance at start of treatment. In an univariate 
analysis BA advance and treatment duration correlated positively with height gain, whereas 
CA at start of treatment correlated negatively. 
The methodological problems in the analysis of FH data concern mainly the 
dependence of height predictions on current BA and height, as well as the a priori 
relationship that can be expected between TH and FH (4). Furthermore, the assessment of 
BA needs close attention. In our studies we used a segmented SA scoring, accounting for 
possible differences in the maturation of carpal or phalangeal bones. 
The selection of children suitable for treatment, e.g. who will benefit from GnRHa 
treatment, is of major importance (11). In this paragraph we limit the discussion to the 
auxological goals of treatment: improvement of final height; the psychological aspects will be 
discussed later in this chapter. In the literature a differentiation has been described between 
children with rapid progression of puberty and children with slow progressive puberty. The 
children with slow progressive forms of puberty, not warranting GnRHa treatment for 
auxological reasons, were defined either by absence of well-defined biochemical evidence of 
activation of the hypothalamo-pituitary axis (12) or by low estrogenic activity and limited 
advance of SA over CA (13). 
We consider a pubertal LH peak in a GnRH or GnRHa stimulation test as the most 
decisive parameter to assess onset of puberty, whereafter further progression of puberty is 
expected. No GnRHa treatment should be initiated when no or insufficient evidence for 
activation of the hypothalamo-pituitary axis is demonstrated. 
The overall picture emerging from the literature and from our studies reported in this 
thesis is that young girls with progressive forms of CPP, thus with a considerable BA 
advance at start of treatment, will benefit most especially when treated tm an appropriate BA 
for CA has been reached. The higher SA at discontinuation of treatment the worse FH will 
be. However, these statements come from retrospective analyses and were never addressed 
in formal prospective studies. 
In the literature several authors make recommendations with regard to the timing of 
discontinuation of treatment in girls, e.g. that SA should not exceed 11 years (4) or 12.0 -
12.5 years (6, 7). The data from our study in chapter 5.1 do not allow to indicate a particular 
bone age to discontinue treatment. However, in our study of FH in girls without a fixed BA 
for discontinuation, we demonstrated that FH was nearly equal to the predicted adult height 
at discontinuation of treatment (9). The same obselVation was made by Heger et al (5), 
suggesting a limited role of BA as a single parameter for the decision to discontinue 
treatment. Besides, it should be noted that discontinuation of treatment is often dictated by 
psychosocial reasons. 
In boys with CPP we showed that FH after GnRHa treatment was close to TH. 
However, in boys with organic CPP FH-SDS was significantly lower than TH~SDS. A mean 
height gain of 5.4 (SO 8.4) cm was obtained compared to initial height prediction at start of 
treatment (chapter 5.2). Boys with an organic cause for CPP ended up at a significantly lower 
FH-SDS compared to boys with idiopathic CPP. Bone age at start of treatment correlated 
negatively with height gain and BA advance at start of treatment correlated positively with 
height gain. 
We conclude that GnRHa treatment in both girls and boys with CPP can restore FH in 
the normal range. A well-defined activation of the hypothalamo-pituitary axis, indicating the 
onset of puberty, has to be demonstrated in order to select children who will benefit from 
GnRHa treatment. No recommendations can be given as to which SA is optimal to 
discontinue treatment. 
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Children with short stature and early puberty 
Some argue that manipulation of the timing of puberty in the relative normal age period for 
puberty is unlikely to affect final height to any great extent (14). Probably this is true when 
maturation occurs within a rather normal age range. Whether this holds for early maturers 
outside the normal range and for children with precocious puberty was subject of our studies. 
In this thesis 2 studies address the issue of pubertal arrest in short children with early 
puberty. The results in adopted children treated with GnRHa alone showed that during three 
years of treatment an improvement in mean predicted adult height of 5.7 cm is obtained (see 
chapter 6.1). [n another group of children with either early or precocious puberty who were 
observed during 18 months of treatment gain in predicted height occurred as well (see 
chapter 4), although no differentiation was made between early and precocious puberty. 
Only few studies have been reported on GnRHa treatment in children with early or 
normal puberty. A preliminary study by Municchi et al. showed an improvement of 5.9 cm in 
height prediction after 4 years of treatment and of 6.4 em compared to placebo treated 
patients (15). In contrast, Carel et al. treated 31 girls for 2 years without a valuable 
improvement of near final height (16). A remarkable finding in the latter study was the rapid 
progression of BA after discontinuation of treatment, causing a substantial decrease in height 
prediction. This phenomenon was also seen in children with precocious puberty after GnRHa 
treatment (6). 
In the above-mentioned study of Carel SA at discontinuation of treatment was 11.8 
years (SO 0.6). In our study in adopted girls on GnRHa alone, SA at discontinuation of 
treatment was 12.3 (0.9) years, thus offering uncertainty about the final height gain. 
At this moment we do not know whether in children with early puberty the same 
pattern of grovvth after discontinuation of GnRHa treatment will be observed as was seen 
after GnRHa treatment for CPP. In precocious puberty height gain can be estimated to be 
approximately 60 - 80% of the gain obtained at discontinuation of treatment (4, 6, 7, 10). In 
our report (chapter 5.1) FH was only slightly lower than predicted adult height at 
discontinuation of treatment, which was Similarly observed by Heger et at (5). 
We conclude that in short Children with early puberty pubertal suppression is effective 
in short-term studies. Final height data can be compromised by a limited post-treatment 
grovvth and should be awaited before an indication for GnRHa treatment can be settled. 
Growth hormone deficient children 
The addition of GnRHa in children already treated with GH for growth hormone deficiency 
(GHO) presenting with early puberty at short stature and/or delayed bone age, resulted in an 
improvement in FH compared to matched controls without gonadal suppression. 
We performed a retrospective analysis and found a mean FH~SDS of -1.31 (0.39) in 
children with GnRHa addition whereas the group without gonadal suppression ended up at a 
mean FH-SDS of-1.77 (0.34). We choose to compare the difference between FH and TH as 
effect parameter. In the group with both GH and GnRHa the outcome was Significantly beUer 
than in the group without gonadal suppression. These data are in accordance with a recent 
prospective study of Mericq et al. (17) showing a difference of about 1.4 SDS in favour of the 
children co~treated with GnRHa. However, in that study only a few patients could be 
regarded as 'classical' GHD patients. 
We conclude that adding GnRHa to GH in GHD patients with marked short stature 
who enter puberty at an early (bone) age enables them to reach a FH in their genetic target. 
Criteria for intervention with GnRHa such as age, bone age and height at onset of puberty 
need to be specified in the future. 
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III COMBINED TREATMENT WITH GNRHA AND GROWTH HORMONE 
The observation of impaired growth during GnRHa treatment in CPP stimulated several 
investigators to start GH treatment in combination with GnRHa in those children with 
decreased HV (20-22). In general, they concluded that GH increased HV to normal values 
without accelerating bone maturation, resulting in an increase in predicted adult height. A 
recent report on FH in children with CPP after combined treatment showed a height gain of 
7.9 cm at FH, when GH was added after a decreasing height velocity (23). No additional final 
height data after combination treatment in precocious puberty is available. 
In children with shari stature and in adopted children the addition of GH resulted in 
increased PAH as well (24-26). Final height results show a variable pattern ranging from a 
mean height gain of 10 em compared to initial prediction (27) to a final height not different 
from controls or initial prediction (28, 29). Comparing our studies reported in chapters 6.1 
and 7 with the studies reported in the literature our results, with a considerable height gain of 
6 to 10 em during treatment are encouraging. 
An important issue to address here is the accuracy of the prediction method. A lower 
initial prediction due to the use of the average tables of Bayley and Pinneau may result in a 
larger difference with the attained final height. This issue is of main interest when final height 
data of different studies are being compared. 
The results of the studies combining GnRHa and GH treatment suggest the 
importance of maintaining adequate height velocity during GnRHa treatment. In normal 
children prepubertal growth is characterised by intensity (mean HV) and duration; the 
intensity of prepubertal growth has most influence on FH, in boys more than in girls (30). 
Considering growth during GnRHa treatment (with or without GH) as prepubertal growth, 
elevation of HV should increase FH. A prerequisite to gain height is that GH does not 
accelerate BA maturation. We showed that BA maturation was neither accelerated in 
adopted children nor in children born after IUGR or in ISS children during combined 
treatment with GH and GnRHa. 
In both studies on combined treatment BMI remained within the normal range. Recent 
reports in the literature suggest a major role of pretreatment BMI in children who increase 
markedly in 8MI during GnRHa treatment (31). Theoretically, the lipolytic effect of GH may 
prevent adiposity to occur. Concerning body proportions, relatively longer legs were 
observed in ISSIIUGR children during combined treatment, whereas in the adopted children 
an opposite trend was observed both in children with and without GH addition. No 
explanation can be given to resolve these contrasting findings. 
In both studies on the combined treatment of GnRHa and GH we observed a gradual 
decrease in HV not only in the group on GnRHa alone, but also in the group with combined 
treatment. No readily apparent explanation is present for the decrease in HV during GnRHa 
treatment. In both stUdies the gradual decrease was also visible in the group with GH. GH 
dependent growth factors IGF-I and IGF-II levels remained in the normal range. IGFBP-3 
levels were significantly lower in untreated ISSIJUGR children (chapter 7). The bone 
parameters studied in chapter 7 (e.g. Plep, PIIINP, osteocalcin) were not significantly 
different between children on combined treatment and untreated controls. The decrease in 
height velocity in combination with equal/evels of GH dependent growth factors suggest a 
gradually increasing insensitivity of tissues for growth factors; alternatively, when reaching a 
certain bone maturation or height percentile (e.g. target heights SDS) the response to GH 
may decrease as observed in GHD children during GH treatment. 
We conclude that the addition of growth hormone to GnRHa treatment results in an 
improvement of predicted adult height compared to either GnRHa alone or controls. 
Further research should elucidate whether a higher GH dose or a stepwise increment 
in GH dose would be beneficial. 
215 
Genera! discussion 
IV PSYCHOLOGY AND MOTIVATION 
In deciding whether or not to treat a particular child with early or precocious puberty 
auxo[ogical motives alone are not decisive for initiating GnRHa treatment. In case there is a 
discrepancy between pubertal and psychosocial development GnRHa therapy may be 
indicated to prevent progression of puberty and the occurrence of menarche. Children may 
feel embarrassed or ashamed in comparison with their peers and subject to teasing. GnRHa 
treatment may also be indicated in early pubertal development in mentally retarded children 
where the parents think it to be wise to postpone menarche for a couple of years. 
In adopted children it was suggested that early puberty would increase psychological 
distress. Our conclusion is that in our group of adopted children, using standardised 
instruments, there is no evidence of psychological problems before, during or after treatment. 
When standardised instruments do not demonstrate increased problem behaviour while 
there is a clinical suspicion, one can doubt the seriousness of the psychological problems in 
early puberty (32). Alternatively, refined instruments should be designed to assess the 
specific emotional suffering that can be observed clinically. 
We extensively described the background of the study regarding the motivation in 
adoptive parents and the remarkable demand for the evaluation of motivation specifically in 
this group. One of the concerns was that adverse motives of the parents could harm the 
child, or that conflicting interests between parents and their child in participation or refusing 
participation in a clinical trial would be present. 
We concluded in our study that an adequate parental motivation was present. 
Therefore, adoptive parents should be approached just as other parents in clinical research. 
Further psychological evaluation of the children with IUGR or ISS before and during 
treatment with GnRHa and GH described in chapter 7 is in progress. These data will provide 
a picture of the psychosocial aspects of ISS/IUGR and wlll be compared with normative data. 
V ETHICAL ASPECTS 
The use of growth promoting treatment, either by GH alone or by the combination of GnRHa 
and GH in adopted children does not deserve an isolated approach per se. However, specific 
considerations in these children deserve specific attention. First the role of catch*up growth 
providing the opportunity to reach a higher adult height than would probably have been 
obtained in the country of origin. Second, the relatively frequent occurrence of early onset of 
puberty, resulting in a compromised adult height Third, early puberty is presumed to cause 
or increase psychological distress. However, we found no evidence for such a distress 
present in our patient group. Another reason not to isolate growth*promoting treatment in 
adopted children is our conclusion that adoptive parents have normal motivation for 
treatment, probably indistinguishable from parents of non*adopted children. 
In this thesis we addressed the ethical issue from the suffering point of view, 
reasoning that when suffering is present in children growth promoting treatment should be 
considered (33). The studies described in this thesis do not specifically show suffering in 
adopted children with early puberty in the age group we studied. The increase in predicted 
adult height was accompanied by an increase in social acceptance. However, whether these 
increases relieve suffering cannot be concluded. Final height data should be awaited before 
a final conclusion can be drawn Whether this intervention can relieve or prevent suffering. 
However, additional instruments are probably necessary to establish an ethical basis for 
treatment. 
The use of growth hormone in short children has been discussed many times and 
especially the use in non GH*deficient children has received wide attention. The American 
Academy of Pediatrics, Committee on Drugs and Committee on Bioethics highlighted several 
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ethical issues: the agreement on the appropriate goals of GH treatment, the lack of an 
established risk~benefit ratio for GH therapy and how to define treatment "success" (34). In 
their conclusions the committee states that the benefits of GH therapy will remain somewhat 
elusive, as the individual child can escape from the stigma of being very short, but a group of 
short healthy children will always exist. The question remains whether the child with gain in 
adult height actually experiences a psychosocial benefit, In line with this, Haverkamp 
provided an analysis of the ethical dilemma pertaining to GH treatment in short children, 
emphasising the need for empirical evidence of suffering for recognition of the ethical need to 
improve this situation (35). 
Until final height data are available from our studies on the combined treatment with 
GnRHa and GH we do not advocate standard GH treatment in these children. In the 
meantime, the current degree of suffering and the expected gain in FH has to be carefully 
balanced in the decision whether or not to treat adopted children with GnRHa alone or in 
combination with GH. 
VI INDICATIONS AND RECOMMENDATIONS 
AUXOLOGY 
The age definition for the diagnosis of precocious puberty should be maintained at 8 years 
for girls and at 9 years for boys. Children with central precocious puberty should be treated 
with GnRHa as soon as possible, after it is shown that puberty has a progressive course. 
Puberty can be assumed to be progressive by a pubertal LH response> 10 lUlL in a GnRHa 
stimulation test combined with either an advanced BA or other signs of sex steroid action. In 
case of absence of signs of sex steroid action or a minimal presence of breast development 
GnRHa testing should be postponed. Clinical observation for 3~6 months is warranted in 
these cases, 
In children with early, not precocious, puberty there is uncertainty about gain in FH 
after GnRHa treatment. This implicates that in this group no indication for GnRHa can be 
established just for the sake of height gain. Further considerations regard the predicted adult 
height and the psychological situation, including the suffering aspect. For prediction of adult 
height the use of the average BP tables is recommended. 
In general, GnRHa treatment in girls> 10 yrs and boys> 11 yrs is not recommended. 
Specific conditions may warrant GnRHa treatment for example in children with mental 
retardation or in children with GHD, In GHD patients pubertal suppression can improve FH 
outcome when puberty starts at an early age, with delayed BA and at a marked short stature, 
In the figure we summarise our recommendations. 
During GnRHa treatment in CPP gonadal suppression needs to be confirmed by the 
puberty suppression score and/or a GnRH stimulation test. No recommendation can be given 
on the moment of discontinuation of treatment. This should be determined by psychological 
and auxological parameters, for example the conformity with peers, BA and height velocity 
during treatment. 
Before FH results of the combined treatment will become available, the addition of 
growth hormone to GnRHa treatment is not advocated as yet. Addition of growth hormone 
may be provided in a setting of a clinical study in children with a marked decrease in height 
prediction (before or during GnRHa treatment) or in height velocity during GnRHa treatment. 
We recommend that patients treated with GnRHa will be monitored until FH is reached and 
afterwards, not only to evaluate growth, but also to assess the development of gonadal and 
reproductive function. 
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PSYCHOLOGY 
The psychological aspects and concerns of early development of puberty should be 
considered in the work-up of both adopted and non-adopted children (11). These include the 
emotional impact of the appearance of secondary sexual characteristics, the fear to have 
menarche, aspects of teasing and embarrassment and the expected future height. Specific 
questionnaires addressing these items should be developed in order to assess eventual 
suffering and the effects of interventions with GnRHa or other gonadal suppressants. 
Adoptive famities were shown to be adequately motivated for treatment and should not be 
treated differently when they ask for any treatment or participation in a clinical trial. 
ETHICS 
For establishing indications for growth promoting treatment around puberty in adopted and 
non-adopted children, either by GH or by the combination of GH and GnRHa the suffering 
criterion needs careful consideration. Especially in non-GHO patients the use of GH 
deserves a specific attention in the context of cost and gain (33). 
VII FURTHER RESEARCH 
First of all, future research includes the analysis of final height data of the present studies. 
When a beneficial effect has been established in the final analysis, it is interesting to know 
whether adaptation of the GH regimen might further improve auxological outcome during 
GnRHa treatment. Maybe a short period with a GH dose higher than used in our studies (4 
IU/m2) might be beneficial. An alternative option is to treat patients with addition of growth 
hormone only when height velocity becomes impaired by GnRHa treatment. 
The development of prediction models for the effect of treatment with GnRHa for 
CPP, as used in children with GHD, might improve the assessment of the patients suitable 
for treatment. 
Prospective studies should elucidate the question whether the factors retrospectively 
found to improve FH outcome represent reliable predictive factors. The obvious ethical 
problems connected to these kind of studies need careful attention. 
The issue of the timing of discontinuation of treatment for auxological reasons has not 
been resolved yet and would require a prospective randomised trial design. 
Further research could also involve other patient groups in which gonadal 
suppression could be considered, e.g. IUGR children treated with growth hormone or 
children with renal insufficiency on GH treatment. 
The use of the GnRHa stimulation test during treatment as a means to evaluate efficacy of 
pubertal suppression needs further validation. 
Figure: Flow diagram of considerations regarding eventual initiation of treatment in children 
with pubertal development 
218 
Chapter 10 
Pubertal development 
girls: :: 82 boys: testisvolume :: 4 ml 
.. .. .. No indication for 
Onset of puberty Onset of puberty Onset of puberty GnRHa treatment 
Girls < 8 yrs Girls 8-10 yrs Girls> 10 yrs Unless: 
Boys < 9 yrs Boys 9-11 yrs Boys> 11 yrs GH deficiency 
~ mental retardation 
.. ... 
I ASSESS INDICATION FOR TREATMENT 
1 
Signs of sex steroid action 
~ Clinical progression 
HV increased 
Pubertal pelvic ultrasound 
~ BA>CA 
I 
1+ -1 3 - 6 months 
Central activation observation 
GnRH (agonisl) Rule out 
stimulation test -> r gonadotrophin i pubertal LH peak independent PP I- I No GnRHa I 
-
+ treatment 
... Suffering 
DECISION I Psychology Teasing Predicted 
I I 
Fear for 
adult height menarche T 
Age group: girls < 8 yrs girls 8·10 yrs 
boys < 9 yrs boys 9·11 yrs 
PAH compromised 1 + + + + 
Psychological reason + + + + 
GnRHa treatment + + + ~ 1# +/1>. +/1>. + 
1 < _ 2 SOS #: follow clinical course and PAH; .A.: treatment in study, consider combinaUon GnRHa 
and GH when PAH « - 2 SOS, HV decreases or PAH deteriorates during GnRHa treatment 
219 
General discussion 
To alleviate the treatment for children, new modes of GnRHa administration that have been 
introduced in adult oncology, for example a 3 months depot of leuprolide acetate, need to be 
studied in order to establish its efficacy and safety. 
Whether aromatase-inhibitors deserve a place in the treatment of precocious puberty 
remains to be investigated, as no central inhibition will occur during this treatment. On the 
other hand, aromatase inhibitors are shown to inhibit oestrogen action effectively. 
The impact of either short stature or early puberty on quality of life during 
adolescence and adulthood and the effect of any endocrine intervention deserve further 
scientific attention. 
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Summary 
Summary 
This thesis contains the results of several studies on growth promoting treatment around 
puberty in adopted and non-adopted children. Indications for treatment as well as short-term 
and final results were subject of the studies and presented in this thesis. 
After a general introduction (chapter 1), the thesis starts with 2 articles on the timing of 
puberty in normal children. 
In the Netherlands the fourth nation-wide growth study from 1997 provided new data 
and new reference curves on the occurrence of puberty in healthy children (chapter 2.1). 
The P" of the age of menarche has decreased slightly from 13.28 years in 1980 to 13.15 
years in 1997. The age of onset of puberty in girls defined by the presence of Tanner breast 
stage 2 (B2) changed from 10.5 yrs in 1980 to 10.7 yrs in 1997. In boys an increase in the 
age of Tanner G-stage 2 was observed from 11.3 yrs in 1980 to 11.5 yrs in 1997. With 
regard to testicular volume, the 4 ml volume is reached in 50% of the boys at 11.5 years, 
compared to about 12 years in 1965. Based upon these data, there is no need to adapt the 
current definitions for precocious puberty in The Netherlands. 
The influence of body mass index (BMI) on the age of menarche was analysed; we 
found that, besides chronological age, height and weight contributed to the timing of 
menarche. Further, we found a high agreement between the pubic hair stages and stages of 
pubertal development. 
We conclude that the decrease in age of puberty has been stabilised between 1980 
and 1997. 
In chapter 2.2 the literature on changes in the age of onset of puberty and of menarcheal 
age is reviewed, concluding that a positive secular trend is observed in most European 
countries towards earlier puberty. The role of environmental factors such as improvement of 
socia-economic circumstances and public health is discussed. The influence of estrogen-like 
containing food elements needs further research. 
In chapter 3 a new stimulation test with the GnRH-agonist leuprolide-acetate was evaluated 
for use in the diagnosis of central precocious puberty. This GnRH-agonist stimulation test 
was compared with the test used to date, a GnRH stimulation test. 
We showed that the GnRH-agonist stimulation test was able to detect central 
activation of the hypothalamo-pituitary-gonadal (HPG) axis in more cases than the GnRH 
stimulation test. This offers the opportunity to eventually start treatment in children with 
central activation at an earlier age or Tanner stage. Besides this, the test is simpler and less 
invasive for the child as no intravenous access is needed for administration of GnRHa. 
Once treated with a GnRH agonist it is important to monitor the gonadal suppression 
carefully. We studied pubertal suppression in children treated for 18 months with the GnRH 
agonist leupralide acetate (chapter 4). The puberty suppression score (PSS) was developed 
as an instrument to monitor the efficacy of treatment. The parameters used in this score are: 
Tanner stage progression, changes in H-SDS, sex steroid levels and bone age progression. 
The PSS appeared to correlate with changes in height prediction during 18 months of 
treatment. Leuprolide acetate, in an usual dose of 3.75 mg per month, was shown to 
suppress puberty effectively. 
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Final height (FH) results of GnRHa treatment were studied in a large population of Dutch 
children. They were previously treated with GnRHa for Central Precocious Puberty (CPP) 
and had reached final height. 
In chapter 5.1 the results were presented with emphasis on girls. We showed that 
GnRH treatment results in a mean FH that is 7.4 (5.7) cm above the mean initial height 
prediction. Expressed in SD scores, a FH-SDS of -0.93 (1.17) was found, significantly lower 
than TH-SDS, but still in the target range. In this study the mean age at start of treatment 
was 7.7 (1.3) years and the mean treatment period was 3.4 (1.3) years. 
Several factors were found that influenced the effect of treatment. Chronological age 
at start of treatment correlated positively with height gain, whereas bone age at start of 
treatment and BA advance at discontinuation of treatment were negatively associated with 
height gain. 
In chapter 5.2, we combined FH data of boys from The Netherlands, Italy and France 
previously treated with GnRHa for CPP. We showed that mean FH was at mean 5.8 (8.4) cm 
above the initial prediction. Expressed in SD scores, FH was not significantly different from 
target height. In multiple regression analysis BA at start (negatively) and BA advance at start 
of treatment (positively) were the most significant contributors to height gain. 
From our studies we conclude that in children with precocious puberty a FH in the 
normal range can be obtained with GnRHa treatment. 
In adopted children early puberty is frequently seen. We performed a randomised clinical 
study in 30 adopted children with early puberty to evaluate the effect of treatment with 
GnRHa alone or in combination with growth hormone. The children were randomised for 
Gonadotrophin Releasing Hormone agonist (GnRHa) treatment alone or in combination with 
growth hormone (GH) for 3 years. This study is described in chapter 6. 
The results concerning growth (chapter 6.1) showed that after 3 years of treatment 
girls treated with GnRHa alone gained 5.7 (SD 3.8) cm in predicted adult height. In the girls 
on combination treatment mean height gain was 10.1 (3.8) em, which was a significant 
difference beween the groups. In both groups a gradual decrease in height velocity was 
observed, despite the absence of a decrease in insulin-like growth factor I (IGF-I). We 
suggest that the decrease in HV is not mediated by changes in the GH axis. 
The evaluation of psychosocial functioning of parents and children in this study 
(chapter 6.2) showed no increased levels of emotional or behavioural problems and normal 
self-perception in adopted children, and no increased levels of family stress as reported by 
the parents. 
The motivation for treatment appeared to be adequate in the fast majority of cases. 
Only in one of 30 cases a family was not allowed to participate in the trial (see chapter 6.3). 
There seems to be no reason to a particular approach to adoptive parents in clinical 
research. 
A randomised trial with an untreated control group described in chapter 7 demonstrates the 
efficacy of combined treatment with GnRHa and GH in 36 children with idiopathic short 
stature and IUGR. The mean increase in FH was 10.4 (SEM 1.2) cm in girls and 6.5 (0.9) cm 
in boys. In the untreated controls height gain was 2.4 (1.7) cm and -3.9 (2.1) cm respectively 
(p < 0.001). Growth hormone treatment preserved a normal height velocity during GnRHa 
treatment. IGF-I and II levels did not differ significantly between the untreated controls and 
the children treated with GnRHa and GH. 
When children with GH deficiency (GHD) enter into puberty at an early (bone) age or short 
stature, GnRHa treatment can be used to extend the prepubertal growth period. We studied 
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final height data in these patients in a retrospective analysis (chapter 8). We concluded that 
in GHD patients with the onset of puberty at small stature or early (bone) age GnRHa 
treatment results in a FH in the normal range (mean -1.31 (0.39) SDS). 
Finally, questions regarding the ethical background of growth promoting treatment with GH 
andlor GnRHa in non-GHD children were addressed in chapter 9, The availability and use of 
GH in several patients without a classical GH deficiency renders questions with regard to 
medical treatment of healthy children, the effectiveness of GH as treatment to improve the 
quality of life or psycho-social well being of children and the costs of GH treatment for the 
society, 
We introduce an approach in which the suffering of a particular child could be the reason to 
treat him or her with GH although no GHD is present. The need for valid instruments to 
estimate suffering before treatment and the effect of the intervention with GH or GnRHa on 
suffering is painted out. 
In chapter 10 the findings of our studies are discussed and recommendations for clinical 
practice as weH as for future research are provided. 
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Samenvatling vaar de niet-medicus' 
ONDERWERP VAN HET PROEFSCHRIFT 
Dit proefschrift heeft als onderwerp de behandeling van (te) vroege puberteit bij klnderen. 
Zowel te vroege puberteit als vroege pubertelt worden in dit proefschrift genaemd. Te vroege 
puberteit, ook wei pubertas praecox genoemd, kenmerkt zieh bij meisjes door het beg/nnen 
van borstontwikkeling v66r het 86 jaar en bij jon gens door een vergroting van de 
zaadballetjes v66r het 96 jaar. Van vroege pubertelt wordt gesproken als deze liehamelijke 
puberteitskenmerken bij het meisje tussen de 8 en 10 jaar en bij de jongen fussen de 9 en 11 
jaar beglnnen op te treden. 
NORMAlE PUBERTEIT 
Met het oog op de juiste hantering van de termen vroege en fe vroege pubertelt moet 
duidelijk zijn op welke leeftijd de puberteit gewoonlijk begint. Dit kan onderzoeht worden met 
grote landelijke of regionale onderzoeken bij gezonde kinderen. Uit de gegevens die deze 
onderzoeken opleveren, kan afgeleid worden welke leeftijd normaal is voor bijvoorbeeld het 
begin van borstontwikkeling of de eerste ongesteldheid. 
In Nederland is in 1997 een landelijk onderzoek ultgevoerd, da! vergeleken kan 
worden met soortgelijke onderzoeken in 1965 en 1980. Hierdoor is het mogelijk om in 
Nederland het verloop van de puberteitsontwikkeling over een periode van ruim dertig jaar te 
bestuderen. De resultaten van deze studie staan besehreven in hoofdstuk 2.1. De normale 
leeftijd waarop meisjes beginnen met de pubertelt is ongeveer 10 jaar en 8 maanden, bij 
jongens is dlt 11 jaar en 6 maanden. De eerste menstruatie bij meisjes treedt op de leeftijd 
van 13 jaar en 2 maanden op, dlt is iets eerder dan in 1980 werd vastgesteld: toen lag de 
leeftijd op 13 jaar en 3 maanden. 
Het totaalbeeld van 1965 tot 1997 laat een liehte vervroeging zien van de leeftijd 
waarop de pubertelt begint fussen 1965 en 1980, en geen verdere vervroeging meer van 
1980 tot 1997. 
In dit onderzoek keken we ook naar de verhouding tussen het optreden van 
publsbeharing ("sehaamhaar") en de eehte kenmerken van beginnende puberteil, namelijk 
borstontwikkeling bij meisjes en toename van de testlsgrootte bij jongens. Het bleek dat voar 
het vaststellen van pubertelt pubisbeharing geen goede maat is. 
Tenslotte is met de cijfers uit de studie uit 1997 onderzocht wat de invloed van lengte 
en gewicht is op het moment van optreden van de eerste ongesteldheid. Samengevat 
vonden wij dat langere en zwaardere meisjes vroeger in de puberteit komen. 
De gevonden resultaten uit deze studie maken duldelijk dat de bovengenoemde 
leefUjden in de definitie van te vroege puberteit niet aangepast hoeven te worden. 
In Europa zijn de afgelopen tientallen jaren in diverse landen dergelijke onderzoeken 
uitgevoerd; een overzieht daarvan wordt gegeven in hoofdstuk 2.2. De trend in de meeste 
westerse land en is dat de puberteit steeds vroeger begint. De rol van de gezondheidszorg en 
welvaartssituatie spelen hierbij waarsehijnlijk de belangrijkste rol. Ook allerlei stoffen in het 
milieu of in de voeding met een werking die Iijkt op vrouwelijk hormoon zouden kunnen 
bijdragen aan de steeds vroeger optredende puberteitsontwikkeling. Dit moet eehter verder 
worden onderzoeht. 
1 Dit is geen letterlijke vertaling van de 'summary' 
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DIAGNOSE VAN (TE) VROEGE PUBERTEIT 
Voorafgaand aan een eventuele behandeling moet de diagnose van (te) vroege puberteit wei 
duidelijk zijn. We willen er zeker van zijn dat er bij het kind sprake is van een norma Ie, door 
de hersenen gestuurde pubertelt (centrale puberteit). Aileen het moment van aanvang van 
de puberteit is am wat voor reden dan ook vervroegd. 
Of er inderdaad sprake is van vervroegde pubertelt werd tot op heden met een 
stimulatietest, de GnRH-test onderzocht, waarbij het kind gedurende een uur een lnfuus 
inkreeg en waarbij de GnRH-testvloeistof werd ingespoten. 
Inmiddels is er een wat eenvoudiger test, de z.g. GnRH§.:test waarbij in het 
onderhuidse vet een kleine hoeveelheid GnRHB-testvloeistof wordt ingespoten. Na drie uur 
kan dan door een bloedafname worden beoordeeld of er sprake is van centrale puberteit. 
In hoofdstuk 3 onderzoehten wij of de GnRHa-test in vergelijking met de GnRH-test de 
centrale pubertelt even goed of zelfs beter kan aantonen. Meer kinderen met een 
liehamelijke puberteitsontwikkeling hadden een positief testresultaat bij de GnRH§.:test dan 
bij de GnRH-test. Oit maakt het mogelijk om met een eenvoudiger test sneller de diagnose te 
stellen en eerder behandeling in te stellen. Je hoeft dan minder frequent de GnRH-test te 
herhalen am zekerheid te krijgen, wat met deze test nogal eens nodig was. 
BEHANDEUNG VAN (TE) VROEGE PUBERTEIT 
Er kunnen twee redenen zijn om bij kinderen met een te vroege lichamelijke 
puberteitsontwikkeling de puberteit met medicijnen te remmen. In de eerste plaats leidt een 
erg vroege puberteit ertoe dat het kind vervroegd is uitgegroeid en daardoor niet de lengte 
haalt die het bij een normaal optredende pubertelt had kunnen bereiken. Oil komt omdat de 
geslaehtshormonen in het bloed ervoor zorgen dat de groeischijven in de batten gaan 
slulten. In de tweede plaats kan (te) vroege puberteit aanleiding geven tot psyehologische 
problemen. Te denken valt daarbij aan het gevoel van 'anderszijn', sehaamte en angst voor 
ongesteldheid. Oit is met name een probleem als het kind qua ontwikkeling nog niet toe is 
aan de puberteit. 
Sinds een aantal jaren kan de puberteit met behulp van medicijnen worden geremd. 
Oit gebeurt met de z.g. GnRH-agonisten (,puberteitsremmers') die via een injectie eenmaal 
in de maand worden toegediend. Dit zijn zogenaamde depot preparaten waarbij het aetieve 
medieijn over een periode van 4 weken langzaam aan het bloed wordt afgegeven. Een 
kortwerkende vorm van dit medieijn wordt ~ zoals hiervoor besehreven ~ gebruikt in de 
GnRH§.:stimulatie test. 
Een van de GnRH-agonisten die voor de behandeling wordt gebruikt is het leuprolide 
aeetaat. In het kader van dit proefsehrift werd bij een groep kinderen onderzoehl hoe effectief 
dit middel de puberteit kan onderdrukken (hoofdstuk 4). Oaarbij werd een bepaalde score 
gehanteerd, de Puberty Suppression Score (PSS). Deze score kan poliklinisch gebruikt 
worden om iets zeggen over hoe effeetief de puberteit wordt geremd. Daarnaast zegt de 
score ook iets over de winst die de behandeling op korte termijn kan geven wat betreft 
lengte. 
In dit proefschrift staan in de hoofdstukken 5.1 en 5.2 de lange-termijn resultaten 
genoemd van de behandeling met GnRH-agonisten bij te woege puberteit. Gekeken is naar 
wat de uiteindelijke lengte van een kind geworden is verge Ie ken met de lengte die voorspeld 
was bij het begin van de behandeling. Wij zagen dat bij meisjes de gemiddelde eindlengte 
ruim 7 em grater was dan de voorspelde lengte bij start. Dus, am een voorbeeld te geven, 
een meisje waarvan bij het begin van de behandeling voorspeld werd dal zij 146 em lang zou 
worden, haalde uiteindelijk een lengte van 153 em. Uit de gegevens van dit onderzoek 
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concludeerden wij verder dat vaar een goed resultaat tijdig begonnen maet worden met de 
behandeling. Juist bij kinderen met een snel verlapende vorm van te vraege puberteit en 
snelle batijping kan GnRHa-behandeling winst in lengte opleveren. 
Bij jangens komt te vroege pubertelt veel minder vaak voar en daarom hebben we 
gegevens van een graep Nederlandse jongens ultgebreid met gegevens van Italiaanse en 
Franse jangens. Oak blj jangens met te vroege pubertelt bleek de GnRHa-behandeling winst 
ap te leveren: de eindlengte was 5.8 cm hager dan de voorspelde eindlengte bij start van de 
behandeling. 
BEHANDEUNG VAN VROEGE PUBERTEIT BIJ ADOPTIEKINDEREN 
Tijdens de behandeling van te vroege puberteit met GnRH-agonisten wardt bij een aantal 
kinderen een te sterke afname van de groeisnelheid gezien. Omdat je behandelt om juist 
lengte te winnen is dat een ongewenst effect. De gedachte kwam daardaor op of de 
toevaeging van graeiharmoon deze groei, en daarmee ook de prognoses vaar de eindlengte, 
zou kunnen verbeteren. Deze vraagstelling werd onderzocht bij een graep geadopteerde 
kinderen. Bij kinderen die uit het buitenland geadapteerd zijn wordt relatief vaak een vroeg 
optredende puberteit gezien. De precieze aorzaak daarvan is niet bekend. De 
anderzaeksgroep bestand uit 30 kinderen die geadopteerd waren uit India, Sri Lanka, Zuid 
Korea of Colombia. Bij hen was de pubertelt vroeg begannen (meisjes voar de leeftijd van 10 
en jangens voar de leeftijd van 11 jaar) en ze hadden een prognose voor een kleine 
eindlengte. 
Deze studie bestaat uit drie onderdelen: een groeistudie (hoofdstuk 6.1), een 
psychalagisch onderzoek (hoofdstuk 6.2) en een onderzoek naar de mativatie van ouders 
en kinderen voor deelname aan de studie en behandeling (hoofdstuk 6.3). 
In de groeistudie zijn de kinderen in twee groepen verdeeld en met elkaar 
vergeleken: graep A werd aileen met puberteitremmer (GnRH-agonist, in dit geval 
lriptoreline) behandeld, terwijl in graep B de behandeling bestond uit zowel GnRH-agonist als 
graeihormoon (GH). De studieperiode was 3 jaar en de kinderen werden om de drie 
maanden op de palikliniek gezien. Wij zagen na de 3 jaar behandeling een toe name van de 
voorspelde eindlengte in groep A van 5,7 cm (van 149.8 naar 155.6 cm) en in groep B van 
10,1 cm (namelijk van 146.8 naar 157.0 cm). Oil was een statistisch significant verschil, wat 
betekent dat het niet door het taeval bepaald is maar een echt behandeleffect is. We 
onderzochten ook groeifactoren in het blaed om te zien welke ral die spelen bij het verschil in 
effect en het bleek dat de GH taediening zorgde voor hogere waarden van de graeifactoren 
in het bloed. Oit geeft een verklaring voar de hogere groeisnelheid die in groep B werd 
gevonden. 
In het psych%gisch onderzoek ging het erom te bestuderen welke lnvloed het 
vroeg in de pubertelt zljn en de behandeling hebben op het psychologisch functioneren van 
de kinderen. Tegelijk werd ook gekeken naar de invloed die het op de ouders heeft en ook 
naar de verwachtingen die ouders en kinderen van de behandeling hebben. De uitkomst liet 
zien dat de behandelde geadopteerde kinderen nlet meer gedrags- of emotionele problemen 
hebben dan hUn niet-behandelde geadopteerde leeftijdsgenaten, en dat er tijdens de 
behandeling geen taename van deze problemen wordt gezien. De klnderen in de studie 
hebben een normaal zelfbeeld en voelen zich geaccepteerd door leeftijdsgenoten, zawel 
vaar als aan het eind van de behandelperiode. Aan het eind van deze periode werd 
vastgesteld dat het gevoel van acceptatie zelfs hoger was dan het gemiddelde van 
Nederlandse kinderen. Ouders blijken reiHere verwachtingen van behandeling te hebben dan 
kinderen. Het hebben van een kind met vroege pubertelt veroorzaakt geen grate stress in de 
gezinssituatie. 
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Het motivatieonderzoek werd verricht om te kijken hoe de motivatie van ouders en kinderen 
was om deel te nemen aan de behandeling en het onderzoek. De achterliggende reden voor 
dit onderzoek was dat door sommigen gevreesd werd dat adoptieouders te gemotiveerd 
zouden kunnen zijn en dat die motivatie soms tegen de wensen van het kind in zou gaan. 
Van overmotivatie is in onze evaluatie niets gebleken. Van de onderzochte ouder-/kind paren 
is er slechts €len afgewezen. Wij concluderen dan oak dat adoptieouders niet anders 
benaderd dienen te worden in anderzoek of behandeling dan ouders van niet-geadopteerde 
kinderen. 
ANDERE STUDIES MET COMBINATIE GNRHA EN GROEIHORMOON 
De studies die beschreven staan in de haofdstukken 7 en 8 onderzochten de vraagstelling 
naar het effect van de gecambineerde behandeling met GnRHa en GH op verschillende 
manieren. In hoofdstuk 8 wordt een evaluatie beschreven van kinderen met een 
groeihormoontekort die behandeld worden met GH en ook met puberteitsremmer omdat ze 
vroeg of klein in de puberteit zjin gekomen. De resultaten van de uitgegroeide kinderen tonen 
dat het remmen van de puberteit gedurende een bepaalde periode de uiteindelijke Jengte 
doet toenemen in vergelijking met kinderen bij wie de puberteit niet is geremd. 
De studie bij kinderen met kleine gestalte (al dan niet na groeivertraging tijdens de 
zwangerschap) die in hoofdstuk 7 staat is een bijzondere studie omdat behalve een groep 
behandelde kinderen oak een zogenaamde controlegroep werd bestudeerd die geen 
behandeling kreeg. Het vergelijken van deze twee groepen maakt het mogelijk het 
behandeleffect nauwkeurig in kaart te brengen. 
De studie liet zien dat kinderen met de gecombineerde behandeling van GnRH-
agonist en groeihormoon, in vergelijking met een onbehandelde groep een winst in 
voorspelde eindlengte liet zien van 10,4 cm bij jongens en 8,0 cm bij meisjes. Oil is een 
veelbelovend resultaat maar er moet afgewacht worden wat het resultaat is als de kinderen 
zijn uitgegroeid. Oat geldt ook voor de studie bij uit het buitenland geadopteerde kinderen die 
hierboven werd beschreven. 
TensloUe wordt in dit proefschrift (in hoofdstuk 9) vanuit de invalshoek van de ethiek 
gekeken naar het behandelen van kinderen met groeihormoon (GH), met name bij die 
kinderen die geen echt tekort hebben aan GH maar door een andere oorzaak (bijvoorbeeld 
gebruik van puberteitsremmer) slecht groeien. 
Er kan op verschillende manieren naar gekeken worden. AHereerst vanuit het 
uitgangspunt dat als er geen echt tekort is aan groeihormoan, het kind niet ziek is en dus 
geen medicijn - groeihormoon- zou moeten krijgen. Een tweede manier om het te bekijken is 
dat als de ouders zo'n behandeling graag willen, waarom zou een dokter het dan niet 
toestaan? Een derde mogelijkheid, waarvoor wij in het artikel kiezen, is dat uitgegaan moet 
worden van het lijden van het kind, en dat bekeken moet worden of het geven van 
groeihormoon daar echt iets aan kan doen. De maeilljkheid daarbij is dat er weinig 
onderzoek is gedaan naar de mate van lijden van kleine kinderen en evenmin naar het 
'helend' effect van groeihormoon. Wij benadrukken het belang van het ontwikkelen van 
goede instrumenten om 'Iijden' in kaart te kunnen brengen en daarmee te evalueren wat het 
effect van groeihormoon behandeling is. 
In hoofdstuk 10 worden de resultaten van de verschiHende studies besproken en worden er 
aanbevelingen gedaan vaar de praktijk en voor verder onderzoek. 
230 
Abbreviations 
Abbreviations 
a-MSH 
ACTH 
AF 
BA 
BMD 
BMI 
BP 
CA 
CART 
CBCL 
CPP 
DEXA 
DHEA-S 
E2 
FH 
FSH 
FT4 
GAD 67 
GABA 
GH 
GHD 
GnRH 
GnRHa 
GP 
HbA1c 
HPG 
HV 
IFMA 
IGF 
IGF-BP 
IRMA 
ISS 
IU 
IUGR 
LH 
LHRH 
LMS 
MMC 
MPH 
MRI 
NF 
NMDA 
nmol 
NVOS 
17-0HP 
PAH 
PCO 
PHV 
Alpha-Melanocyte Stimulating Hormone 
Adrenocorticotropic Hormone 
Alkaline Phosphatase 
Bone Age 
Bone Mineral Density 
Body Mass Index 
Bayley & Pinneau 
Chronological Age 
Cocajne~ and Amphetamine Regulated Transcript 
Child Behaviour Check List 
Central Precocious Puberty 
Dual Energy X-ray Absorptiometry 
Dehydroepiandrostenedione Sulphate 
Estradiol 
Final Height 
Follicle Stimulating Hormone 
Free Thyroxine 
Glutamic Acid Decarboxylase 67 
Gamma Aminobutyric Acid 
Growth Hormone 
Growth Hormone Deficiency 
Gonadotrophin Releasing Hormone 
Gonadotrophin Releasing Hormone agonist 
Greulich & Pyle 
Glycosyated Hemoglobin 
Hypothalamo-Pituitary-Gonadal 
Height Velocity 
Immuno Fluorometric Assay 
InsuJjn~Jjke Growth Factor 
IGF-Binding Protein 
Immune Radiometric Assay 
Idiopathic Short Stature 
International Units 
Intrauterine Growth Retardation 
Luteinizing Hormone 
Luteinizing Hormone Releasing Hormone 
statistical method for smoothing [smooth (L). mean (M). coelf. of variation (S)] 
Meningo~myelocele 
Midparental Height 
Magnetic Resonance Imaging 
Neurofibromatosis 
N-methyl-D-aspartate 
nanomol 
Nijmeegse Vragenlijst voor de Opvoedingssituatie 
17 - Hydroxyprogesterone 
Predicted Adult Height 
Polycystic Ovary 
Peak Height Velocity 
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PICP 
PIliNP 
pmol 
POMC 
PSS 
RIA 
SO 
SOS 
SE 
SH 
SPPC 
T 
TGF-a 
TH 
TSH 
Carboxyterminal Propeptide of type I Procollagen 
Aminoterminal Propeptide of type III Pro collagen 
picomol 
Pro-opiomelanocortin 
Puberty Suppression Score 
Radio Immuno Assay 
Standard Deviation 
Standard Deviation Score 
Standard Error (SEM: standard error of the mean) 
Sitting Height 
Self-perception Profile for Children 
Testosterone 
Transforming growth factor-alpha 
Target Height 
Thyroid Stimulating Hormone 
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Dank bUjft soms - misschien weI te vaak - onuitgesproken. Vooral bij degenen die dichtbij zijn 
of met wie je nauw samenwerkl. Oat maakt een dankwoord tot een goed gebruik aan het 
eind van een proefschrift. 
Mijn co-promotor, Dr. W. Oostdijk. Wilma, je hebt een drive in je die energie geeft om 
moeder te zijn, een pittige baan als kinderarts-endacrinoloog te hebben en daarnaast een 
flinke portie wetenschappelijk onderzoek te begeleiden en stimuleren. En hoe: nauwkeurig, 
consistent (elke keer weer De PunO, vasthaudend en niet zomaar accoord ....... Maar daarbij 
ook met menselijke aandacht voor de niet wetenschappelijke kant van het leven. 
Mijn promotor, Prof Dr S.LS. Drop. Sten, ik heb een plezierige onderzoekstijd doorgebracht 
bij de Endo. Ons eerste telefonisch contact verraadde a[ veel over je: een snelle spreker, 
klassieke muziek op de achtergrond en een 'Ieuk' onderzoek in de aanbieding. De 
gedrevenheid bleef, ("meer is beter"), met steeds positief en opbauwend commentaar bij de 
artikelen. En, heel belangrijk, plezierig laagdrempelig, wat de vraag oak was. 
Sabine de Muinck Kelzer-Schrama, bij een aantal van de artikelen in dlt proefschrift was je 
betrokken, het meest nauw bij het in hoofdstuk 2.2 beschreven review dat we 'even' snel 
moesten afronden. Je werkkracht en enthousiasme zjjn inspirerend. 
De overige leden van de grote en kleine commissie bedank ik voor hun bereidheid een 
aandeel in deze promotie te leveren. 
Prof. J.P. Bourguignon, thank you for your willingness to participate in the thesis defence 
ceremony, and to give a lecture afterwards. Merci beaucoup! 
Verschillende leden van de adviesgroep GH bedank ik voor de geboden gelegenheid 
patientgegevens te verzamelen. 
In het bijzonder noem ik Dr. J. Waelkens, Johan, bedankt voor de samenwerking in de 
adoptiestudie. Het blijft een raadse[ waar je aUijd weer patienten vandaan weet te halen! 
Tegelijk oak dank aan de medewerkers van het secretariaat kindergeneeskunde van het 
Catharina Ziekenhuis voor de plezierige contacten en adequate ondersteuning. 
Sehalve dichtbij de koffie-automaat was de ligging van de 'fellow-kamer' met het oog op de 
samenwerking met de afdeling kinder- en jeugdpsychiatrie van het SKZ heel strategisch. Ik 
bedank dr. Herma Versluis en dr. Froukje Slijper voar de uitvoering en verwerking van de 
psychologie-gere[ateerde stukken van het proefschrift en hun specifieke inbreng op het 
gebied van adoptie en pubertas praecox. 
Mijn endo-collega's (van onder andere die kamer): Annemieke Boot en Theo Sas voor mij en 
daarna [nge van der Sluis, Yvonne van Pareren, en de IUGR dokters Nicolette Arends en 
Venje Boonstra ..... Tja, hoe zeg je het als het nooit vervelend was de werkp[ek weer op te 
zoeken, gezamenlijk te lunchen, bij te praten of een halve dag rug aan rug in stilte te 
werken? Bedankt allemaal voor het delen van onderzoekslief en -Ieed en de persoonlijke 
noot! De nieuwe man (?I) komt bij jullie goed terech!. 
De andere bewoners van die paar vierkante meter zijn de onderzoeksverpleegkundigen. Ik 
noem met name Ingrid van Slobbe die de noodzakelijke ondersteuning van de reumastudie 
verzargt en daarnaast breed inzetbaar wilde ,zijn. Bedankt daarvoor, al duurt het nog even 
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voordat daarover iets in een proefschrift verschijntl Janneke van Nieuwkasteele, Lydia Velt 
en Esther Lems, succes verder in de wereld van de hormonen! 
En nu we toch in het endowereldje zitten: bedankt ook Dini Seip en Jacqueline Drost, de 
'endo-managers' op het secretariaat. Wie gaat nu de post doen? 
Er is meer dan Endo-onderzoek aileen, getuige de vele arts-onderzoekers en AIO's die het 
SKZ rijk is en was. Bedankt voor collegialiteit of meer. 
Gerdine Kamp (LUMC Leiden) bedank ik voor de gelegenheid het artikel uit hoofdstuk 7 op 
te nemen in dit proefschrift. We hebben tach veel te danken aan de email! 
Het artikel over de puberteitsgegevens in Nederland kon van de verlanglijst af en realiteit 
worden, mede dankzij de intensieve samenwerking met nog meer 'Leidenaren': Miranda 
Fredriks, Jan Maarten Wit, Stef van Buuren en prof. Verloove. Veel dank daarvoor! 
De onmisbare pOlikliniek-assistentes van de endopoli SKZ dank ik voor hun medewerking, 
meedenken en regelen van diverse zaken als er weer eens een onderzoekje liep. 
Tussendoor was er gelukkig tijd voor een praatje. 
De medewerkers van de dagverpleging bedank ik voor nauwgezette wijze waarop zij de 
verschillende endocrinologische testen ultvoeren. 
Marijke Fr61ich van het klinisch chemisch lab van het LUMC, hartelijk bedankt voor de 
soepele samenwerking! 
Ik bedank de diverse adoptieverenigingen die Nederland rijk is voor hun medewerking bij het 
verspreiden van informatie over vroege puberteit bij adoptiekinderen via mailing of 
verenigingsorgaan. 
Guders en kinderen die deelnamen aan de "adoptiestudie", erg bedankt voor het meedoen, 
de vele trouw afgelegde polikliniekbezoeken, soms van ver (!) en de leuke contacten. De 
behandeling was intensief maar is geweldig volgehouden! Ik hoop dat ik aile deelnemende 
kinderen kan blijven vervolgen. Het ga juHie goed! 
Prof Dr Th Stljnen, bedankt voor de vriendelijke uitleg over statistiek aan weer een endo-
dokter ...... 
I thank Silvano Bertelloni from Pisa and Jean-Claude Carel from Paris for their cooperation 
and enthusiasm to analyse the data of boys with precocious puberty. 
Het verzamelen van gegevens over niet behandelde adoptiekinderen leidde tot in de kelders 
van het Overvecht ziekenhuis in Utrecht. Ik bedank dr. Stijn Rupert voor zijn bewegwijzering 
en hulp. De samenwerking met oud-Overvecht 'adoptie-dokter' Schul pen was plezierig. Leuk 
dat je in de grate commissie zit! 
Ineke Bolt, je lezing waarin ook 'mijn' adoptiekinderen werden genoemd bracht ons 
uiteindelijk tot het gezamenlijk artikel in dlt proefschrlft. Bedankt voor de gelegenheid het 
artikel op te nemen en daarmee een belangrijk element toe te voegen. Hopelijk een 
voorbeeld voor verdere kruisbestuiving tussen kliniek en ethiek. 
Jan van den Sroeck en de medewerkers van de nederlandse groeistlchting: bedankt voor 
ieders eigen ondersteuning en behulpzaamheid. 
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Het contact met de sponsors van de studies was gelukkig niet aileen financieel van aard. 
Een aantal mensen die betroken Waren bij de eerste periode van de adoptiestudie zijn 
inmiddels elders werkzaam. Yvonne Snel, als Jangstzittende vertegenwoordiger dank ik je 
voor je meedenken en betrokkenheid. Aile anderen ook bedankt voor de plezierige 
samenwerking. 
De samenvatting in het nederlands is door Annemiek op begrijpelijk nivo gebracht, en mijn 
tweelingbroer Aart voegde de benodigde taal~technische 'transparantie' toe. Bedankt! 
Mijn paranimfen, Simone en Inge, bedankt dat jullie me terzijde willen staan rondom de 
promotie. Een gerust gevoel! 
Lieve Annemiek, voor jou en mij breken nieuwe tijden aan, waarin elke dag, behalve een 
kado ook een surprise kan zijn! 
235 

cv & publications 
Curriculum Vitae 
The author of this thesis was born on October 3rd 1968 in Barneveld. He attended secondary 
school in Amersfoort (gymnasium, gereformeerde scholengemeenschap) were he passed his 
exam in 1987. 
From 1987 to 1994 he studied Medicine at the Free University Amsterdam. While studying in 
Amsterdam he was member and president of a christian students society. In 1994 he 
obtained his medical degree (cum laude), 
He performed research in the Free University Hospital at the departments of paediatric 
haematology and oncology (head: Prof, Dr, AJ.P. Veerman) and paediatric endocrinology 
(head: Prof. Dr, H,A. Delemarre-van de Waal) as well as in child and adolescent psychiatry 
at the Academic Medicat Centre Amsterdam (head: Prof. Dr. JAR. Sanders-Woudstra). 
Further, he was involved in research on anxiety disorders in the Valeriuskliniek (supervision: 
Dr. A.J.L.M. van Balkom). 
For a short period he teached nurses-in-training. In 1995 he served in the army as a teacher 
in medical skills and knowledge, Thereafter, he wrote his first book for the education of 
nurses in general paediatrics. 
From March 1st 1996 the research presented in this thesis was performed at the department 
of Paediatrics I Subdivision Endocrinology (head: Prof. Dr. S.L.S. Drop), of the Sophia 
Children's Hospital Rotterdam in close collaboration with Dr. W. Oostdijk, paediatric 
endocrinologist from the Department of Paediatrics, Leiden University Medical Centre. 
Besides the research concerning early puberty he coordinates a clinical trial on the effects of 
growth hormone treatment on growth and bone mineral density in children with rheumatic 
disease. 
At Jan, 1st 2001 he will start his training in Paediatrics first as AGNIO at the Sophia 
Children's Hospital Rotterdam (Head: Prof. Dr. H.A. BOiler). 
Dick lives with his wife Annemiek in the northern part of the city of Rotterdam, 
237 

CV & publications 
List of publications 
... BOOKS I BOOK SECTIONS 
D Mul, SMPF de Muinck Keizer-Schrama: LHRH behandeling van (te) vroege puberteil. In: 
Therapeutisch handel en in kindergeneeskunde en kinderverpleegkunde II, redactie: LWA 
van Suijlekom- Smil, Rotterdam 1996, ISBN 90-801804-6-7 
o Mul: Kindergeneeskunde. Serie UBouwstenen voor gezondheidszorgondelWijs". Bohn 
Stafleu Van Loghum 1998, ISBN 90-313-2661-x 
MF Schutte, OP Bieker, G Huygebaert, D Mul, EMV Hertogs (red): Verloskunde, 
gynaecologle en kindergeneeskunde. Serie "Bouwstenen voor gezondheidszorgonderwijs". 
Bohn Stafleu Van Loghum 1998, ISBN 90-313-2580-5 
D Mul: Aspecten van groei bij adoptiekinderen. In: syllabus PAOK symposium uMondiale 
kindergeneeskunde" Red. LWA van Suijlekom-Smit en AJCM van der Velden, Rotterdam 
1998. ISBN 90-76220-03-4 
D Mul, SMPF de Muinck Keizer-Schrama: Te vroege en te late pubertelt. In: syllabus PAOK 
symposium "GynaecoJogie en androJogie, ook in de praktijk van de kinderarts" Red. LWA van 
Suijlekom-Smit en WA van der Zijden, Rotterdam 1999. ISBN 90-76220-05-0 
D. Mul, 1M van der Sluis, SMPF de Muinck Keizer-Schrama: Endocrinologische aspecten van 
corticosteroid geinduceerde osteoporose en groeiretardatie. In: Nascholingsweek 
Kindergeneeskunde Leiden 1999 ( Red. JM Wit et al.); Boerhaave Commissie voar 
Postacademisch OndeIWijs Geneeskunde Universiteit Leiden, 1999 ISBN 90-6767-417-6 
... ARTICLES 
Mul D, Schouten-van Meeteren AYN, Kamp GJ van, Tan KEWP: Tumormarkers in 
retinoblastoma. Med Pediatr Oneal 1999, 32(2): 146-147 
Mul D, Pieters R, Veerman AJP: Te weinig en te grote bloedplaatjes op de kinderleeftijd: de 
"giant platelet'syndromen. NTvG 1999, 143 (38) 1918-1922 
Mul D, de Muinck Keizer-Schrama SMPF, Oostdijk W, Drop SLS: Auxological and 
biochemical evaluation of pubertal suppression with GnRH-agonist leuprolide acetate in early 
and precocious puberty. Harm Res 1999, 51 (6): 270-276 
Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarre-van de Waal HA, Waelkens JJJ, 
and Drop SLS: Final height after Gonadotrophin Releasing Hormone agonist treatment for 
central precocious puberty: the Dutch experience. 
J Ped Endocrinol Metab 2000;13(suppI1): 765-772 
Bolt LLE, Mul 0,: Growth hormone in short children: beyond medicine? 
Acta Paediatr (accepted for publicaUon) 
GA Kamp, D Mul, JJJ Waelkens, M Jansen, HA Delemarre-van de Waal, L Verhoeven-Wind, 
M Fr6lich, W Oostdijk and JM Wit: A randomized controlled trial of three years Growth 
Harmone (GH) and GnRH agonist treatment in children with Idiopathic Short Stature and 
Intrauterine Growth Retardation. J Clin Endocrinol Metab (accepted for publication) 
239 

